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Abstract 
 
Purpose: Patients’ decisions about whether or not to adhere to their prescribed regimens 
are shaped not only by their knowledge and beliefs about their condition and its treatment 
options, but also by what they value in these domains. This study represents an 
integration of theory and methods from nursing/public health, psychology and economics 
to explore the additive effects of knowledge, beliefs and preferences on adherence to 
preventer medication in a sample of patients with asthma. It was hypothesized that 
knowledge, beliefs and preferences pertaining to long term outcomes would 
independently predict improved adherence. Method: 140 patients with asthma were 
asked to complete a series of surveys assessing their knowledge and beliefs about asthma 
and its treatments as well as a discrete-choice task (DCE) in which they selected which 
hypothetical medication they would choose from among eight choice sets that varied 
along seven attributes (Long Term Efficacy, Short Term Efficacy, Immediate Relief, 
Number of Inhalers, Steroid Dose, Administration Time, and Side Effects). Adherence 
was measured using the self-report Medication Adherence Report Scale one month after 
their clinic visit. Results: A latent cluster analysis of the DCE data suggested four 
distinct groups of patients, namely, those whose choices were guided by (1) long term 
benefits, (2) medication side effects, (3) the trade-off between side effects and efficacy 
and (4) all attributes equally. Multiple regression analyses indicated that pathophysiology 
knowledge, the belief that preventer medication is necessary and membership in the 
group valuing long term outcomes each uniquely predicted reported adherence, together 
explaining 39% of the variance. Preferences for long term outcomes predicted an 
additional 10% of the variance above and beyond that accounted for knowledge about 
  
iv 
 
asthma pathophysiology and treatment beliefs alone. Conclusion: These findings suggest 
that to improve patient adherence to asthma preventer medications, patients should be 
helped to understand why they require medications. Once the long term effects of asthma 
are understood, believed and valued, patients will be more likely to adhere. Via DCE 
methodology, we have also demonstrated a novel approach to elucidating patient 
variations in treatment-related values. 
 
Key Words: Asthma, Adherence, Illness Beliefs, Treatment Beliefs, Knowledge, Discrete 
Choice Experiments 
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Introduction 
 
Decision making is a fundamental part of the health care provision process. From 
patients’ initial decision to seek treatment, to the treatment option(s) offered by the health 
care provider, to whether patients choose to adhere to the regimen – all are decisions that 
affect the course of an illness. There is increasing recognition of the importance of 
including patients in the health care decision making process (Little et al., 2001). 
Systematic reviews have shown that involving patients in treatment planning results in 
better quality of care, higher patient satisfaction and self-esteem (Crawford et al., 2002; 
Kinnersley et al., 2007), improved physical outcomes (Michie, Miles, & Weinman, 2003) 
and better self-management by patients (Heisler, Bourknight, Hayward, Smith, & Kerr, 
2002; Mead & Bower, 2002). Thus, collaborative decision making is increasingly being 
recognized as the key to effective control of chronic diseases (Leventhal, Weinman, 
Leventhal, & Phillips, 2008). 
According to the World Health Organization (2003), in the developed world, 
roughly half of those with chronic diseases fail to use their medications- often a central 
component of self-management plans- as recommended. Suboptimal patient adherence to 
chronic disease management programs poses a serious health threat. Therefore, although 
governments and health organizations invest considerable effort and expense developing 
and improving efficacious treatments, these resources are wasted if the programs are not 
reliably adopted by patients.  
In an effort to combat non-adherence, practitioners and researchers, largely drawn 
from the fields of public health, medicine and nursing have developed and implemented 
educational programs aimed at enhancing patients’ knowledge about their conditions and 
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associated treatments. In contrast, the psychological literature has tended to focus on 
patients’ beliefs about their conditions and treatment options. However, as the ensuing 
literature review will indicate, targeting what people know and believe is not sufficient to 
influence adherence. 
 Health care decision making is a complex process which involves the weighing 
of risks and benefits as well as personal values (Schapira, Gilligan, McAuliffe, & 
Nattinger, 2004). The central tenet of this thesis is that to understand and subsequently 
improve adherence, one also has to know what matters to people, that is, their values and 
preferences. Values and preferences, while not a focus in the adherence literature, have 
been of interest to health economists invested in gauging health care consumer’s 
“willingness to pay” for services and treatments. To do so, they have developed a range 
of innovative approaches to assess patient preferences, one of which- the Discrete Choice 
Experiment- will be used in this study.  
To date, research on patient knowledge, beliefs, and preferences has been 
conducted largely in different professional ‘silos’ (nursing/policy, psychology and 
economics, respectively).Yet, knowledge, beliefs and preferences likely work additively 
on adherence and should be examined in tandem. For example, patients may know that an 
inhaled corticosteroid is designed to prevent subsequent asthma attacks, but this does not 
necessarily mean that they believe it will help control their asthma symptoms. Similarly, 
patients may know that a preventer medication is designed to improve their asthma in the 
long-term (but not relieve their symptoms in the short-term) and believe that it will work. 
However, they may be seeking treatment for immediate symptom relief and are, 
therefore, disinclined to use a medication that will prevent long-term effects. In essence, 
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although correct knowledge and treatment-compatible beliefs may steer patients towards 
making the proper health care decisions, without the necessary motivation, patients will 
not engage in the behaviour. As noted by the World Health Organization (WHO, 2003, p. 
44), “Patients’ knowledge [italics added] and beliefs [italics added] about their illness, 
motivation [italics added] to manage it, confidence in their ability to engage in illness 
management behaviours and expectations… interact in ways not yet fully understood to 
influence behaviours”.  
Accordingly, this research project represents an integration of theory and/or 
methods from three disciplinary literatures- nursing/public health, psychology and 
economics- to explore the additive effects of knowledge, beliefs, and preferences on 
preventer medication adherence in a sample of patients with asthma. In the sections that 
follow, the relevant literatures in these three spheres are reviewed with an eye towards 
showing how current efforts to increase adherence in the domain of asthma self-
management have been hindered by not taking into account all three elements.  
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Chapter I: Literature Review 
Adherence: An Ongoing Challenge 
Given that the benefit of medical advice is contingent on whether or not patients 
choose to follow it, adherence has been deemed the “key” mediator between medical 
practice and patient outcomes (Kravitz & Melnikow, 2004). The consequences of non-
adherence are troubling. They include poor medical outcomes, higher health care costs, 
as well as increased frequency of emergency room visits (Phillips, 2008). In general, 
adherence rates tend to be lower for chronic than acute conditions (WHO, 2003). 
Anywhere from 20-50 percent of patients with chronic conditions do not adhere to their 
prescribed medication regimen (Kripalani, Yao, & Haynes, 2007) and more than 70 
percent do not adhere to their diet or exercise programs (Their et al., 2008). Pulmonary 
diseases, diabetes and sleep disorders are chronic conditions with the lowest adherence 
rates (DiMatteo, 2004).  
Accordingly, although there has been widespread improvements in our 
understanding of the pathophysiology of many conditions and consequently treatment 
efficacy (Sweeny, Edwards, Stead, & Halpin, 2001), treatment effectiveness has not kept 
pace with these developments. Thier et al. (2008) conducted a retrospective analysis of 
claims from a national insurer and found that, although physicians, on average, tended to 
follow evidence-based practice guidelines 59 percent of the time, patients followed their 
physician’s advice only between 11 and 42 percent of the time. 
Research on the gap between physician’s recommendations and their patients’ 
behaviours has shown that treatment characteristics, such as medication side effects 
(Catz, Kelly, Bogart, Genosch, & McAuliffe, 2000) and treatment complexity (Ley, 
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1997) negatively correlate with adherence. In contrast, contextual factors such as social 
support (Tanner & Feldman, 1997) and the quality of the patient-physician relationship 
(Ciechanowski, Katon, Russo, & Walker, 2001) positively correlate with adherence. 
Other predictive factors include, but are not limited to, poor instruction by the health care 
provider, poor patient memory and cost of treatments (Haynes, Ackloo, Sahota, 
McDonald, & Yao, 2008).  
Adherence Interventions: Is Education Enough? 
Poor adherence rates have catalyzed practitioners and researchers to develop 
interventions to improve adherence in a broad range of populations and across a large 
number of treatments. Educational interventions to improve adherence have been applied 
to a range of patient populations, including individuals with asthma (e.g., Lemiere et al., 
2003), chronic heart failure (Clark et al., 2009), hypertension (Devine & Reifschneider, 
1995; Schroeder, Fahey, & Ebrahim, 2004), hyperlipidemia (Schedlbauer, Schroeder, 
Peters & Fahey, 2004), diabetes (Lutoto et al., 2011), HIV (Khachani, et al., 2011) and 
chronic obstructive pulmonary disease (Simone et al., 2011). Unfortunately, although 
some successful interventions exist, at least half fail to produce meaningful changes in 
adherence (van Dumlen et al., 2007). Moreover, many interventions are time consuming 
and complicated and result in only modest behaviour changes (Awad, 2004; Simpson, 
2006). 
After conducting a systematic review of 38 reviews of the literature on adherence 
in the health care domain across a wide range of conditions, Van Dumlen et al. (2007) 
concluded that technical (e.g., reducing the complexity of treatment) and behavioural 
interventions (e.g., memory aids, reminder calls, etc.) were most effective.  However, 
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education, defined as “any intervention given with the intent of improving the person’s 
ability to manage his or her disease” (p. 9), though effective in the short term, was less 
effective over time. For example, an educational program for those with diabetes yielded 
strong immediate (post-intervention) effects (d = 1.05) on adherence, but smaller effects 
at four week follow-up (d = .46; Devine & Reifschneider, 1995).  
 Haynes et al. (2008) conducted a review of the efficacy of a broad range of 
adherence interventions that involved instruction and counseling about a disease in 
conjunction with other approaches (e.g., family and/or couple intervention, 
psychotherapy, group meetings, providing reminder aids, or a combination thereof). They 
found that less than half (45%) yielded statistically significant improvements in 
adherence. Moreover, those that were most effective in the long term were quite labour 
intensive, thereby reducing their cost-effectiveness and clinical utility.  
Van Dumlen et al. (2007), commenting on the stagnancy of adherence rates over 
the prior decade despite research proliferation, suggest it might be due to the lack of 
guidance by suitable theoretical frameworks. Moreover, most interventions do not take 
patients’ perspectives into account. Rather, they give patients information and 
erroneously assume that they will then “think the right way” and behave accordingly. 
However, helping physicians recognize that their patients’ views of their condition may 
not match their own has been shown to improve physical and mental functioning 
(Berkanovic, Hurwicz & Lachenbruch, 1995) and to decrease poor medical appointment 
attendance (Chesney, Brown, Poe, & Gary, 1983). Therefore, for adherence intervention 
research to move forward, we need to better understand how patients’ health beliefs and 
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perspectives lead them to follow (or not) health care recommendations. This literature is 
reviewed in the upcoming section.   
Psychological Theories of Health: Do Beliefs Have a Role to Play In Medical 
Decisions? 
Health psychologists have long been interested in how individuals perceive their 
health and what guides health behaviours. Early models, such as the Health Belief Model 
(Janz & Becker, 1984), the Theory of Reasoned Action (Ajzen & Fishbein, 1980) and the 
Subjective Expected Utility Theory (Sutton, 1982) emphasize the role of perceived health 
risks in predicting health protective behaviours. However, these models rely on the 
assumption that people use information in a linear fashion when deciding how to behave 
(Brannon & Feist, 2004). The more recently proposed Transtheoretical Model (Prochaska 
& DiClemente, 1983; Prochaska, Redding, & Evers, 2002) better accounts for the 
complexity of health care decisions, in that it suggests that people move through a 
sequence of defined, qualitatively different stages (i.e., precontemplation, contemplation, 
preparation, action, maintenance) and takes into consideration how people initially 
consider a problem as well as how they decide to act and maintain health actions. 
However, this model has not been adequately supported by the literature as there is little 
evidence for sequential movement across stages (Little & Girvin, 2002). Furthermore, the 
model has not proved to be particularly predictive in longitudinal studies (Wilson & 
Schlam, 2004).  
To date, perhaps the most comprehensive model of patient health-protective 
behaviour is Leventhal and colleagues’ (1984) Common Sense Model of Illness (CSM). 
The CSM is predicated on a recursive, parallel processing system which is proposed to 
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explain both the development and maintenance of health behaviours (Leventhal, Nerenz, 
& Steele, 1984; Stuifbergen, Phillips, Voelmeck, & Browder, 2006). According to the 
CSM, the noticing of symptoms or the receipt of a diagnosis activates schematic and 
organizational frameworks, referred to as cognitive and emotional illness representations. 
Cognitive and emotional representations work in parallel, but are proposed to have 
reciprocal influences (Wearden & Peters, 2008). They prompt coping behaviours, the 
consequences of which are appraised by the individual for effectiveness and changed 
based on the information gleaned during the appraisal phase (Hagger & Orbell, 2003; 
Leventhal, Brissette, & Leventhal, 2003; Scharloo & Kaptein, 1997). 
Research over the past few decades (Hagger & Orbell, 2003; Moss-Morris et al., 
2002; Rutter & Rutter, 2007) has shown  that cognitive representations can be grouped 
into five distinct but correlated domains including: (1) individual beliefs about the 
diagnostic label and associated symptoms (identity), (2) beliefs about the cause, (3) 
beliefs about the course of the illness (timeline), (4) views about the consequences of the 
illness and (5) beliefs about the controllability of the disease. More recently, illness 
coherence, or the extent to which individuals feel they understand their illness, has been 
added as a domain (Moss-Morris et al., 2002).   
The construct and discriminant validity of these five cognitive components have 
been studied extensively (Hagger & Orbell, 2003; Heijmans & de Ridder, 1998; 
Frostholm et al., 2007; Moss-Morris et al., 2002; Petrie, Jugo, & Devcich, 2007; Rutter & 
Rutter, 2007). Evidence for the distinctness of the categories has been found in studies of 
patients with chronic illnesses (Leventhal et al., 1984), acute illnesses (Lau, Bernard, & 
Hartman, 1989) as well as among undergraduates assessing hypothetical illness (Bishop, 
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Briede, Cavazos, Grotzinger, & McMahon, 1987). A meta-analysis of 45 empirical 
studies suggests strong support for a consistent five factor structure and provides 
evidence of conceptual distinctions among the domains (Hagger & Orbell, 2003). 
Moreover, to-be-expected relationships among the domains are observed, with high 
positive correlations between the identity, chronicity and consequences domains and 
strong negative correlations among the identity and cure dimensions. That is, patients 
who attribute more symptoms to their condition construe it as having a larger impact on 
their daily functioning and see it as more chronic.  
Empirical studies have supported the hypothesis that illness representations are 
associated with health outcomes. For example, illness representations have been shown to 
predict return to work (Lacroix, Martin, Avendano, & Goldstein, 1991), success in 
coping with chronic illness (Hampson, Galsgow, & Toobert, 1990) and functional 
outcomes (Petrie, Jago, & Devcich, 2007; Scharloo et al., 1998). A considerable amount 
of literature also exists on the illness representations of patients with cardiac disease 
(Cooper, Lloyd, Weinman, & Jackson, 1999; Lau-Walker, 2006), type II diabetes 
(Hampson et al., 1990), psoriasis (Fortune, Richards, Main, & Griffiths, 2000), kidney 
disease (Fowler & Baas, 2006), cancer (Hagger & Orbell, 2006; Scharloo, Baatenburg de 
Jong, Langeveld, van Velzen-Verkaik, Doorn-op den Akker, & Kaptein, 2005), 
rheumatoid arthritis (Murphy, Dickens, Creed, & Bernstein, 1999; Scharloo et al., 1998), 
Addison’s disease (Heijmans & de Ridder, 1998) and epilepsy (Kemp, Morley, & 
Anderson, 1999).  The importance of each dimension varies among the conditions. In the 
context of various illnesses, cognitive illness representations have been shown to be 
related to the decision to seek health care (Leventhal, Diefenbach, & Leventhal, 1992) 
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and satisfaction with medical consultations (Frostholm et al., 2005). Additionally illness 
representations have been associated with quality of life at a six month follow-up 
(French, Lewin, Watson, & Thompson, 2005).  
Thus, there is good evidence that patients’ subjective interpretations of their 
physical ailments, or the “psychology” of physical symptoms has implications for health 
outcomes.  Moreover, certain dimensions of the illness model are differentially associated 
with outcomes. For example, the perception of a strong illness identity, serious 
consequences and chronic timeline are negatively associated with psychological and 
physical well-being, whereas those with greater perceived control of their illness do 
better psychologically and socially (Hagger & Orbell, 2003). It should be noted that the 
majority of studies in this arena are cross-sectional, which makes it difficult to discern 
whether these illness representations caused maladjustment or were its consequence.  
Beliefs and Adherence 
Leventhal et al. (2003) postulate that the process of constructing a representation 
is symmetrical in that there is pressure to connect both abstract (disease labels and the 
meaning of illness) with concrete physical symptoms. That is, once patients are given a 
diagnosis, this hierarchical processing system compels them to search for symptoms that 
confirm the diagnosis. Similarly, experiencing symptoms motivates individuals to seek 
out a diagnosis. The interpretation of both sources of information leads to the formation 
of distinct thematic dimensions that comprise a cognitive illness representation and have 
important implications for treatment adherence. For example, in an actively treated 
sample of patients with hypertension, Meyer (1981, as cited in Leventhal, Nerenez & 
Steele, 1984) noted that the majority of the group used vacillations in a symptom to 
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monitor changes in their condition. Of the patients who believed that the treatment was 
acutely and directly affecting their symptoms, 70% were compliant with their medication. 
In contrast, only 31% of patients who felt the medications were not affecting their 
symptoms adhered to the treatment regimen, suggesting that perceived symptom 
reduction is an essential component of medication adherence.  These findings 
demonstrate the difficulty in promoting adherence to occult conditions that do not 
provide feedback in the form of symptom relief. 
 Horne and Weinman (2002) have argued that the CSM be extended to include 
beliefs about the necessity of a treatment and concern for the adverse effects of 
medications, because just as people have thoughts and beliefs about their illnesses, they 
have thoughts and beliefs about the treatments being offered (Horne, 1996). In a study of 
patients with several chronic disorders (i.e., asthma, diabetes, cardiac disease, and 
cancer), Horne and Weinman (1999) found that self- reported non-adherence was 
correlated with doubts about the necessity of the medication and concerns about potential 
adverse effects. Thus, treatment beliefs are now frequently assessed alongside illness 
beliefs, particularly when adherence is the outcome of interest. Beliefs, both about 
illnesses and their treatments, have been shown to predict adherence to, among others, 
HIV HAART treatment (Gellaitry et al., 2005), coronary treatments (Sud et al., 2005), 
asthma preventer medication adherence (Horne & Weinman, 2002), Type II diabetes 
treatments (Farmer, Kinmonth, & Sutton, 2006) and follow-up attendance at a lipid clinic 
(Avishay, Lishner, & Melamed, 2011). Moreover, a narrative systematic review of both 
patient and pharmacy level studies identified patients’ concerns for their treatment as well 
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as their perception that medication was not necessary as the primary reasons they did not 
fill their prescriptions (McHorney & Gadkari, 2010). 
While beliefs account for a considerable amount of variance in adherence 
(approximately a quarter of the variance as per Horne and Weinman, 2002), they do not 
tell the whole story. As Kuhl (2000) notes, cognitive representations and subsequent 
coping strategies cannot energize behaviour unless they have personal meaning. In other 
words, behavior may be influenced by factors beyond clinical efficacy, including how 
patients weigh the costs (e.g., side effects, inconvenience, and price) and benefits (e.g., 
immediate and long term symptom relief) of treatments, as well as how important these 
costs and benefits are to them. As has been argued (Chapman & Sonnenberg, 2000) 
patients choose whether or not to adhere, and so a better understanding of what drives the 
decision would be helpful. 
Decision Theory: What Really Matters to Patients? 
Decisions, ubiquitous to daily life, are important in so far as they direct 
behaviours. Ultimately, it is values and preferences that drive decisions and choices (an 
overt expression of what is important to people) and their associated behaviours. In 
addition, the value one places on the outcome motivates behaviours (Borders, 
Earleywine, & Huey, 2004). To make a decision, one has to consider the range of 
available options, each of which vary along a range of attributes. Each attribute, in turn, 
is differentially valued. Thus, decision making can be a cognitively demanding task, 
made even more difficult when stakes are high, as is the case with one’s health.   
Notably, decisions are easy when one outcome is clearly valued over another. For 
example, some individuals may value being medication free. But, these same individuals 
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may place more value on their eyesight than being medication free. Consequently, when 
faced with the decision as to whether to take their medication for glaucoma or risk 
becoming blind, they opt for the medication. Decisions become considerably more 
complicated when valued outcomes are equally preferred. In fact, often it is not until 
values come into conflict that individuals realize that they have competing values 
(Schwartz, 1996). For example, patients with asthma may not want to take a medication 
containing steroids but also want to improve their symptoms in the long term. When this 
occurs, people are required to make “trade-offs” between different attributes to ultimately 
make their choice and act upon it.   
Cognitively engaging in the trade-off process can be difficult and stressful 
(Tetlock, Peterson, & Lerner, 1996). First, individuals may be hesitant to make these 
types of decisions because the more important the value, the greater the potential for 
anticipatory regret over the sacrificed value (e.g., getting rid of a pet because one is 
allergic to it and the allergies exacerbate one’s asthma). Second, these types of decisions 
involve difficult cognitive comparisons, as it is often the case that options are not 
evaluated along the same metric. For example, how does one weigh the love of pet 
against one’s long term health? 
 The Value Pluralism Model (VPM; Tetlock 1986) was proposed to explain the 
cognitive strategies people use when it is necessary to make the kinds of trade-offs 
described above. The theory suggests that individuals use increasingly complicated 
coping strategies as trade-offs become increasingly difficult. If the value conflict is weak 
(i.e., if one value is clearly stronger than another) individuals will downplay the weaker 
value and focus on the stronger value (termed denial and bolstering). As the value 
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conflict increases, individuals begin to engage in lexicographic strategies in which they 
use the most important value as a criterion to rank order their options and select the 
highest ones. The most intense conflicts involve the comparison of interdimensional 
values and at this stage individuals will use explicit trade-off reasoning, deciding how 
much of one value they are willing to give up for the other (Tetlock, Peterson, & Lerner, 
1996).  
Trade-offs are inherent in decisions about whether or not to adhere to a prescribed 
treatment regimen. As Horne et al. (2007) note, “In real life, patients make choices 
between different attributes of the disease and its treatment, trading off one aspect for 
another (p. 11)”. Given that real life decisions involve trade-offs, health economists have 
developed techniques to quantify patients’ decisional “trade-offs” (Lanscar et al., 2007; 
Lanscar & Louviere, 2008). Economic models, however, assume that preferences are 
stable, consistent and rational (Phillips and Abramson, 1992). Because of the assumption 
that preferences remain stable, health economists have been less concerned with how 
preferences emerge. Moreover, classic economic theory has had difficulty explaining 
inconsistent choices (Phillips, Johnson, & Maddala, 2002), though it should be noted that 
the sub-field of behavioural economics, spawned by Kahneman and Tversky’s (1979) 
Nobel winning work on cognitive heuristics, has made some significant inroads in this 
domain. 
Measuring preferences. 
Measuring patient preferences for health care interventions and medications, 
however, has proven to be a significant challenge for health care researchers (Phillips et 
al., 2002). Many rely on attitude surveys in which individuals are asked to indicate the 
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extent to which they favour or disfavour a particular entity (Eagly & Chaiken, 1996). 
However, attitudes (i.e., judgments about the degree of like or dislike for something) are 
not the same as preferences. Preferences, by definition, involve the relative weighing of 
one option against another. For example, one may have a strong negative view/attitude of 
medication side effects. However, when given the choice between taking a medication 
with known side effects and taking no medication, people might choose medication 
because alleviating symptoms is more highly preferred than experiencing side effects.  
The theoretical differences between attitudes and preferences have 
methodological implications. The social psychology literature on attitude measurement is 
vast and the most widely used instruments tend to involve ranking or rating scales. 
However, ranking or rating scales do not allow for the assessment of trade-offs so 
relevant to daily life. Methodologies used in the field of economics more accurately 
assesses preferences and trade-offs. In particular, recent studies have employed a type of 
conjoint analysis, known as discrete choice experiments (DCEs).  
In DCE’s, individuals’ preferences are revealed through their pattern of choices 
when presented with multiple pairs of hypothetical scenarios. The technique assumes that 
a product or program (or for the current purposes, treatment) can be described by a range 
of characteristics or attributes (Lanscar et al., 2007). Each scenario contains a series of 
these attributes, varying along different levels. The combinations of the levels of each 
attribute vary across the scenarios such that when respondents make decisions about the 
gestalt of the scenarios, they are, in essence, making “trade-offs” between the attributes. 
By analyzing their pattern of choices, it is possible to glean the extent to which people 
value each attribute (McTaggart-Cowan et al., 2008).  
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The application of DCE methodology to discern patient/health care consumer 
preferences is relatively new. However, research suggests that it provides different 
information than attitude surveys. For example, Phillips et al. (2002) compared the 
preferences gleaned from an attitude survey and a conjoint analysis tasks. Their 
participants observed that they had to think ‘harder’ while doing the conjoint analysis 
task than attitude survey. And, while the approaches yielded some consistent results, 
there were halo effects in the attitude survey wherein respondents used evaluations of one 
attribute as a marker for other attributes. Consequently, an attribute that was ranked 
highly on the rating task turned out to be the least significant predictor of choice when 
participants were forced to make trade-offs in the conjoint analysis task.   
Given that DCEs allow for the consideration of the mix of outcome (e.g., 
improved health in 10 years) and process (e.g., treatment regimen characteristics) 
variables, DCEs serve as an ecologically valid measure of patient preferences and are 
useful to address policy relevant issues and patient preferences for medical treatments 
(Kellet, West, and Finlay, 2006). DCEs have also demonstrated good levels of both 
internal and convergent validity and have been shown to be relatively insensitive to the 
ordering and levels of attributes (Ryan, Bate, Eastmond, & Ludbrook, 2001). As such, 
DCE’s  may help us better to understand the role that complex tradeoffs play in patients’ 
decision making about medical treatments,  such as the one required for asthma. For 
example, an individual with asthma may believe (correctly) that using a corticosteroid 
inhaler on a daily basis will prevent subsequent attacks, and also believe (correctly) that 
corticosteroid use is associated with a slight risk of long term effects, such as bone loss.  
However, the extent to which this patient uses his/her steroid inhaler on a daily basis (as 
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prescribed) may be driven in part by the relative ‘weight’ he/she places on these two 
factors, as well as on other treatment features (e.g., number of inhalers, immediate versus 
delayed symptom relief, frequency of dosing, etc.).   
Notably, DCE research tends to be descriptive rather than predictive in nature. 
That is, studies employing this technique have sought to describe group characteristics of 
patients. This has limited the use of this methodology in psychology, which primarily is 
concerned with processes and with predicting behaviour at the level of the individual 
rather than group. Data at the group level and individual level both have their limitations. 
Whereas aggregate data may over-generalize preferences, individual data may paint a 
mosaic of preference that cannot easily be used by policy makers to help guide the 
development of cost effective interventions. There is, therefore, a potential benefit of an 
intermediate approach, whereby one captures the heterogeneity of preferences within a 
large group by identifying subgroups with specific preference profiles. To date, only a 
couple of studies have extracted subgroup data from a conjoint analysis. Namely, Singh, 
Cuttler, Shin, Silvers and Neuhauser (1998) found five preference patterns among 
patients considering growth hormone therapy and Cunningham et al. (2008) identified 
subgroups of parents based on their preferences for children’s mental health care. 
However, both studies are descriptive in nature in that the predictive value of these 
preference patterns was not examined. 
 This study will apply this methodology within a predictive model, by examining 
the extent to which subgroup differences in preferences about various asthma-related 
states and treatment characteristics predict adherence to preventer medication. 
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Asthma: A Case in Point for Studying Knowledge, Beliefs and Preferences 
Asthma is a serious illness, resulting from both chronic inflammation and 
intermittent constriction of the airways (Holgate, Price, & Valovirta, 2006), the latter 
producing the rapid onset of respiratory symptoms (i.e., asthma attack) such as 
breathlessness, coughing and wheezing. In contrast, while inflammation does not directly 
cause acute symptoms, it does so indirectly by increasing the frequency of 
bronchoconstrictive episodes. Thus, given the phasic (bronchoconstrictive) and tonic 
(inflammatory) nature of its underlying pathophysiological processes, asthma treatment 
guidelines stipulate the overall goals of asthma control should include both day to day 
symptom control as well as minimizing future risk (O’Bryne, 2010).  
Accordingly, optimal management of asthma involves the use of both 
corticosteroids as a preventive medication to decrease the chronic inflammation, as well 
as the use of rescue/reliever medications to alleviate the constriction of the airways and 
associated symptoms of an acute attack (Ohm & Aaronson, 2006). Rescue medications, 
which reduce broncoconstriction, produce an immediate improvement in symptoms. As 
such, they are inherently negatively reinforcing, which likely means patients do not need 
convincing or reminding to use their rescue inhalers. In contrast, preventer medications, 
typically prescribed for daily use, target the underlying pathophysiology (airway 
inflammation) and do not provide immediate symptom relief (i.e., are not negatively 
reinforcing). Recently, a new class of “combination inhalers”, which combine preventer 
and rescue medications in one inhaled dose, was introduced. This regimen requires 
patients to take a prescribed dose regularly for the subsequent rescue puffs to be effective 
(C. Licskai, personal communication, October 2008). 
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The incidence of asthma has increased substantially over the past 20 years and the 
increased health care costs, missed days of work and lost productivity pose a heavy 
economic burden (WHO, 2003). Non-adherence to preventer medications is widespread, 
and adherence to asthma medications is the poorest of that for all other chronic medical 
conditions (Claxton, Cramer, & Pierce, 2001; DiMatteo, 2004). Despite physicians’ best 
efforts to prescribe according to empirically supported treatment guidelines (in fact, the 
highest for any disorder), patient non-adherence rates to preventer medications were 37 
percent and 42 percent for adults and children, respectively (Bender, Milgrom, & Rand, 
1997; Thier et al., 2008). In other words, there is a large gap between the efficacy of 
treatments and their use in controlling the disorder (Hancox et al., 2010).  
As such, most individuals with asthma experience an inadequate level of control, 
which leads to unnecessarily high morbidity, mortality, and health care burden (Anis et 
al., 2001; Horne, 2006). These increases are unwarranted because asthma is a disease that 
can be effectively controlled through self-management.  
Factors Affecting Asthma Adherence 
 According to the World Health Organization (2003), non-adherence to inhaled 
corticosteroids results from a number of factors, broadly classified into five categories: 
(1) Socioeconomic factors (poverty, family dysfunction, fear of health system, cultural 
and lay beliefs about illness), (2) Health care factors (health care providers’ inadequate 
knowledge and lack of training in behaviour change principles), (3) Condition- related 
factors (inadequate understanding of the disease), (4) Therapy related factors (complexity 
of treatment, duration of therapy, adverse effects of treatment), and (5) Patient related 
factors (forgetfulness, misunderstanding, drug abuse). In addition, patient personality 
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factors, such as having a high external locus of control, being highly extroverted, as well 
as scoring low on social desirability measures, have been demonstrated to be associated 
with poor adherence to asthma medications and monitoring (Halimi et al., 2010). 
The WHO goes on to suggest that guidelines for the management of asthma 
should consider these factors and argues that the majority of factors (2 -5) can be 
remedied by asthma education programs. Consequently, policy makers and government 
officials have tried to narrow the efficacy-effectiveness gap for asthma treatments by 
advocating and implementing educational programs to enhance patients’ knowledge 
about asthma and its treatment (Allen & Jones, 1998; Schaffer & Yarandi, 2007). 
Current Asthma Adherence Intervention Programs 
While recent reviews have suggested that interventions need to be multifaceted 
and incorporate behavioural and educational components (Haynes et al., 2008; Roter et 
al., 1998; van Dulmen et al., 2008), the majority of asthma adherence interventions are 
solely focused on education. At the recommendation of the National Asthma Education 
Prevention Program (Bethesda, 1997), standard content areas in asthma education 
programs include basic information about  (1) the pathophysiology of the disease, (2) the  
different roles of preventer versus relief medications, (3) the proper techniques for using 
inhalers, (4) self-monitoring approaches, and  (5) ways to reduce environmental triggers 
(Janson, Hardie, Fahy, & Boushey, 2001). However, evidence for the effectiveness of 
knowledge-focused interventions is mixed, at best. As has previously been argued, this is 
likely due to the fact that, to date, these interventions have addressed neither beliefs nor 
preferences. In examining these interventions, it is essential to differentiate those that 
involve purely educational interventions (knowledge interventions) and those that target 
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self-management (i.e., behaviours), as they can be expected to produce different 
outcomes (Leventhal & Cameron, 1987). 
Knowledge interventions.  
Evidence for the effectiveness of knowledge- based interventions on preventer 
medication adherence is mixed. In a meta-analysis of the effectiveness of asthma 
education programs, Bender, Milgrom and Apter (2003) cited nine studies demonstrating 
significant enhancement of asthma control. Yet, Ho and colleagues (2003) found no 
relationship between knowledge and adherence to an asthma treatment regimen. 
Moreover, Bailey et al. (1999) found that patients receiving educational materials and one 
hour of individualized education sessions were no different from a standard care group in 
terms of functional status at follow-up.  A similar null finding recently was observed in a 
sample of adults above the age of 65 (Baptist, Talreja, Clark, 2011). Furthermore, several 
studies have shown improvements in knowledge following an educational intervention 
yet no changes in asthma control or adherence (Cote et al., 1997; Garrett et al., 1994; 
Lopez-Vina & Castillo-Arevalo 2000).  
Notably, the shortcomings associated with knowledge measures may obfuscate 
the ability to interpret the effect of knowledge based interventions. For example, Allen 
and Jones (1998) developed a general knowledge of asthma questionnaire, which served 
as the primary outcome measure in an effectiveness trial of an asthma education program. 
The survey, however, did not differentially assess knowledge about preventer versus 
rescue medications nor did it assess knowledge about how these two classes of 
medications target the pathophysiology of asthma. A more recently developed asthma 
questionnaire (Schaffer & Yarandi, 2007) rectified some of the problems associated with 
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earlier surveys, but continues to have a number of limitations including the failure to 
address knowledge about asthma pathophysiology as well as the absence of items about 
combination inhalers, which have properties of both preventer and rescue medications.  
The failure to assess patients’ knowledge of asthma pathophysiology is 
problematic, in that it’s crucial to understanding why preventer medications are needed. 
Taylor and Bower (2004), for example, demonstrated that giving people an explanation 
as to why they should follow instructions enhances compliance. Thus, an intellectual 
understanding of the “why” may be particularly important for adherence to medications 
that, like asthma preventer medications, do not immediately yield symptom 
improvement. 
Self-management interventions. 
According to the World Health Organization (2003), self-management programs 
have been shown to be cost-effective, reducing both direct (hospitalizations) and indirect 
(loss of productivity) costs. However, individual studies seem to suggest otherwise. For 
example, Bailey et al. (1999) randomly assigned 236 asthmatic patients to receive either 
(1) usual care, (2) an asthma self-management skill-oriented program consisting of a 
minimum of two group sessions in which they focused on a workbook about asthma 
triggers and care services as well as how to use a peak flow meter in addition to follow-
up reminder phone calls at one, two and four weeks, or (3) a shorter version of the 
workbook and a 15 minute session with a nurse educator. Despite the investment of time, 
neither intervention group improved more than the standard care group. 
Similar null findings were observed by Morice and Wrench (2001) who 
randomized 80 patients with acute asthma admitted to hospital into two groups: (1) 
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control group who received standard care, and (2) an intervention group who received a 
minimum of two one-on-one 30 minute sessions with a nurse educator with the goal of 
developing an individualized self-management plan. Hospital re-admission rate, their 
primary outcome variable, was the same for both groups four months post-discharge. 
However, as the authors acknowledge, the study may have been insufficiently powered to 
adequately assess group differences. Levy et al. (2000) delivered a similarly complex and 
controlled nurse educator delivered intervention. The intervention improved self-reported 
adherence as well as symptoms at six month follow-up amongst the severe asthmatic 
patients in their sample, but not in those with mild asthma.  
Conclusion: Knowledge is not enough.  
Despite these mixed findings, experts rightly note that correct knowledge is a   
prerequisite for self-management (Gibson & Boulett, 2001; Gibson, Ram, & Powell, 
2003). However, studies that have demonstrated that educational interventions focusing 
on these content areas improve asthma control (e.g. Bonne et al., 2002; Couturaud et al., 
2002) all have entailed time consuming educational programs that take place over a series 
of weeks or even months. Indeed, coverage of all content areas dictated by educational 
guidelines would require a significant amount of clinician and patient time, making the 
cost-effectiveness and even patient attendance of the educational program themselves 
potential concerns. 
What has become clear is that educational interventions alone are not sufficient. 
Accordingly, recent adherence intervention programs have begun to incorporate client-
specific risk factors to improve adherence (Jinhee et al., 2010). Moreover, Elliot (2006) 
suggests that knowledge based interventions, while providing patients with correct 
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factual information fail to address patients’ misguided beliefs about asthma, thereby 
limiting their effectiveness. The psychological literature on lay illness beliefs and models 
helps one to understand why, despite increased knowledge following education programs, 
a patient’s behaviour may remain unchanged.   
Beliefs about Asthma 
The proper use of asthma medications requires patients to understand both the 
chronic (tonic) nature of the disease as well as the episodic (phasic) exacerbation of the 
symptoms associated with the disorder. Most patients, however, view asthma as a series 
of discrete acute illnesses, separated by what appear to be (given that they are 
asymptomatic) normal, disease-free time frames (Insel, Meek & Leventhal, 2005). Halm, 
Mora, and Leventhal (2006) found that 53% of asthmatic patients believed that their 
asthma was episodic because they had symptoms only occasionally. In essence, patients 
subscribed to the view that when they have no symptoms, they do not have asthma. This 
poses a significant problem for medication adherence, as patients with asthma who hold 
this belief adhere less to their preventative treatment regimens (Halm et al., 2006; Horne 
& Weinman, 2002). As a case in point, Jessop and Rutter (2003) explored the role of 
illness beliefs on asthma medication adherence and found that those who believed their 
asthma could be controlled were more likely to adhere to their preventer medications, 
whereas those who attributed their asthma symptoms to external causes (e.g., 
environmental pathogens) were less likely to adhere.   
Asthma specific treatment beliefs that drive adherence to corticosteroid inhalers 
may be particularly instructive.  As noted earlier, corticosteroids, prescribed as 
‘preventer’ medications for asthma, offer no immediate symptom relief. Rather, they 
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afford only long-term benefits (Hand & Bradley, 1996), decreasing the number of future 
asthma attacks by improving lung functioning and presumably preventing structural 
airway changes (Bender et al., 1997). Also as noted earlier, given that preventer 
medications are not negatively reinforcing (i.e., they do not immediately remove 
symptoms), their sustained use would, arguably, need to be guided and driven by internal 
working models (Jessop & Rutter, 2003).  
Research within the CSM framework has shown that beliefs about the necessity of 
a treatment and concerns about the risks associated with it correlate with adherence to 
asthma preventer medications. Namely, Horne and Weinman (2002) found that treatment 
beliefs partially mediated the relationship between illness representations and adherence 
to asthma preventer medications. Moreover, they demonstrated that non-adherence was 
associated with greater doubts about the necessity of the medications, concerns about its 
potential side effects and perceived negative consequences of the illness.   
In a recent position paper, Horne et al. (2007) argue that “…it may be possible for 
healthcare professionals to improve asthma control [i.e., consistent use of inhaled 
corticosteroids] by achieving a greater understanding of the patient’s perspective” (p. 9).  
Certainly, exploring patients’ illness models would facilitate understanding and improve 
current asthma education protocols. In fact, there have been efforts to target and alter 
patients’ illness models to effect behavioural outcome. For example, Petrie, Cameron, 
Ellis, Buick, and Weinman (2002) conducted a brief hospital intervention for patients 
who had recently suffered a myocardial infarction (MI) that targeted individuals’ 
negative illness perceptions (as assessed by the Illness Perception Questionnaire) to 
specifically alter beliefs about the timeline of recovery and consequences of having an 
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MI (e.g., that individuals would have to significantly reduce exercise activity over the 
long term). They found that those receiving the intervention returned to work faster and 
reported fewer symptoms at follow-up than those in the control group. Similarly, in a 
prospective study, Moss-Morris et al. (2007) found that illness representations changed as 
a function of a cognitive-behavioural intervention for pain, and that reductions in beliefs 
about the negative consequences predicted improved physical functioning and reductions 
in emotional representations and also found that an improved sense of coherence 
predicted psychological functioning. 
 While statistically significant, the correlations between treatment beliefs and 
adherence are quite modest, ranging from only .31 to .43 (Horne & Weinman, 2002). 
Why might beliefs, in and of themselves, account for no more than 21 percent of the 
variance in adherence? It may be because behavior is driven not only by patients’ beliefs 
about the costs (e.g., side effects, inconvenience, and price) and benefits (e.g., immediate 
and long term symptom relief) of treatments, but also how important each of the costs 
and benefits are to them. 
This weighing of risks and benefits may be especially important for asthma 
preventer medications, which, while providing relief, also include a number of inhaled 
corticosteroids that may result in side effects (McTaggart-Cowan et al., 2008) and daily 
exposure to steroid medication. The decision to take preventer medications, therefore, 
involves balancing the probability of a desirable outcome (e.g., future symptom 
reduction) against that of an undesirable outcome (e.g., current and long term side 
effects). The health economic and marketing literatures provide useful frameworks for 
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examining the role that patient preferences may play in adherence to preventer 
medication. 
Assessing what Matters to Patients with Asthma 
The use of preference-based models in health care is relatively new. However, a 
few studies have applied a DCE paradigm to better understand the trade-offs patients 
with asthma are willing to make both in terms of symptoms as well as treatment. For 
example, McKenzie, Cairns, and Osman (2001) presented patients with moderate to 
severe asthma with a series of pairs of scenarios characterized by different combinations 
of symptoms, including cough, breathlessness, wheeze, chest tightness and sleep 
disturbance. Analysis of respondents’ choices suggested that, as a group, participants saw 
cough as the most important symptom to target and reduce. The authors suggest that 
identifying patient preferences for symptom alleviation has important implications for 
treatment development.  
In terms of treatment attributes, Haughney et al. (2007) administered a DCE to 
147 patients with asthma. Based on qualitative interviews, the six attributes deemed most 
important for asthma self-management were: (1) symptom relief, (2) steroid dose, (3) 
asthma action plan, (4) management of acute exacerbations, (5) number of inhalers, and 
(6) response to deterioration. The overall relative importance of the attributes was 
assessed. As a group, participants were willing to trade some symptom relief for a 
simpler treatment regimen involving fewer inhalers and a lower dose of steroid.   
Also using a DCE paradigm, McTaggart-Cowan and colleagues (2008) assessed 
patient preferences for various forms of asthma treatment. Participants were provided 
with scenarios which varied with respect to the degree of symptom free days, side effects 
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(i.e., the number of tremors/palpitations per month and oral thrush episodes per year), out 
of pocket costs, number of medications, and frequency of use per day. As did Haughney 
et al. (2007), they found that patients, as a group, were willing to trade symptom free 
days for a more convenient regimen with a decreased number of side effects.   
With the introduction of the combination inhalers, however, new variables must 
be considered. For instance, the Symbicort and Advair combination inhalers require 
patients to carry only one inhaler (likely seen as an advantage by patients) yet it delivers a 
larger dose of corticosteroids than most stand-alone preventer inhalers (which might be 
seen as a disadvantage). In addition, for the “reliever” portion to work effectively, 
patients must also take their medications at set times each day, rather than “as needed”, as 
per standard reliever medications. Therefore, preferences for steroid dosing, frequency of 
medication use and complexity (one versus two inhalers) must also be assessed. 
Knowledge, Beliefs and Preferences for Asthma: Can We Study Them Together? 
The Multiattribute Utility Model (MAU) is based on the premise that decisions 
are complex and that different factors are hierarchically weighted to influence ultimate 
behaviour (Chang, Chan, Chang, Yang, & Chen, 2008). This model provides a good 
framework for examining non-adherence to asthma medications for two reasons. First, it 
stipulates that many elements are incorporated into a decision. Second, it demonstrates 
that the elements influencing a decision form a hierarchical structure such that some are 
more important to the ultimate behaviour than others. For example, knowledge about 
asthma medications may not be as important to the decision making process as patients’ 
preferences for treatment. The methodology adopted most typically by MAU researchers 
requires patients to explicitly state the importance of each category in their decision 
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making process. Given that patients could not be expected to have insight into the relative 
importance of their knowledge, beliefs or preferences in their decision making process, 
the methodology of MAU research is unsuitable for use in this study. The theory, 
however, offers a rationale for exploring the individual roles and combined effects of 
knowledge, illness and treatment beliefs and preference on adherence behaviour.  
Study Rationale and Hypotheses 
Although effective treatments for asthma have been developed and have been 
shown to reduce asthma morbidity and mortality (WHO, 2003), their utility is highly 
contingent on proper use by patients. That is, efficacy does not translate to effectiveness. 
This is why an understanding of factors governing adherence is a crucial element of 
health research.  However, as Van Dulmen et al. (2007) have observed, adherence 
research over the last decade has remained largely atheoretical or driven by theories that 
are too circumscribed in scope.   
As the previous review indicates, proper asthma preventer medication use may be 
driven by a number of factors, including the degree of knowledge about proper inhaler 
technique and asthma pathophysiology, beliefs about asthma and its treatment, and 
preferences for various health states and treatment regimens. Efforts to enhance patient 
adherence to preventer medication that take patient knowledge, beliefs, and preferences 
into account are likely to be more successful than those that do not and research on how 
these three elements work additively to produce adherence could be instructive.  
Unfortunately, to date, these three components have been studied in relative isolation, in 
the nursing, health psychology and health economics/medical decision making literature, 
respectively.  
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Accordingly, the proposed study will seek to integrate these three lines of 
research and model their additive effects on adherence behaviours. Specifically, it is 
predicted that: 
Hypothesis 1: Increased knowledge about the pathophysiology of asthma will predict 
adherence to preventer medication. 
Hypothesis 2: Beliefs about the chronicity of the disease, amount of control, severity of 
symptoms, sense of coherence and necessity of preventer medications will predict 
increased treatment adherence. 
Hypothesis 3: Patient preferences will predict adherence. In particular, those who value 
long term outcomes will be more adherent to their preventer medications. 
Hypothesis 4: Patient preferences for elements of their medication will predict adherence 
above and beyond that predicted by knowledge of their disease and beliefs about the 
disease and its treatment.  
In addition, this study will extend the DCE methodology by generating preference 
parameters at a subgroup (rather than overall group) level. To my knowledge, this will be 
the second study in the adult health care domain (the first being Singh et al., 1998) to 
attempt to extract subgroup data from a conjoint analysis technique, and the first to apply 
the extracted data to predicting behavioural outcomes. Accordingly, an exploratory 
analysis will be conducted to assess the degree of convergence between patients’ 
explicitly stated preferences (as measured by a standard 10 item rating scale) and their 
implicit preferences, as indicated by the discrete choice preference parameters and their 
differential effects on adherence. 
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The study was conducted in four phases: (1) Knowledge questionnaire 
modification, (2) Preference measure development, (3) In-field pilot study of 
questionnaires and, (4) Main study.  
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Chapter II: Methods and Results of Phases 1 - 3  
Phase I: Knowledge Questionnaire Modification 
This phase consisted of three stages: (1) Item modification and generation, (2) 
Assessment of item relevance and clarity, (3) Assessment of content validity. 
Stage 1: Item modification and generation.   
Currently, the most comprehensive self-report measure of asthma knowledge is 
the Asthma Knowledge Questionnaire developed by Schaffer and Yarandi (2007). The 24 
item self-report, True-False measure taps the five content areas specified as necessary for 
asthma self-management by the National Asthma Education and Prevention Program: (1) 
Asthma pathophysiology, (2) Roles of medications, (3) Skills of inhaler use, (4) 
Environmental Controls, and (5) Rescue Medication Information. The total scale 
demonstrates a reasonable internal consistency of .69 (Schaffer and Yarandi, 2007). 
 In reviewing this measure with the consulting respirologist (C. Lisckai), however, 
it was apparent that knowledge of asthma pathophysiology, arguably the most important 
for understanding the rationale behind one’s prescribed self-management regimen, was 
not adequately assessed in the original scale. Accordingly, four items pertaining to the  
pathophysiology of asthma either were generated or taken from other sources: (1) Having 
swollen airways does not increase the risk of having an asthma attack (F; New), (2) 
During an asthma attack, the muscles around the airways tighten and the airways 
become narrow (T; as per Allen & Jones, 1998), (3) Asthma is a disease that comes and 
goes (F; New), and (4) If asthma attacks stop, it means that the asthma has gone away (F; 
as per Grant et al., 1999).  
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In addition, the questions on the original scale were worded in either personal 
(i.e., “you”, “your”) or general (i.e., “people”) terms. We changed personal to general 
wording to increase the likelihood that responses to the items would tap global 
knowledge about asthma in general rather than reflecting the particulars of an 
individual’s condition.  Thus, items such as “Keeping your bedroom windows open at 
night will help prevent asthma symptoms” were changed to “Keeping bedroom windows 
open at night will help prevent asthma attacks”. Finally, two items were eliminated. The 
first, “Getting rid of cockroaches in your house may help your asthma” was removed 
because it applies to densely populated cities and was deemed irrelevant for our sample, 
largely drawn from small to mid-sized urban and rural communities. The second, “To use 
an asthma inhaler correctly, you need to breathe in as you press down on the inhaler” 
was removed as our consulting physician deemed it inaccurate.    
We also included an “Unsure” response option to discourage guessing, 
particularly by those prescribed single inhalers who thus might not be expected to have 
knowledge about combined inhalers. 
The interim measure (Appendix A) consisted of 30 items that were then rated for 
relevance and clarity by a group of clinician experts (Phase 2).  Based on their feedback, 
the scale was further altered and the 36 items of the revised scale were then rated by a 
group of graduate students for content validity (Phase 3). These stages are outlined 
below.   
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Stage 2: Assessment of item relevance and clarity. 
Method. 
Participants.  A panel of approximately 35 respirologists, allergists, and/or 
asthma nurse educators from clinics across Ontario and Quebec were recruited by C. 
Lisckai, the consulting respirologist. 
Procedure. Panelists, by means of an on-line survey, were presented with items 
from 6 content areas, including pathophysiology, medications and their effects, 
technique, symptoms, environmental triggers, and other asthma facts, purportedly 
covered by the survey.  They were asked to rate the relevance/clarity of each item (1 = 
not relevant, 2 = confusing and cannot be assessed without revisions, 3 = relevant but 
requires minor changes, or 4 = succinct and relevant to content area; as per Schaffer & 
Yarandi, 2007). Space was also provided for written feedback.  
Results. 
  Twenty-one of the thirty-five (a response rate of 60 percent) expert reviewers 
responded. The results are presented in Appendix A. All items received a mean rating 
above 3.32 (out of 4), suggesting that, on balance, they were deemed acceptable. Minor 
semantic modifications were made and conceptual issues were readdressed with the 
consulting physician (C. Lisckai). To enhance clarity, two items (#15 and  #19) each 
were subdivided into two questions and one item (#23) was deleted because it was 
deemed inaccurate. Moreover, based on the panelists’ comments, it was clear that more 
questions were needed to address knowledge about combination inhalers. As such, in 
collaboration with the consulting physician, the following two questions were added, (1) 
A combination medication includes two types of medication to control asthma (T), (2) A 
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person with asthma can use a combination inhaler for quick relief, even if they do not use 
it every day (F). In addition, the symptom and technique subscales were deemed to need 
more items and so the following three questions were added: (1) Chest tightness is a 
common symptom of asthma (T), (2) People with asthma get relief from their symptoms 
at night (F), (3) Asthma attacks often come on suddenly without any warning (F).  
The revised scale, consisting of 36 items, was then evaluated for content validity, 
as described below. 
Stage 3: Assessment of content validity. 
Method. 
Participants.   Raters were 11 graduate students in psychology from the 
University of Western Ontario and Concordia University, ten of whom had training in 
survey design. The raters were not expected to have much previous knowledge about 
asthma and indeed rated themselves as only slightly knowledgeable (i.e., mean rating = 
4.36 on a 10 point Likert scale, where 0 = no knowledge and 10 = extremely 
knowledgeable).  
Procedure. The raters were presented with six content areas and descriptions of 
each (See Table 1, column 2) and were asked to indicate which of the six constructs each 
item was most consistent with. They were instructed to select “other” only if they were 
really unsure which category the item should be placed.  
Results. 
For an item to be considered indicative of a given content area, at least seven of 
the eleven raters had to place the item in its corresponding category. The items they rated 
pertaining to each category are presented in Table 1. The amount of agreement indicated  
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Table 1 
 
Knowledge Domain Descriptions and Questions 
Domain Description  Allocated Questions after Graduate Student Ratings 
Pathophysiology Physiology and functional changes 
associated with asthma and its acute 
exacerbations, and about the course 
of the disease in general. 
1. People with asthma can have swollen and inflamed airways even 
when they feel well. (T) 
2. Asthma is a disease that does not last for a long time. (F) 
3. It is possible for someone’s asthma to be worse without them noticing 
a change in their breathing. (T) 
4. Asthma can be cured. (F) 
5. During an asthma attack, the muscles around the airways tighten and 
the airways become narrow. (T) 
6. Having swollen airways does not increase the risk of having an 
asthma attack. (F) 
7. When someone’s asthma attack is over, it means that the asthma has 
gone away. (F) 
8. Untreated asthma can cause death. (T) 
9. If a person does not have asthma by age 40, they will never get it. (F)  
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Domain Description  Allocated Questions after Graduate Student Ratings 
Medication and 
Effects 
Purpose and effects of asthma 
medications. The three types of 
asthma medication include: (1) 
Inhaler steroid (controller) 
medications- used to prevent asthma 
attacks; (2) Quick relief medications- 
used to relieve an asthma attack once 
they begin; (3) Combination inhalers- 
combine control and relief 
medications in one inhaler. 
1. Quick relief medications should be taken every day, even if people 
are feeling well. (F) 
2. Inhaled steroids (controller medications) prevent asthma attacks. (T) 
3. People with asthma should wait until their symptoms are really bad 
before using a quick relief medication. (F) 
4. A person with asthma can use a combination inhaler for quick relief, 
even if they do not use it every day. (F) 
5. Taking an antibiotic such as penicillin will help most bad asthma 
attacks. (F) 
6. People may not notice improvements in their breathing for 1-4 weeks 
after they start using inhaled steroids. (T) 
7. The purpose of steroid medication inhalers is to stop an asthma attack 
when it happens. (F) 
8. People with asthma can usually help control their symptoms by 
taking the appropriate medications. (T) 
9. It is okay to take inhaled steroids (controllers) only when people 
notice their symptoms getting worse.  (F) 
10. Inhaled steroids will relieve an asthma attack within 20 minutes. (F) 
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Domain Description  Allocated Questions after Graduate Student Ratings 
  11. People with asthma do not need to take their daily inhaled steroids 
(controller) if they feel well.  (F) 
12. A combination inhaler includes two types of medication to control 
asthma. (T) 
Technique  The way technical skills and 
procedural information needed to 
effectively use an asthma inhaler. 
1. People with asthma should try to hold their breath for 8-10 seconds 
after each puff of their inhaler. (T) 
2. People with asthma should rinse and gargle after each use of their 
inhaled (controller) steroid. (T) 
3. People with asthma should wait about one minute between puffs of 
their quick relief medication. (T) 
4. People with asthma should breathe out partially, but not fully, just 
before taking their medication. (F) 
Environmental 
Triggers 
Environmental conditions (e.g., 
irritants, allergens) that can worsen 
asthma symptoms. 
1. Molds can trigger asthma symptoms for some people. (T) 
2. Being around others who smoke does not bother a person’s asthma, 
so long as they do not smoke themselves. (F) 
3. Cold air can make asthma symptoms worse. (T) 
4. People can usually help control their symptoms by avoiding things 
(triggers) that make their asthma worse. (T) 
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Domain Description  Allocated Questions after Graduate Student Ratings 
  5. People with asthma should avoid exercise.(F) 
6. Keeping bedroom windows open at night will help prevent asthma 
attacks. (F) 
Symptoms Changes in the body or its function 
experienced by the patient and 
indicative of disease. 
1. Frequent coughing can be a symptom of asthma. (T) 
2. Asthma may cause wheezing during exercise. (T) 
3. Chest tightness is a common symptom of asthma. (T) 
4. People with asthma get relief from their symptoms at night. (F) 
5. Asthma attacks often come on suddenly without any warning. (F) 
Other Information about asthma that does 
not fit into any of the other five 
categories. 
None 
 
 
 
 
 
  
40 
good content validity, and so the version rated by the students was not altered further. 
Accordingly, the final scale (See Appendix B) consisted of 36 items, with nine in the 
disease category, 12 in the medication category, 4 in the technique category, 6 in the 
environment category, and 5 in the symptoms category. 
Phase II: Development of the Preference Measures 
Method. 
Discrete choice scenarios. 
McKenzie, Cairns and Osman (2001) stipulate that the process of creating discrete 
choice scenarios involves a series of steps. These steps include: (1) Identifying the 
attributes important to the population in question, (2) Reducing the scenarios to a 
manageable number of combinations, and (3) Deciding how to establish preferences 
based on the selected scenarios. As per previously conducted DCEs in health care 
(Lanscar et al., 2007), the attributes and their  levels adopted for this study reflected 
common variations in asthma treatments and their outcomes,  informed by consultations 
with two respiratory specialists (C. Lisckai and N. Patterson), a thorough literature 
review and perusal of asthma treatment guidelines. The factors were then culled to the 
seven pertaining most directly to the study’s main questions. All (binary) attribute levels 
were plausible and clinically relevant. The attributes and their levels were as follows:  
1. Long-term outcomes (Asthma will be the same in 10 years versus worse in 10 
years)  
2. Short-term consequences (Fewer asthma attacks over next six months versus 
the same number of attacks over the next six months)  
3. Immediate effects (Relief within 5 minutes versus Relief within 30 minutes)  
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4. Side-effects (Major/ Long-term versus Minor/Short-term)  
5. Fixed dosing (Every day at set times and more if I need it versus Only when 
needed)  
6. Number of Inhalers (1 versus 2)  
7. Dose of Steroid (High versus Low) 
Given that DCEs applied to consumers’ health care decision-making have involved as 
many as 12 factors (Lanscar & Louviere, 2008), the cognitive load for participants 
imposed by a seven-factor manipulation was deemed reasonable.  
The most common DCE design involves factors each having only two levels, thus 
referred to as a ‘binary attribute design’. To keep the design and resultant data analysis 
reasonable, the binary approach was used here as well. Although a limitation of the 
binary attribute design is that it cannot generate non-linear effects, it can estimate main 
factor effects, thereby capable of providing meaningful information (Street & Burgess, 
2007). The present study is unique in that unlike previous DCE studies applied to asthma 
or its treatment, these scenarios captured treatment features (complexity and frequency) 
that differentiate combination therapy from regular asthma treatments.    
Rating scale development. 
 To date, the standard approach to eliciting patient preferences is for participants to 
rate individual attributes with respect to their importance (Phillips, Johnson, & Maddala, 
2002; Ryan et al., 2001; Singh et al., 1998). To compare information derived from these 
rating scales with those from DCEs, we generated items that captured the attributes of 
interest and wrote instructions designed to encourage participants to think about the 
“trade-offs” involved in making a decision about taking a medication. The intent was for 
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these rating scales to explicitly gauge the variables assessed more implicitly in the 
discrete choice experiments. The instructions read: “There are different things people 
have to weigh when deciding whether or not to use an inhaler. For example, while some 
people with asthma may worry about a medication’s side effects, they feel that the 
benefits from the medication are worth the risk. Others are not so sure. We are interested 
in what kinds of things you consider when deciding whether or not to use an inhaler. 
Trying to keep the list of things below in mind, for each item, please circle on the scale 
the number that best describes the importance of each of the following.”  The scale was 
designed such that 1 = Least important and 10 = Most important. Items included: (1) The 
number of inhalers I need to take, (2) Having to take an inhaler every day, (3) Being able 
to take an inhaler only when I need it, (4) Possible short-term side effects of the inhaler, 
(5) Possible long-term side effects of the inhaler, (6) Risk of addiction from the inhaler, 
(7) The inhaler can take my symptoms away within minutes, (8) The inhaler can help 
keep my asthma from getting worse over the next 10 years, (9) The inhaler can reduce 
how often I get asthma attacks over the next 6 months, (10) The cost of the inhaler. The 
scale is presented in Appendix C. 
Results. 
The scenarios were developed for a partial factorial design. Seven attributes each 
with two levels (i.e., 27) yielded 128 permutations. By means of SPSS ORTHOPLAN 
and Addelman’s formula (1962), the scenarios were culled into 8 orthogonal scenarios. 
Using the “shifted-set” method (Chrzan & Orme, 2000), another 8 scenarios were 
generated and paired to create the choice sets. The sets met the three criteria for 
generating a DCE (McTaggart-Cowan et al., 2007), namely: (1) orthogonality, to ensure 
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a minimum amount of overlap between the attributes, (2) level balance, so that all levels 
occurred  with equal frequency, and (3) minimum overlap, such that no attribute appeared 
twice within the same choice set. Moreover, care was taken to ensure that all level 
combinations were plausible treatment options. 
The choice sets and instructions are presented in Appendix D. 
Phase III: In-Field Feasibility Study 
Method. 
 To ensure that the DCE task and self-report measures were comprehensible to the 
target population, a pilot study was conducted. All procedures were approved by the 
University of Western Ontario Health Sciences Review Board (Protocol # 16500E, 
Appendix E). 
Participants.  
All consecutive patients over the age of 18 attending the asthma clinic reporting 
that they could understand written English were invited to participate. Of the roughly 70 
individuals approached, 56 (for a response rate of 80%) individuals consented to 
participate.  
Measures. 
 Asthma Knowledge Questionnaire. 
 This self-report measure developed in Phase I (See Appendix B) consisted of 36 
items assessing participants’ knowledge across five domains: (1) Pathophysiology of the 
disease, (2) Knowledge of Medication, (3) Technique, (4) Environmental Triggers, and 
(5) Asthma symptoms. Participants were asked to record the extent to which they 
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believed each item was true or false. There was an “unsure” option to discourage 
guessing. 
 Discrete Choice Experiment (DCE) measure. 
Participants were presented with the same eight discrete choice sets (16 scenarios) 
developed in Phase II (Appendix D) which varied along the seven factors relevant to the 
study hypotheses.  
 Rating scales. 
Participants were presented with the 10 item rating scale developed in Phase II 
(Appendix C) with the preamble described above. To ensure that overt ratings did not 
influence more implicit ratings associated with the DCE, half the participants were given 
the rating scales before completing the DCE and half were given the rating scale after 
completing the DCE.  
Demographic and health history information. 
Self-reported demographic and health history information was collected on 
gender, age, years of education, years with asthma and the frequency of asthma-related 
medical visits over the past year. 
Procedure. 
 Once participants arrived at the asthma clinic they were asked by the receptionist 
if they would be willing to hear about a research study. If they agreed, a research assistant 
approached patients in the waiting area and went through the informed consent 
procedure. Those who consented were asked to complete the knowledge questionnaire, 
discrete choice scenarios, demographics page and rating scales while waiting to see their 
physician. This took approximately 10 minutes.  
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Results. 
Demographic information. 
Participants’ demographic information is presented in Table 2.  The average age 
was 46 years and 65% were female. Over 50% reported some college or university 
education. This was the first asthma clinic visit for 30% of the sample. They had carried 
their asthma diagnosis for an average of 21.64 (sd = 14.82, range = 1 – 57) years and 
reported having visited an emergency room an average of 1.3 times over the previous 
year for asthma-related concerns.  
Knowledge questionnaire. 
 Participants’ knowledge of the pathophysiology of asthma, asthma medications 
and inhaler technique were all normally distributed. The normality statistics for the 
subscales are presented in Table 3. Knowledge with regards to both environmental 
triggers as well as asthma symptoms was significantly negatively skewed. Total scores 
were normally distributed, suggesting that participants had a range of knowledge about 
asthma and its management. The percentage of participants responding correctly is 
presented in Appendix F.  One item, Asthma attacks often come on suddenly without any 
warning symptoms, was responded to incorrectly by 80% of the participants. In 
consultation with clinic staff, it was decided that the wording of the question was 
ambiguous and the item was removed from the scale.  
The total scale was not internally consistent (α = .40), nor were the subscales (all 
α’s < .52; See Table 3). However, one would not necessarily expect pockets of 
information to hang together.  Accordingly, the knowledge subscales were retained.  
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Table 2 
 
Demographic Information of Participants in Pilot Study 
 
 
N (%) M (SD) 
Observed 
Range 
Demographics     
Age 52 46 (16.80) 18 - 85 
Years of education 55 4 (1.26) † 1-6 
Years with asthma diagnosis 44 21.64 (14.82) 1 - 57 
Health Care Use Variables     
Attendance at Clinic          56   
     First Visit  18 (30) - - 
     Second Visit 7 (11.7) - - 
     Third Visit 5 (8.3) - - 
     Greater than 3 visits 26 (42.3) - - 
Family doctor visits in past year 
for asthma related concerns 56 2.52 (3.04) 
 
0-12 
ER visits in last year for asthma 
related concerns 56 1.30 (2.16) 
 
0 - 10 
† 1 = Completed grade 8, 2 = Some high school, 3= Completed high school, 4 = Part 
college/University, 5 = Completed college or university, 6 = Graduate school 
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Table 3  
Descriptive Data for Knowledge Subscales from Pilot Study Sample  
 
Scale N of Items Ma SD Cronbach’s α Skew Kurtosis 
Pathophysiology  9 2.74 .22 .31 -.72 -.42 
Medication  12 2.39 .27 .45 -.37 -.78 
Technique  4 2.64 .32 .12 -.47 -.65 
Symptom  4 2.87 .24 .52 -2.17 4.84 
Environment  6 2.84 .20 .14 -1.05 .08 
Total Scale 35 2.61 .16 .40 -.70 .57 
Note. N = 56. 
a1 = Incorrect, 2 = Unsure, 3 = Correct. 
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Discrete choice experiments. 
 Participants reported that they understood what they generally were being asked 
to do for the DCE and their behaviour during the task seemed to bear this out. However, 
participants were confused by the long-term outcome option, in which they were asked to 
decide whether or not they would choose their asthma to be the same or worse in 10 
years, not knowing whether to term referred  to pathophysiology (as intended) or 
symptoms. Accordingly, in the final version of the task, the term asthma was replaced 
with airways.  
Rating scales. 
 Participants stated to the research assistant that they understood the explicit rating 
task. Given that we were asking participants to rate their preferences both implicitly 
(through the use of DCEs) and explicitly (through the rating scale) we wanted to ensure 
that one rating was not affecting the other.  Accordingly, MANOVA analyses were 
conducted on the rating scale items to assess whether those participants who completed 
the DCEs before the ratings had significantly different ratings on the scales than those 
who completed the DCEs after the ratings. The analysis was non-significant, F(10,43) = 
6.99, ns, indicating that there were no group differences on the rating items whether the 
DCEs were given before or afterwards.  Similarly, a MANOVA on the implicit (i.e., 
DCE) scores revealed no order effect, F(7,48) = 1.95, ns. 
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Chapter III: Method for Main Study 
Participants 
One hundred and forty individuals between the ages of 19 and 82 (M = 45.29, 
SD= 15.97) with a diagnosis or possible diagnosis of asthma were recruited from the 
Asthma Centre at St. Joseph’s Hospital in London, Ontario. The Centre is a tertiary care 
facility serving adults outpatients. It receives approximately 30-40 % of its referrals from 
the local emergency department, approximately 40 % from general practitioners, and the 
remainder from various specialists’ offices. As such, it treats individuals with varying 
levels of asthma severity. As standard practice, patients are seen by either a respirologist 
or an allergist during their first visit and are seen by the other specialty during their 
second visit. Patients found to have a primary diagnosis of another respiratory condition 
are referred to the appropriate clinic (e.g., venom and allergy, the chronic obstructive 
pulmonary disease clinic, etc.).  
All patients over 18 years of age, who had sufficient comprehension of written 
English and were prescribed a preventer medication, were approached to participate. 
Patients with significant other lung diseases (e.g., Chronic Obstructive Pulmonary 
Disease, emphysema, lung cancer, vocal cord dysfunction) were excluded from the study.  
The study was approved by the University of Western Ontario Health Sciences 
Review Board (Protocol # 16869E, Appendix G). Participants read a letter of 
information, signed an informed consent form (Appendices H and I, respectively) and 
received a total of $50.00 for their participation, paid in intervals based on study 
completion. Funding was provided by the Canadian Institutes of Health Research (CIHR- 
CGD Fellowship 87781: Awarded to N. Gryfe). 
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Measures 
Asthma Knowledge Questionnaire.  
The self-report measure used in this study was a modified version of the recently 
developed Asthma Self-Management Questionnaire (Schaffer & Yarandi, 2007). The 
current 35 item self-report scale was based on the expert panel ratings as well as the 
content validity ratings, as described earlier. Participants were asked to indicate whether 
they believed each item was true or false. An “unsure” option was also given. 
Beliefs about illness. 
The most widely used quantitative measure of illness cognitions is the Illness 
Perception Questionnaire- Revised (IPQ-R; Moss-Morris et al., 2002), which has three 
sections: The first section, an ‘identity’ subscale, consists of 14 common symptoms (e.g., 
pain, nausea, upset stomach, breathlessness). Respondents are asked both to indicate the 
extent to which they are bothered by each symptom and to indicate whether they think 
each of the  symptoms they have endorsed are related to the illness in question (asthma). 
The instructions for this scale were modified slightly to increase clarity for the reader. 
The second section is comprised of 50 items rated by the respondent on 5 point 
Likert-type scales (1 = strongly disagree 5 = strongly agree). Items include statements 
about the consequences of asthma for patients (e.g., My illness has major consequences 
on my life), the extent to which it makes sense to them (e.g., My condition is a mystery to 
me) and causes them emotional distress (e.g.  When I think about my condition I get 
upset). Moreover, they are asked about the perceived timeline (e.g., My condition will last 
a long time), personal controllability (e.g., There is a lot which I can do to control my 
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illness) and treatability  (e.g., My treatment will be effective in curing my condition) of 
their asthma.   
The third section, an 18 item cause subscale, includes common causes of illnesses 
(e.g., germ or virus, heredity, my own behaviour). The authors encourage a tailoring of 
the measure to the illness in question (Moss-Morris et al., 2003) and, as such, two 
asthma-specific causes were included: 1. A physical problem with my breathing airways, 
2. My sensitivity to physical changes in my breathing airways.  
Prior research (Moss-Morris et al., 2002) has shown the subscales to have good 
internal reliability with Cronbach's alphas ranging from .79 for the cyclical timeline 
dimension to .89 for the timeline chronicity. Previous data collected in our lab indicate 
similarly high internal consistencies with asthma patients, the one exception being the 
treatment control subscale (α = .33). One possible explanation for this low score is that 
the treatment control subscale was designed as a broad based  measure to gauge 
perceived efficacy of a variety of medications and thus is not  sufficiently nuanced to  
distinguish between perceptions of different classes (i.e., preventer versus recue) of 
asthma medications. Given our specific interest in perceptions of preventer medication, 
the necessity scale of the beliefs about treatment scale (see below) was taken as the index 
of perceived preventer medication efficacy.   
Beliefs about treatment. 
The Beliefs about Medicines Questionnaire- Asthma Specific (BMQ) is a 14 item 
self-report Likert-type scale (1 = strongly disagree to 5 = strongly agree) that taps 
patients’ concerns about the potential adverse effects of preventer medications as well as 
their doubts about the necessity of taking the medication (Horne, Weinman, & Hankin, 
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1999). Ten of the fourteen items assess beliefs that can apply to a range of chronic 
illnesses, and four items specific to asthma medication were later added by Horne and 
Weinman (2002). Sample items include: “This inhaler is the most important part of my 
asthma treatment” (necessity) and “People who use these inhalers should stop their 
treatment every now and again” (concern). The treatment concern and necessity 
subscales have adequate internal consistency (α’s =.71 and .82, respectively). Scoring is 
such that higher values on the treatment concern subscale indicate more concern about 
adverse effects and higher scores on the treatment necessity scale indicate stronger beliefs 
about the importance of the medication for their management. Participants completed this 
measure not only with reference to their preventer medication but also with reference to 
rescue inhalers, as we reasoned that beliefs about the necessity for and concerns about 
this class of medication might also influence the use of preventers. The presentation of 
these measures was counterbalanced. 
Preference tasks. 
 Discrete Choice Experiments (DCE). 
 Discrete choice scenarios were designed specifically for this study. Participants 
were presented with 8 choice sets (16 scenarios) that varied along 7 dimensions, each 
with two levels (See Appendix D). The pilot study (Phase III)  confirmed that the  
cognitive load for participants was not too large, consistent with work in the area which 
suggests that 8 or 9 choice sets can be effectively processed (Street & Bourgess, 2007). 
Rating scales. 
 Respondents were asked to rate 10 items (created specifically for this study) 
pertaining to asthma treatment (e.g. side-effects, cost, long-term effects, etc.) on a scale 
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of 1 (least important) to 10 (most important). The instructions encouraged participants 
think about the “trade-offs” involved in making a decision about taking a medication. The 
rating scales are presented in Appendix C. 
Medication adherence. 
Medication Adherence Report Scale (MARS). 
 Measurement of adherence is controversial and fraught with methodological 
limitations. For example, electronic monitoring as well as biochemical data can be 
prohibitively costly and pharmacy data is logistically difficult to obtain (Rau, 2005). In 
addition, while self-report measures tend to be the most widely-used measures in 
research, they have been found to underestimate non-adherence by approximately 20 
percent (Horne & Weinman, 1999), probably because patients are loathe to admit (to 
themselves and others) that they do not follow their health care providers’ prescriptions. 
Self-report measures, however, are easily implemented and allow for the examination of 
behavioural and psychological processes that underlie adherence behaviour (Mora et al., 
2011; Wroe, 2002).  
The Medication Adherence Report Scale (MARS) is a self-report measure of 
adherence designed to measure respondents’ tendencies that impede the regular use of 
prescribed medications (Cochrane et al., 1999). Different versions of the MARS for 
asthma have been studied, but research suggests that behaviours as assessed by both the 
full (10 item) and short (5 item) version of the scale to be significantly correlated with 
more objective measures of adherence such as electronic monitoring (Cohen et al., 2008; 
Ohm & Aaronson, 2006) and pill counting (Menckeberg et al., 2008). 
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In this study, a nine-item self-report measure, using a five point (ranging from 1 = 
always to 5 = never) Likert-type scale was administered to assess adherence (Horne & 
Weinman, 2002). The 9 items scale was selected as it has been validated for use in other 
studies measuring illness beliefs along with adherence (Horne & Weinman, 2002). The 
scale demonstrated good internal validity (α = .85 and a single factor principal 
component analysis accounting for 88.7% of the variance) and good criterion validity 
when compared to electronic monitoring, and strong construct validity (Cohen et al., 
2008). In addition, Cohen et al. (2008) found that patients who claimed to use inhaled 
corticosteroids even when they were not symptomatic were more likely to classified as 
adherers by the MARS for asthma as were those who responded that their inhaled 
corticosteroid medication was a controller medication.  
Following the suggestion of Rand and Wise (1994), the MARS was administered 
with the following preamble, aimed at promoting a non-defensive mindset: “Many people 
find a way to use their inhaler preventer medicine which suits them. This may differ from 
the instructions on the label or from what their doctor had in mind. Here are some ways 
in which people have said they use their medicines. For each statement, circle the 
number which best applies to you”. By focusing on non-adherence, rather than 
compliance with practitioner instruction, the preamble purportedly makes it easier for 
respondents to report acts that interfere with the ‘proper’ use of their preventer 
medications.  
To further minimize social desirability, many of the items are worded to refer to 
non-adherent behaviour (e.g., “I alter the dose”), rather than adherent behaviours (e.g. I 
take the dose as prescribed) (Cohen et al., 2008) because reports of non-adherence tend 
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to be more accurate than reports of adherence (Haynes et al., 1980). Horne and Weinman 
(2002) reported that 73.2% of asthma patients reported that they sometimes, often or 
always, engaged in one of the eleven non-adherent behaviours assessed by the MARS. 
These levels of non-adherence are similar to levels of non-adherence to asthma 
medications found in other studies that have used more “objective” measures of 
adherence such as tablet count and drug serum assays (e.g. Bosley, Fosbury, & Cochrane, 
1995; Horne & Weinman, 2002). 
To ensure participants were thinking about their preventer (and not rescue) 
medications while answering the questions, they were instructed to write down the name 
of their preventer medication at the top of the questionnaire. Scores for each item were 
summed to give a total score ranging from 9 – 45, with higher scores indicating greater 
adherence.  
Medication diaries. 
 To assess the frequency with which patients used their rescue and preventer 
medication, participants completed a daily medication log. A sample of the medication 
diary is presented in Appendix J. Although Oldenmenger et al. (2007) demonstrated 
patients’ ability to complete medication diaries each day for 28 days, so as to encourage 
full study participation patients were asked to complete these logs only for the first week 
following their appointment and for a full week four weeks later. Participants prescribed 
combination inhalers (which contain both preventer and rescue medication) were 
instructed to record any additional puffs that they took for relief purposes in the rescue 
medication space provided. 
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Dose counter. 
 Many preventer medications are equipped with a mechanism that counts down 
the remaining inhaler doses. While this does not indicate whether patients are taking their 
medications when they are supposed to, it theoretically provides an inexpensive and 
objective measurement of the number of doses taken. Accordingly, participants were 
asked to record the “number on their inhaler” at the end of each week’s treatment diary. 
Unfortunately, even though this procedure was clearly explained to participants and we 
encouraged participants to ask questions, the data obtained from this measure ultimately 
were unusable. This is both because some participants confused the dose counter with the 
dosage accompanying the  brand of medication (e.g., Advair 500mg, Symbicort 200mg) 
and because the dose counters on the combination inhalers do not record each 
administration of the medication, but rather, demarcate blocks of 10 or 20 doses. 
Individual difference variables. 
Demographic information. 
Participants provided information about their gender, age, annual household 
income, years of education, relationship status, years with asthma and the frequency of 
asthma related medical visits over the past year (Appendix K). 
Patient enablement. 
  Patient enablement was gauged by the Modified Patient Enablement Instrument 
for asthma patients (Haugney et al., 2007). The scale is a 6 item Likert-type self-report 
measure in which patients rate (from 0 = Same, less or not applicable to 3 = Much better) 
their perceived ability to cope with and participate in their own care as a consequence of 
a medical encounter. For the purposes of this study, the rating scale was changed to a 5 
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point scale (where 0 = Not applicable, 1 = Less, 2 = Same, 3 = Better, 4 = Much Better). 
Sample items include “Able to cope with life” and “Confident about your health”. The 
measure is highly internally consistent (α = .92).  
Patient satisfaction. 
 The Satisfaction Questionnaire (Jackson, Kincey, Fiddler, Creed, & Tomenson, 
2004) is a 15 item self-report measure that assesses how satisfied patients are along four 
dimensions: (1) patient-provider interaction, (2) information given to them by their 
provider, (3) their health (4) the health care environment. The satisfaction with the 
environment subscale was omitted for the purpose of this study. All subscales have been 
validated and the summed scores demonstrate excellent levels of internal consistency (α 
= .94).  
Quality of life. 
 The Asthma Quality of Life Scale- Mini Version (Juniper, Guyatt, Cox, Ferrie, & 
King, 1999) is a disease-specific instrument comprised of 15 items, grouped into four 
domains: (1) asthma symptoms, (2) responses to environmental stimuli, (3) limitations in 
activities, and (4) emotional dysfunction. Respondents are presented with a 7 point 
Likert-type scale on which they are asked to rate their degree of impairment (1 = Greatest 
impairment to 7 = Least impairment). The AQLQ-mini has been demonstrated to be 
reliable (ICC = .83) and is a valid measure of asthma quality of life. 
Panic-Fear. 
 The Panic-Fear Subscale of the Asthma Symptom Checklist (Ritz, Bobb, 
Edwards, & Steptoe, 2001) is a 7 item, Likert-type (where 0 = Never and 4= Always) 
scale assessing patients’ emotional responses (being frightened, afraid, or worried) during 
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an asthma attack. The scale demonstrates excellent internal consistency (Cronbach’s α = 
.94).   
 Positive and Negative Affect Schedule (PANAS). 
 The PANAS (Watson, Clarke, & Tellegan, 1988) is a 20-item self-report 
questionnaire in which participants rate, on a five-point Likert-type scale (where 1 = very 
slightly or not at all and  5  = extremely) the extent to which a range of  emotional 
adjectives such as “enthusiastic”, “excited”, “distressed” and “nervous”  describe them in 
general. The PANAS generates two subscale scores: Negative Affect and Positive Affect. 
Each subscale demonstrates good internal consistency and test-retest reliability.  
Procedure 
For ease of presentation, the following elements of the protocol will be presented 
chronologically: (1) Recruitment, (2) Pre-clinical encounter, (3) Post-clinical encounter, 
and (4) Follow-up. 
Recruitment. 
Upon arrival at the clinic, those patients who met the eligibility criteria were 
asked by the receptionist if they would mind being approached about a research study 
under way at the clinic. Two hundred and fifty four patients (119 new clinic patients and 
135 patients returning for follow-up visits) were approached to participate, given a verbal 
overview of the study and asked to read over a letter of information. Figure 1 illustrates 
the recruitment procedure and consent rates for the study participants. One hundred and 
seventy four patients (68%) consented.  The primary reasons cited by those who declined 
to learn more about the study were time constraints (n = 33), disinterest (n = 22) and  
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Figure 1 
Flow of Participants Through Study 
                               Reasons for Exclusion 
 
Patients 
Approached 
(n = 254) 
 
 
Agreed to Learn 
More About the 
Study (n=174) 
 
 Were Disinclined 
to Participate  
(n=80) 
Time Constraints 
(n = 33) 
Disinterest 
(n = 22) 
Unsure About  
Ability to Follow 
Through 
(n = 25) 
 
Provided Consent and Completed First 
Package at Clinic 
(n=140) 
 
Usable One Week Follow-Up Packages 
(n=129) 
 
Usable One Month Packages 
(n=120) 
Other 
Respiratory 
Condition 
(n = 12) 
No Preventer 
Medication 
Prescribed 
(n = 9) 
Excluded for 
Other Reasons 
(n = 13) 
Reasons for Declining 
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concerns that they would not follow through (n = 25).  Of the 174 who consented, 34 
subsequently did not meet eligibility requirements, leaving 140 participants, 11 of whom 
did not complete the one-week post-appointment questionnaires. An additional nine did 
not submit the one-month post appointment measure. Accordingly, complete data were 
available for 120 participants. 
Pre-clinical Encounter. 
Once eligibility criteria were established and patients consented to the study, 
while waiting for their pulmonary function test, participants were asked to complete a 
booklet containing the demographics information questionnaire, the Asthma Quality of 
Life Measure (AQLQ), the Positive-Negative Affect Scale (PANAS), the Panic-Fear 
Scale, and the Medication Adherence Report Scale (MARS). Those who did not have 
time to complete these measures before the pulmonary function test finished them 
afterwards while waiting to see their physician or nurse.  
Post-clinical Encounter. 
Following the clinical visit, patients were asked to complete the Discrete Choice 
Experiment Task (DCE), the Illness Perception Questionnaire (IPQ-R), the Beliefs about 
Medicines Questionnaire (BMQ), the Asthma Knowledge Questionnaire and the 
preference rating scales. To mitigate  against respondent fatigue,  participants were given 
the patient satisfaction and enablement scales to complete at home along with the first 
seven day treatment diary. The diary also included a space for them to indicate the dose 
count from their inhaler (though, as noted earlier, these data were not included in the 
analyses).  
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Patients had the option of completing the satisfaction and enablement measures as 
well as the treatment diary online, and, if so inclined, were instructed on how to do so.  
Those choosing to complete hard copies of these measures were given a return-addressed 
postage paid envelope. The researcher ensured that participants understood the 
instructions for all take-home measures. They were reimbursed $10 for their time and 
additional parking expenses. 
 Follow-Up. 
The 61 participants who completed the follow-up portion of the study by mail 
were contacted three weeks following their appointment by telephone to remind them that 
a medication diary, a copy of the MARS, and an AQLQ would arrive shortly by mail. 
Included in the package was a return-addressed postage-paid envelope as well as 
instructions to start completing the MARS and AQLQ and diaries the evening they 
received the package. 
The 79 participants completing the follow-up portion of the study online were 
sent an email one month after their appointment to ensure they were prompted at the 
same time as those who chose the mailing option. The email included links to the AQLQ 
and MARS as well as the daily records. Participants were instructed to complete the 
AQLQ and MARS on the evening that they began the records.  
Participants were compensated for the portion of the follow-up study they had 
completed ($20.00 for each of the two-week records) once their final packet was 
received. 
Once all data were collected, participants’ prescription regimens were extracted 
from their clinical records by an administrative clerk employed by the hospital. 
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Moreover, a nurse educator affiliated with the asthma clinic reviewed patients’ clinical 
files to confirm that they did indeed have asthma, which they all did.  
Statistical Analyses 
Statistical analyses were carried out using PSAW 18 and LatentGold 4.5 software 
packages.  
Relationships between the predictor and outcome variables were examined using 
Pearson and Spearman correlation coefficients, as appropriate. Preference data were 
explored through latent class analysis.  
The contributions of knowledge, beliefs and preferences individually on 
adherence were evaluated using simple linear regressions. The relative contribution of 
each of these variables as predictors of adherence was assessed using a hierarchical linear 
multiple regression analysis, with reported MARS scores as well as diary reports as the 
dependent variables and predictors entered in the following order:  1. Knowledge of the 
pathophysiology of asthma; 2. Illness beliefs and Treatment Beliefs and 3. Treatment 
preferences. All study analyses were repeated to determine whether there was a main 
effect of gender or previous experience at the clinic (i.e., number of prior clinic visits) 
and whether inclusion of these variables as co-variates altered the findings. No such 
effects were observed. 
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Chapter IV: Results 
Sample Demographics 
 The demographic and asthma-related characteristics of the sample are presented 
in Table 4. The majority of the sample (69%) was female. On average, participants had 
been diagnosed with asthma at age 24 (SD = 18.71). The majority (74%) had visited their 
family doctor for respiratory related issues at least once in the previous year, with the 
mean number of visits close to three. Fifty-three percent had visited the emergency room 
for respiratory related symptoms at least once in the previous year.   
 The criteria for normal distribution adopted for the study were a skew between -3 
and +3 (see Kline, 2009) and kurtosis less than 2.58, as recommended by Field (2009). 
All demographic variables were appropriately distributed, with the exception of 
participants’ asthma related visits to their family physician and ER related visits. That is, 
these distributions peaked at 0, as 27 % of participants stated that they had not gone to 
see their family doctor in the past year and 47 % stated they had not visited the ER.  
These patterns of health care use statistics are similar to those reported by other 
community- managed asthma patients (Horne & Weinman, 2002). 
At the point at which they were recruited into the study, 46% of participants were 
attending the asthma clinic at St. Joseph’s Hospital for the first time, with the remainder 
(54%) attending for a follow-up visit. The majority (78.5%) had been prescribed a 
combination medication inhaler as part of their asthma treatment regimen.  
The demographic characteristics of those completing the follow-up questionnaires 
and diaries by mail (44% of the sample) did not differ (as per independent samples t-tests  
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Table 4  
Participant Characteristics 
 
N (%) M (SD) 
Observed 
Range 
Skew Kurtosis 
Demographic Information      
     Age 135 45.39 (15.97) 19 - 82 .19 -1.02 
     Age at diagnosis 127 24.04 (18.71) 0 - 68 .59 -.72 
     Years of education                      138 14.98 (3.31) 4 - 25 -.25 1.38 
     Household incomea 125 3.30 (1.74) 1 - 6 .15 -1.26 
     Employment statusb 138 6.13 (2.73) - - - 
        Employed (Full time) 53 (37.9) - -   
        Working from Home 4 (2.9) - -   
        Employed (Part time) 25 (10.7) - -   
        Homemaker 4 (2.9) - -   
        Student 8 (5.7) - -   
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N (%) M (SD) 
Observed 
Range 
Skew Kurtosis 
      
        Retired 26 (18.6) - -   
        On Disability 15 (10.7) - -   
        Unemployed 6 (4.3) - -   
        Other 7 (5) - -   
Health Care Use Variables       
     Attendance at Clinic       140   .48 -1.42 
        First Visit  64 (45.7) - -   
        Second Visit 13 (9.3) - -   
        Third Visit 20 (14.3) - -   
        Greater than 3 visits 43 (30.7) - -   
     Asthma related visits to family  
     physician (in past year) 140 2.89 (3.35) 
 
0 - 24 
 
2.50 
 
10.87 
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N (%) M (SD) 
Observed 
Range 
Skew Kurtosis 
      
     Asthma related visits to ER  
     (in past year) 140 1.49 (2.06) 
 
0 - 12 
 
2.06 
 
5.82 
Quality of Life Variables      
     AQLQ 140 3.71 (1.22) 1 - 7 -.01 -.60 
Prescribed Medications      
     Combination Inhalers 110 (78.5) - -   
     Non-Combination Inhalers 20 (21.5) - -   
 
Note. Missing data may result in n’s not totaling 140. 
a1= Under $ 20,000, 2= $21,000–40,000; 3=$41,000–60,000 4= $61,000-$80,000, 5 = $81,000- 100,000, 6 = Over $100,000 
b9= Employed full time, 8 = Working from home, full time, 7= Employed part time, 6 = Homemaker, 5 = Student, 4 = Retired, 3 = On 
Disability, 2 = Unemployed, 1 = Other
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with Bonferroni corrections) from those completing the measures on-line. Accordingly, 
all subsequent analyses were collapsed across these two groups.  
Descriptive Statistics on the Outcome Measures 
 Descriptive statistics for the adherence measures – MARS at Time 1 and 2 and the 
diary measures - are presented in Table 5. Internal consistency for the MARS was good 
(α = .86 at Time 1 and α = .87 at Time 2). The scale means of 4.21 and 4.37 respectively, 
were close to the highest possible score of 5, indicating that participants reported high 
levels of compliance. Consistent with the elevated reported compliance levels, both 
MARS scores were negatively skewed. Transformations failed to produce normal 
distributions.  
Adherence was derived from the daily diaries as follows: The number of 
prescribed medication doses was subtracted from the absolute value of the number of 
doses participants reported taking. These scores were averaged across each week. 
Accordingly, a score of 0 would indicate perfect adherence, whereas other values indicate 
the degree to which patients deviated from their prescribed regimen. For ease of 
interpretation, these scores were multiplied by -1 so that higher scores (the maximum 
being 0) reflect better adherence. Notably, the distributions for diary scores at Time 1 and 
Time 2 were highly peaked at 0, as 58.5 and 61.2 percent of patients reporting being 
perfectly adherent at Time 1 and 2, respectively.  
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Table 5  
Descriptive Statistics for the MARS and Diary Recordings 
   
 
Range   
 n M (SD) α Potential  Observed  Skew Kurtosis 
MARS- 
T1 
137 4.21 
(.76) 
.86 1-5 1.89-5 -5.57 1.67 
MARS- 
T2 
113 4.37 
(.65) 
.87 1-5 1.78-5 -5.85 3.80 
Diary T1 121 .22 (.73) - - 0 to 3.57 2.39 7.19 
Diary T2 105 .27 (.87) - - 0 to 4 1.98 4.90 
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  A repeated measures t-test of MARS-T1 versus MARS-T2 scores indicated that 
reported adherence across the sample increased from baseline to one month post-
appointment, t(110) = 2.35, p < .05. This effect was driven by changes in those   
attending the clinic for the first time at baseline (t(48) = 2.25, p < .05); those whose 
baseline measure was taken at a follow-up visit did not have higher adherence scores one-
month post appointment, t(61) = 1.19, ns. A comparable analysis of participants’ diary 
scores assessed at one and four weeks post appointment indicated no difference between 
diary scores at one week and four weeks either in the entire sample, t(101) =. 53, ns, or in 
the new or returning clinic attendees (t(45) = .69, ns, and t(55) = 1.38, ns, respectively). 
Accordingly, diary scores were collapsed across the two time points.  
Spearman correlations among the adherence measures are presented in Table 6. 
Diary scores were significantly, albeit weakly, correlated with the MARS scores at T1 (rs 
= .26) and modestly correlated with the MARS scores one month post-appointment (rs = 
.35).  
Belief Measures 
Descriptive statistics.  
 The descriptive statistics for the illness belief (IPQ-R) and views about asthma 
medications (BMQ) subscales are presented in Tables 7 and 8, respectively. All IPQ-R 
subscales were reasonably internally consistent (all α’s higher than .60), except for the 
immunity as cause subscale (α = .44). Of the remaining IPQ-R scales, the next lowest 
internal consistency was for the treatment control scale (α = .63). This is not surprising, 
given that the treatment control subscale does not differentiate between preventer versus 
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Table 6  
Spearman Correlations Amongst Adherence Measures 
 
Scale 2 3 
1. MARS T1 .52** .26** 
2. MARS T2 - .35** 
3. Diary Scores    - 
 
**
 p < .001. 
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Table 7  
Descriptive Statistics for Beliefs about Asthma Measures 
     Range   
IPQ-R Subscale n N of items M (SD) Cronbach’s α Potentiala Observed  Skew Kurtosis 
Identity 76 14 4.80 (2.69) n/a 0 – 14b 0 - 14 -.17 6.94 
Timeline 
Acute/Chronic 
139 5 4.05 (.88) .89 1 – 5  1.6 - 5 -3.46 .50 
Consequences 139 6 3.24 (.85) .83 1 – 5 1.17 - 5 -.09 -.10 
Personal Control 139 6 3.97 (.61) .77 1 – 5 2.33 - 5 -1.43 -.56 
Treatment Control 137 5 3.79 (.53) .63 1 – 5 1.8 - 5 -2.87 4.02 
Illness Coherence 137 5 3.55 (.82) .88 1 – 5 2 - 5 -1.15 -1.47 
Timeline Cyclical 137 4 3.35 (.73) .68 1 – 5 1.25 - 5 -.14 .25 
Emotion 137 6 2.72 (.85) .85 1 – 5 1 – 4.67 .08 -1.38 
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     Range   
IPQ-R Subscale n N of items M (SD) Cronbach’s α Potentiala Observed  Skew Kurtosis 
Causes         
      Psychological  137 6 2.59 (.85) .87 1 – 5 1 – 4.33 -.99 -1.65 
      Risk Factors 137 6 2.71 (.77) .70 1 – 5 1 – 4.5 .30 -.28 
      Immunity  137 3 3.16 (.76) .44 1 – 5 1 - 5 -1.21 .96 
     Accident/Chance 137 1 2.16 (1.09) n/a 1 – 5 1 - 5 3.40 -.68 
     Breathing Airways 137 2 3.46 (1.03) .80 1 – 5 1 - 5 -3.32 .61 
a1 = Strongly Disagree, 2 = Disagree, 3 = Neither Agree nor Disagree, 4 = Agree, 5 = Strongly Agree.  b0 = Experiencing no 
symptoms to 14 = Experiencing all listed symptoms. 
  
7
3
Table 8 
Descriptive Statistics for Beliefs about Asthma Medication Scales 
       Range 
BMQ Subscale n N of items M (SD) Cronbach’s 
α 
Skew Kurtosis Potential Observed  
Necessity 
Preventer 
135 6 3.86 (.74) .87 -2.11 1.83 1 - 5 1 - 5 
Concerns 
Preventer 
135 8 2.70 (.66) .76 -2.09 .10 1 – 5 1.13 – 4.25 
Necessity Rescue 123 6 3.36 (.96) .90 .38 -1.28 1 – 5 1 – 5  
Concerns Rescue 123 8 2.70 (.71) .79 -.09 -1.02 1 – 5 1.13 – 4.25 
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relief medications. In contrast, the BMQ was administered twice, once with reference to 
preventer and once with reference to rescue medications, and so each of the scales are 
understandably more internally consistent because all questions pertain to the same (and 
specific) class of medications. Accordingly, for the purposes of this study, the BMQ -
Necessity of Medication subscale was used to gauge perceived efficacy of treatment 
rather than the IPQ Treatment control subscale.   
 With respect to distributional properties, the majority of the illness belief scales 
(severity, consequences, coherence, cause, timeline and emotional toll) and views of
medicines scales were normally distributed.  Exceptions were the IPQ-R Acute/Chronic 
Timeline subscale and Airway Problem Causal subscale (both negatively skewed) and the 
Accident/Injury Causal subscale (positively skewed). Consequently, correlations 
involving these scales were conducted using both parametric (Pearson) and non-
parametric (Spearman) approaches. 
Intercorrelations among the belief measures.  
 Pearson and Spearman correlations yielded identical results and so only Pearson 
correlations are presented in Table 9. Given the large number of correlations (120) and 
the accompanying risk of Type I error inflation, only those correlations exceeding .40 are 
considered indicative of meaningful associations.  
 Evident from the pattern of correlations, people with asthma clearly differentiate  
between the therapeutic and adverse effects of their medications; for rescue medication, 
the necessity and concern scales were only slightly correlated (r = .28,  p < .05); these 
scales were uncorrelated for preventer medications (r = .01, ns).  However, those who 
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Table 9 
Pearson Correlations among the Illness and Treatment Belief Subscales 
Subscales 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1. Timeline - 
Acute/Chronic 
-.00 .28** -.02 -.31** .21** -.06 -.00 .10 .02 .11 .02 .42** -.04 .23* -.10 
2. Timeline - 
Cyclical 
- .31** .07 .05 -.03 .28** .33** .24** .19* .12 .25* .07 .25* .27* .31** 
3.Consequence  - -.08 -.20* -.13 .29** .23** .16 .26** .24** .58** .40** .37** .47** .38** 
4. Control- 
Personal 
  - .51** .20* .07 .12 .11 -.08 .07 .20** .23* -.08 -.01 .01 
5. Control- 
Treatment 
   - .15 -.00 -.01 -.01 -.06 -.08 -.16 -.01 -.21* .05 -.11 
6. Coherence     - -.16 -.08 -.02 -.01 .05 .22* .18* -.25* -.01 -.28** 
7.Psychological 
Causes 
     - .65** .47** .47** .41** .44** .04 .32** .19* .28** 
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Subscales 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
8. Risk Factors        - .52** .57** .37** .21** .05 .24** .14 .23** 
9. Immunity        - .44** .51** .10 .17 .21* .16 .06 
10. Accident          - .27** .05 .12 .28** .21* .18* 
11. Airway 
Problem 
         - .21** .13 .28** .15 .12 
12. Emotional           - .17* .45** .24* .45** 
13. Necessity 
Preventer 
           - .01 .47** .03 
14. Concern 
Preventer 
            - .26** .84** 
15. Necessity 
Rescue 
             - .28* 
16. Concern 
Rescue 
              - 
**
 p < .001 , * p < .05 
  
had concerns about their preventer medications were also quite concerned about rescue 
medications (r = .84, p < .001). Beliefs about the efficacy of these two classes of 
medication appear less closely coupled (r = .47, p < .001). Interestingly, participants 
believed more strongly about the need for their preventer than rescue medications (3.86 
versus 3.36, repeated measures, t(119) = 6.45, p < .001), though were equally concerned 
(2.70) about both, t(119) = .24, ns. 
 With respect to the association between medication belief and illness belief 
subscales, necessity for preventer medication was correlated with the Timeline- 
Acute/Chronic subscale (r = .42, p <.001), indicating that those who viewed their 
condition as more chronic believed that their preventer was more necessary. Not 
surprisingly, this association was weaker for beliefs about the need for rescue medication 
(r = .23, p < .05). Moreover, the consequence scale (which can be taken as an index of 
perceived severity) was significantly positively correlated with the perceived needs for 
both preventer and rescue medications (r = .40, p < .001, r = .47, p < .001, respectively) 
and, to a lesser degree, with concerns about taking them (r = .37, p < .001, r = .38, p < 
.001, respectively).  
Knowledge Data 
 As noted earlier, each of the items on the knowledge scale was scored as either 3 
= “correct”, 2 = “unsure”, or 1 = “incorrect”. A total score as well as subscale scores 
were calculated by adding up all the relevant items and dividing them by the number of 
items in the scale. Accordingly, higher scores indicate more knowledge in given domain. 
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Descriptive statistics for the knowledge questionnaire subscales are presented in 
Table 10. The internal consistency scores for the various subscales (which, as reported 
earlier, were classified as such based on expert ratings) are quite low, with none 
exceeding an α of .51. This is not a concern because units of knowledge reasonably could 
be expected to be discrete.  
A repeated measures MANOVA with contrasts on the means demonstrated that, 
as a group, participants were most knowledgeable about their symptoms and 
environmental triggers and least knowledgeable about their medications, F(4,132) = 
91.14, p < .001. Participants who were attending the asthma clinic for the first time when 
recruited for the study were no less knowledgeable in any of the content areas than those 
for whom it was a follow-up visit, F(5, 130) = 1.8, ns. Items, grouped by category, are 
presented in the order of most to least correctly answered in Appendix L. 
Whereas overall knowledge, knowledge of the pathophysiology and knowledge 
about medication were normally distributed, the technique and environment subscales 
were significantly negatively skewed and the symptom subscale was highly negatively 
skewed and had a very peaked distribution. Notably, 66% of the sample responded 
correctly to all symptom scale items (i.e., obtained a mean score of 3 on this scale). 
Accordingly, Spearman correlations were conducted in subsequent analyses to meet 
assumption criteria.  
Pearson and Spearman correlations amongst the knowledge subscales are 
presented in Table 11. The strongest correlation was between knowledge about the 
pathophysiology of the disease and the medications necessary to treat it (r = .42, p < 
.001). 
  
7
9
Table 10  
Descriptive Statistics for Knowledge about Asthma Subscales 
 
Scale N of Items n Ma SD Cronbach’s α Skew Kurtosis 
Pathophysiology  9 137 2.72 .23 .42 -2.95 .47 
Medication  12 137 2.44 .28 .51 -.57 -1.44 
Technique  4 139 2.64 .32 .04 -3.34 .59 
Symptom  4 139 2.86 .25 .13 12.37 20.65 
Environment  6 139 2.84 .18 .40 -5.44 2.34 
Total Scale 35 139 2.65 .16 .64 -2.47 1.27 
a1 = Incorrect, 2 = Unsure, 3 = Correct. 
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Table 11 
Intercorrelations Among Knowledge Subscales 
 
Subscale 2 3 4 5 
1. Pathophysiology r = .42** 
rs  = .40** 
r = .05 
rs  = .08 
r = .26** 
rs  = .27** 
r = .30** 
rs  = .30** 
2. Medication - r = -.07 
rs  = -.06 
r = .28** 
rs  = .31** 
r = .19* 
rs  = .21* 
3. Technique  - r = .23** 
rs  = .21** 
r = .01 
rs  = -.04 
4. Environment   - r = .27** 
rs  = .12 
5. Symptoms    - 
** p < .01 , * p < .05 
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Correlations between Knowledge and Belief Data 
 Given that this is the first study to explore the relative roles of asthma knowledge 
and beliefs, exploratory Pearson correlations were conducted for the normally distributed 
variables. Both Spearman and Pearson correlations were conducted for the non-normally 
distributed variables, and yielded equivalent findings. Accordingly, only Pearson 
correlation coefficients are reported (See Table 12). Again, given the large number of 
correlations (96) only those exceeding .40 were deemed meaningful. Only two such 
correlations met these criteria. Specifically, the belief that asthma is chronic (rather than 
acute) was positively associated with overall knowledge about asthma (r = .41, p < .001) 
and more specifically with knowledge about its pathophysiology (r = .48, p < .001). 
Correlations between Predictor Variables and Adherence Measures  
 Correlations among the beliefs and knowledge subscales and the adherence 
outcome measures are presented in Table 13. Given that MARS and diary scores were 
significantly skewed, both Pearson and Spearman correlations were conducted. To 
control for Type I error (given 44 associations were being examined), only correlations in 
which either the Spearman or Pearson coefficient exceeded .25 were deemed to indicate 
statistically meaningful associations. Only three such associations met this criterion. 
Specifically, self-reported adherence at Time 2 (i.e., MARS-T2) was positively correlated 
with the belief that asthma is a chronic condition (r = .26), the belief that preventer 
medications are necessary (r = .36) and with knowledge about the pathophysiology of 
asthma (r = .27). Notably, adherence as gauged by the diary method was not correlated 
with any of the knowledge nor belief measures.  
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Table 12 
Pearson Correlations between Belief and Knowledge Subscales 
 Knowledge Scales 
Belief Scale Knowledge 
Total 
Pathophysiology 
Subscale 
Medication 
Subscale 
Technique 
Subscale 
Environment 
Subscale 
Symptoms 
Subscale 
Timeline - 
Acute/Chronic 
 
.41** .48** .24** .18* .19* .13 
Timeline - Cyclical 
 
-.06 .02 -.14 -.01 .09 .16 
Consequence -.01 .10 -.10 .06 .05 .10 
 Control- Personal 
 
.14 .16 .08 .05 .14 .10 
Control- Treatment 
 
.05 .01 .02 -.03 .11 .04 
Coherence .22** .22** .16 .04 .14 .04 
Psychological 
Causes 
-.08 -.02 -.21* .14 .09 .04 
  
8
3
Belief Scale Knowledge 
Total 
Pathophysiology 
Subscale 
Medication 
Subscale 
Technique 
Subscale 
Environment 
Subscale 
Symptoms 
Subscale 
Risk Factors  -.08 .01 -.14 .01 .06 -.01 
Immunity .10 .14 -.06 .12 .24** .10 
Accident  -.10 -.01 -.13 -.00 -.01 -.07 
Airway  
Problem 
.15 .14 .07 .11 .17* .04 
Emotional -.17* -.12 -.18* -.01 -.06 .04 
Necessity 
Preventer 
.10 .22** -.03 .08 .12 .11 
Concern Preventer -.22* -.25** -.13 -.05 -.10 -.08 
Necessity Rescue -.13 -.13 -.15 -.08 -.01 .04 
Concern Rescue -.29** -.29** -.20* -.01 -.04 -.07 
**
 p < .001 , * p < .05 
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Table 13 
 Correlations of Belief and Knowledge Scales with Adherence Measures 
Subscale MARST2 Diary Recordings 
 r rs r rs 
Beliefs     
   Identity -.04 -.10 -.02 -.06 
   Acute/Chronic .27** .25** .06 .01 
   Timeline- Cyclical -.12 -.16 .06 .06 
   Consequences .05 -.08 .06 .06 
   Personal Control .15 .12 -.05 -.06 
   Treatment Control -.01 .06 -.12 -.11 
   Coherence .09 .05 .04 .06 
   Emotional -.05 -.10 .14 .13 
   Psychological  -.18 -.21* -.00 -.02 
   Risk Factors -.11 -.17 .01 .04 
   Immunity -.06 -.05 -.04 -.02 
   Airways -.07 -.10 .11 .12 
   Accident -.11 -.16 -.02 .05 
   Preventer 
Necessity 
.36** .33** .11 .07 
   Preventer Concern -.20* -.21* .00 .03 
   Rescue Necessity .09 .07 .01 .04 
  
85 
   Rescue Concern -.06 -.14 -.04 -.04 
Knowledge     
   Pathophysiology  .27** .25** .11 .12 
   Medication  .17 .23** -.08 -.01 
   Technique -.00 -.01 -.05 -.08 
   Environment .14 .08 .01 .03 
   Symptoms .08 .09 .07 .04 
Note. r = Pearson correlation, rs = Spearman correlation. 
*
 p < .05, ** p < .001. 
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Preference Data 
Preference data were extracted though a series of steps. First, a given choice was 
coded as either 0 (for the presumed undesirable option for each attribute) or 1 (for the 
presumed positive option). See Table 14 for the coding scheme. To gauge the weight a 
given participant placed on each of the seven attributes, total scores (ranging from 0 = 
Never selected a scenario with a positive level of a given attribute to 8 = Always selected 
the scenario with the more positive level of a given attribute) were then computed. This 
calculation yielded 7 total scores for each participant. Higher scores indicated that 
participants had selected scenarios wherein that attribute level had appeared more often. 
Therefore, higher scores reflect a greater weighing of the attribute.  
Latent class cluster analysis. 
Total scores were analyzed using cluster analysis techniques. All analyses were 
conducted using Latent Gold 4.5 latent cluster analysis (LCA). LCA segments 
individuals into clusters based on estimated membership probabilities (Magidson & 
Vermunt, 2005).  How best to determine the number of appropriate classes is the subject 
of some debate within the cluster analysis literature. However, many look to the Bayesian 
Information Criterion (BIC) to determine model fit (Trivedi, Ayotte, Thorpe, Edelman, & 
Bosworth, 2010). BIC scores aim to balance fit with model parsimony. Thus, lower BIC 
scores represent models with better fit.  Another valuable index of model fit is the 
parametric likelihood ratio tests (LRT) with bootstrapped values, which compare 
progressive iterations of models. Should the LRT be significant, the model with a greater 
number of classes is deemed a better fit to the data (Trivedi et al., 2010).  
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Table 14 
Coding of Attribute Levels 
Attribute  Coded 0 Coded 1 
Long Term Outcomes (10 
Years) 
Your airways will be worse in 10 years Your airways will be the same in 10 years 
Short Term Outcomes (6 
Months) 
You will have more asthma attacks over 
the next 6 months 
You will have less asthma attacks over the next 6 
months 
Immediate Effects Your medication will relieve your 
symptoms within 30 minutes 
Your medication will relieve your symptoms within 5 
minutes 
Steroid Dose High dose of steroids Low dose of steroids 
Number of Inhalers Two One 
Dosing Only As Needed Every day at set times and more when I 
need it 
Only when I need it 
Side Effects There is a risk of major/long term side 
effects 
There is a risk of minor/short term side effects 
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To determine the presence of latent classes among preference choices, 1,2,3,4, 
and 5 class models were tested.  As per the fit indices presented in Table 15, the five 
cluster model had the lowest BIC score and the LRT was significant and so would have 
been chosen on solely empirical grounds. However, on the basis of interpretability (see 
below), the four cluster model was deemed superior to the five cluster model. 
 The 4 and 5 cluster models are illustrated in Figures 2 and 3, respectively. 
Patterns among the mean scores of the first two clusters (i.e., long term outcomes and 
side effects) are virtually identical in the 4 and 5 cluster models (see Figures 4 and 5). 
Cluster 1 (long term outcomes) accounts for 30% of the sample in both models and 
Cluster 2 (side effects) accounts for approximately 20% of the sample in both models. As 
is evident in Figure 6, both the 4 and 5 cluster models produce a group of participants 
who weigh all the attributes more or less equally when making their decision (Cluster 3- 
equal weighting). In the four cluster model, this group accounts for approximately 30% 
of the sample. However, in the five cluster model, this group accounts for only 18% of 
the sample. This is because in the 5 cluster model, this group, hovering around the middle 
range of scores (i.e., between 3 – 5), is differentiated into 3 groups (refer back to Figure 
3). However, given that the design was not perfectly balanced this distinction may simply 
be a function of methodological error. In addition, the last cluster of the 4 cluster model 
was no longer differentiated in the 5 cluster model. Given these issues, the 4 cluster 
model was deemed a better fit.   
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Table 15 
Model Fit Indices 
 
Model LL BIC (LL) Npar L2 BIC (L2) df p-
value 
1 Cluster -1449.41 3089.84 39 2046.43 1581.14 1.1e-
363 
0.000 
2 Cluster -1349.75 2929.70 47 1847.11 1420.99 9.9e-
328 
0.005 
3 Cluster -1309.20 2887.78 55 1766.00 1379.07 2.8e-
316 
0.012 
4 Cluster -1287.41 2883.39 63 1722.43 1374.68 1.0e-
312 
0.018 
5 Cluster -1242.64 2833.02 71 1632.88 1324.31 1.2e-
299 
0.012 
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Figure 2 
Four Cluster Latent Class Model 
 
 
 
 
 
 
 
 
 
 
Note. LT = Long term total, ST = Short term total, IM = Immediate effects, STER = 
Steroid Dose, TIME = Time of day required to take medications, IN = Number of 
inhalers, SE = Side effects. 
 
 
 
 
 
  
91 
Figure 3 
Five Cluster Latent Class Model 
 
Note. LT = Long term total, ST = Short term total, IM = Immediate effects, STER = 
Steroid Dose, TIME = Time of day required to take medications, IN = Number of 
inhalers, SE = Side effects. 
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Figure 4 
Attribute Weights for Long Term Outcome Group in 4 and 5 Cluster Models  
 
 
 
 
 
 
 
 
 
 
 
Note. LT = Long term total, ST = Short term total, IM = Immediate effects, STER = 
Steroid Dose, TIME = Time of day required to take medications, IN = Number of 
inhalers, SE = Side effects. 
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Figure 5 
Attribute Weights for Side Effect Group in 4 and 5 Cluster Models  
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. LT = Long term total, ST = Short term total, IM = Immediate effects, STER = 
Steroid Dose, TIME = Time of day required to take medications, IN = Number of 
inhalers, SE = Side effects. 
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Figure 6 
Attribute Weights for Equal Weight Group in 4 and 5 Cluster Models  
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. LT = Long term total, ST = Short term total, IM = Immediate effects, STER = 
Steroid Dose, TIME = Time of day required to take medications, IN = Number of 
inhalers, SE = Side effects. 
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Focusing then on the 4 cluster model, a numerical depiction of how the four 
clusters identified by the model differentially weighed attributes is presented in Table 16.  
The largest number of participants (n = 44; 33% of the sample) fell into Cluster 1 which 
most valued the long term (i.e., 10 year) outcomes associated with their medications.  
Individuals in this cluster almost always selected scenarios in which lung function would 
remain the same (rather than worsen) over the next 10 years. Those in Cluster 2 (n = 28; 
21% of the sample) appeared to value low side effects. That is, they almost always chose 
scenarios describing minor and short term (rather than major and long term) side effects. 
Cluster 3 (n = 36; 27% of the sample) respondents appeared to accord equal weight to all 
seven attributes. And finally, those in Cluster 4 (n = 26; 19% of the sample) valued all 
outcomes, be they immediate, intermediate or long-term. Participants in this cluster were 
willing to trade off  more side effects, a higher dose of steroids and a more complex 
treatment regimen (more inhalers, fixed dosing plus as needed versus only as needed) for 
better efficacy  immediately, and in the short and long term treatment range. 
A MANOVA revealed no significant differences in demographic characteristics 
(gender, age, education, employment status, and clinic visits) between the clusters, 
F(21,327) = .67, ns. 
Differences in beliefs and knowledge among clusters.  
 Exploratory MANOVA analyses were conducted to determine whether 
individuals in the clusters differed with respect to their beliefs and knowledge about 
asthma. Box’s tests were all non-significant, indicating that the matrices were equivalent 
despite the unequal sample sizes across groups. As such, all analyses met the assumption 
of homogeneity of the covariance matrices.
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Table 16 
Means of Total Scores among Clusters 
 Cluster 1: Long 
Term Outcome 
(n = 44) 
Cluster 2: Side 
Effects 
(n = 28) 
Cluster 3: 
Equal 
Weighting 
(n = 36) 
Cluster 4: 
Medication 
Efficacy 
(n = 26) 
10 Year Effects 7.16 4.41 5.07 3.71 
6 Months 
Effects  
5.48 4.81 5.48 3.89 
Immediate 
Effects 
4.40 3.67 4.93 4.04 
Steroid Dose 2.78 3.07 4.80 2.08 
Medications As 
Needed 
3.52 4.16 4.35 2.10 
Number of 
Inhalers 
2.80 4.90 4.98 2.74 
Side Effects 4.49 7.40 5.41 3.31 
 
Note. Column totals are not all equal because the design is orthogonal, but not perfectly 
balanced. 
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 As per Roy’s largest root, there was a significant effect of clusters on beliefs, 
F(14,114) = 2.17, p < .05, partial ε2 = .21. Separate univariate ANOVAs (Table 17) on 
the outcome variables revealed that the groups differed with respect to their beliefs about 
problems with their airways being the cause of their condition. Follow-up contrasts with 
LSD corrections indicated that participants who preferred long term outcomes were more 
likely to believe that  “airway problems” were the cause of their condition than both those 
who weighed all treatment elements equally and those valuing treatment efficacy (Table 
18). 
A second MANOVA also was conducted to assess differences in asthma 
knowledge across clusters. Again, as per Roy’s largest root, there was a significant 
multivariate effect of clusters on knowledge, F(5,125) = 2.45, p < .05, partial ε2 = .09.  
Separate univariate ANOVAs revealed that the groups differed with respect to knowledge 
about asthma pathophysiology as well as asthma medications (see Table 19). Follow-up 
contrasts (LSD correction; Table 20) for asthma pathophysiology indicated that those 
weighing all attributes equally (Cluster 3) were less knowledgeable about asthma 
pathophysiology and asthma medications than were those who privileged long term 
outcomes (Cluster 1) and those who valued medication efficacy above the negative 
elements of medications (Cluster 4). Moreover, those most concerned about side effects 
(Cluster 2) were less knowledgeable about asthma pathophysiology than those who most 
valued short, intermediate or long- term outcomes (Cluster 4).
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Table 17 
Summary of Univariate ANOVA Statistics of Beliefs by Cluster 
 
Sum of 
Squares df Mean Square F 
 
Partial eta2 
Timeline- Acute/Chronic .11 3 .04 .05 .00 
Consequences .15 3 .05 .07 .00 
Personal Control .29 3 .10 .17 .00 
Treatment Control .44 3 .15 .53 .01 
Coherence 3.19 3 1.06 1.60 .04 
Timeline- Cyclical .50 3 .17 .31 .01 
Emotional .29 3 .10 .14 .00 
Psychological Cause 5.23 3 1.75 2.55 .06 
Risk Factors .57 3 .19 .31 .01 
Immunity .95 3 .32 .54 .01 
Problem with Airways 8.99 3 2.99 3.03* .07 
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Sum of 
Squares df Mean Square F 
 
Partial eta2 
Accident/Injury 3.92 3 1.31 1.09 .03 
Necessity of Preventer 1.26 3 .42 .76 .02 
Concern for Preventer 2.27 3 .76 1.8 .04 
*p < .05. 
  
  
100 
Table 18 
Estimated Marginal Means for Beliefs about Airway Problems as a Cause of Asthma by 
Cluster Group 
Cluster Group M SE 
Long term effects (C1) 3.77 .17 
Side Effects (C2) 3.39 .19 
Equal Weighting (C3) 3.16 .15 
Medication Efficacy (C4) 3.73 .20 
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Table 19 
Summary of Univariate ANOVA Statistics for Difference of Knowledge by Clusters 
 
Sum of 
Squares df 
Mean 
Square F 
Partial 
eta2 
Pathophysiology .40 3 .13 2.70* .06 
Medications .61 3 .20 2.79* .06 
Technique .20 3 .07 .65 .02 
Symptoms .20 3 .07 1.04 .02 
Environmental Triggers .15 3 .05 1.41 .03 
*p < .05. 
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Table 20 
Estimated Marginal Means for Knowledge of Pathophysiology and Medication by 
Cluster 
 Pathophysiology Medication 
 M SE M SE 
Long term effects (C1) 24.72 .31 29.95 .49 
Side Effects (C2) 24.18 .38 28.68 .61 
Equal Weighting (C3) 23.92 .33 28.17 .54 
Medication Efficacy (C4) 25.29 .41 30.04 .66 
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 Testing Study Hypotheses 
Hypothesis 1:  Knowledge about the pathophysiology of asthma will predict treatment 
adherence. 
As per a linear regression analysis, knowledge of asthma pathophysiology predicted  
MARS scores one month post-appointment, accounting for 6 percent of the explained 
variance, R2 = .06, F(3,106) = 2.15, p < .05. This finding remained unchanged when the 
demographic variables which correlated with pathophysiology knowledge (i.e., education 
level and number of family doctor visits in the past year) were entered at step 1 (Table 
21).   
As expected, given the non-significant correlations between any of the knowledge 
subscales and reported diary adherence, knowledge of the pathophysiology of asthma did 
not predict diary reported medication use, R2 = .01, F(1, 120) = 1.47, ns. 
Hypothesis 2: Beliefs about the chronicity of the disease, amount of control, severity 
of symptoms, sense of coherence and necessity of preventer medications will predict 
increased treatment adherence. 
As noted earlier, of the illness belief variables, only the Acute/Chronic Timeline scale 
was appreciably correlated with adherence scores. Because the hypotheses were related to 
the unique contribution of each belief, rather than their contribution as a belief set, only 
the Acute/Chronic Timeline variable was used as predictor in the regression analysis. 
With respect to beliefs about medication, both beliefs about the need for and concern  
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Table 21  
Summary of Multiple Regression Analysis for Patient Knowledge as a Predictor of 
Reported Adherence (MARS-T2) to Asthma Preventer Medication 
 Model 
Variable 1 β 2 β 
Demographics   
    Level of Education -.01 -.00 
Visits to Family MD in   
past year for breathing 
symptom 
.07 -.04 
Pathophysiology Knowledge  .24* 
R2 .01 .06 
∆R2 - .05 
F .29 2.15 
∆F - 5.86* 
*p < .05. 
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about preventer medications were correlated with adherence and were thus retained  in 
the regression analysis (Table 22), which indicated that the hypothesized beliefs predicted 
MARS scores at one month post-appointment, accounting for approximately 20 % of the 
explained variance, R2 = .21, F(7,96) = 3.63, p < .01. The amount of variance accounted 
for was unchanged when the demographic variables which correlated with the belief 
scales (i.e., participants’ education level, current job status, age, and number of ER and 
clinic visits) were entered at step 1 (Table 22).  
Surprisingly, when entered simultaneously, treatment beliefs (i.e., the belief in the 
necessity of taking a preventer medication and less of a concern about the effects of the 
medication) but not illness beliefs (about timeline) significantly predicted adherence. To 
test the possibility that this arose because the predictive power of believing one has  a 
chronic illness is mediated by  beliefs about the necessity of preventer medications (the 
variables are correlated r = .42), a Sobel test (Preacher and Leonardelli, 2001) was 
performed to test whether treatment necessity mediated the relationship between 
chronicity beliefs and adherence (Baron and Kenny, 1986). The Sobel test indicated that 
necessity did partially mediate (t = 2.70, p < .001) the relationship between chronicity 
beliefs and adherence. And, parenthetically, the opposite did not hold; that is, chronicity 
beliefs did not mediate the relationship between treatment necessity and adherence. 
A regression including all the hypothesized beliefs measures explained virtually none 
of the variance in diary-reported adherence, R2 = .01, F(3,116) = .51, ns. 
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Table 22 
Summary of Multiple Regression Analysis for Patient Illness and Treatment Beliefs as Predictors of Reported Adherence (MARS-T2) 
to Asthma Preventer Medication 
 Model 
Variables 1 β 2 β 
Demographics   
   Age .16 .16 
   Education .10 .06 
Visits to Family MD in past year for breathing symptoms -.04 -.03 
Visits to ER in past year for breathing symptoms -.01 .02 
Beliefs   
   Acute/Chronic Timeline  .04 
   Preventer Necessity  .34*** 
   Preventer Concern  -.23* 
R2 .04 .21 
∆R2 - .17 
F 1.01 3.63** 
∆F - 6.88*** 
*p < .05. ** p < .01. *** p < .001. 
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Hypothesis 3: Patient preferences will predict adherence. In particular, patients who 
value long term outcomes will be more adherent than those who do not value long term 
outcomes. 
Participants were assigned to a cluster (1 - 4) based on their proximity to a cluster 
pattern. Categorical membership was dummy coded for the purpose of the regression 
analysis. The long term group was used as the constant comparator and was therefore 
assigned all zeros. As such, univariate contrasts compared each group against the long 
term group.  
 As per a regression analysis, preferences (as defined by cluster membership) 
predicted MARS scores at one month post appointment, accounting for 13.4 percent of 
the variance in adherence scores, R2 = .13, F(3,105) = 5.43, p < .01 (Table 23). Beta 
values indicated a significant difference between participants who valued long term 
outcomes and those who weighed all attributes equally such that those who valued long 
term outcomes were more adherent to their preventer medication. Participants who 
valued long term outcomes were not more adherent than those who consistently preferred 
scenarios with minor medication side effects nor those who valued the efficacy of 
treatment over side effects with respect to adherence. 
A regression including group classification explained virtually none of the variance in 
diary-reported adherence, R2 = .00, F(3, 116) = .12, ns. 
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Table 23  
Summary of Regression Analysis for Patient Preferences as a Predictor of Reported 
Adherence (MARS-T2) to Asthma Preventer Medication 
Variable β 
  Equal Weighting – Long Term -.40*** 
  Side Effects – Long Term -.04 
  Efficacy – Long Term -.16 
R2 .13 
F 5.42** 
***p < .001. **p < .01. 
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Hypothesis 4: Patients’ preferences for elements of their medication will predict 
adherence above and beyond that predicted by knowledge of their disease and beliefs 
about the disease and its treatment. 
A hierarchical multiple linear regression revealed that preferences for long term 
outcomes accounted for an additional 10% of the variance in adherence scores on the 
MARS at one month follow-up,  after demographic variables were included in step one 
(i.e., age, income, and education), clinical factors included in step two (i.e., number of 
family doctor and emergency room visits for respiratory related problems in the past year, 
and number of asthma clinic visits), knowledge of pathophysiology in step 3, and beliefs 
in step 4 (Table 24). The full model explained 39% of the variance in reported adherence.  
Moreover, a reverse analysis in which preferences were entered in step 1 and beliefs and 
knowledge in step 2 confirmed that preferences accounted for a unique portion of 
explained variance (Appendix M).  
An examination of the standardized beta coefficients revealed that, when the  
knowledge and belief variables were entered simultaneously, only the  belief that  
medication is necessary predicted  adherence (partial correlation = .42); knowledge of  
asthma pathophysiology was no longer predictive. To determine whether the drop in the 
predictive power of knowledge of pathophysiology was due to its being mediated by the 
belief that preventers are necessary, a Sobel test was performed. It indicated that the 
perceived necessity of preventer medication did, indeed, partially mediate, (t = 2.16, p < 
.05) the relationship between pathophysiology and adherence. 
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Table 24  
Summary of Hierarchical Regression Analyses for Patient Knowledge, Beliefs and 
Preferences as Predictors of Reported Adherence (MARS-T2) to Asthma Preventer 
Medication  
 Model 
Variable 1 β 2 β 3 β 4 β 5 β 
Demographics      
  Income .04 .06 .03 .07 .07 
  Education .14 .12 .05 .05 .04 
  Age .13 .09 .09 .07 .07 
Clinical Factors      
Visits to Family MD in 
past year for breathing 
symptom 
 .00 -.02 .03 .00 
Visits to ER in past year 
for breathing symptoms 
 .01 .04 .05 .09 
Visits to Asthma Clinic  .12 .13 .07 .11 
Pathophysiology 
Knowledge 
  .26* .17 .24 
Beliefs      
  Timeline- Acute/Chronic    -.01 -.05 
  Necessity of Medication   
 .42*** .37*** 
  Concern of Medication    -.15 -.10 
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   Model   
Variable 1 β 2 β 3 β 4 β 5 β 
Preferences      
  Equal Weighting -Long  
  Term 
   
 -.30** 
  Side Effects – Long Term     .06 
  Efficacy – Long Term     -.18 
R2 .05 .06 .12 .30 .39 
∆R2   - .01 .06 .18 .10 
F 1.41 .86 1.51 3.25** 3.86*** 
∆F   - .35 5.16* 6.55*** 3.90** 
*
 p < .05. ** p < .01. *** p < .001. 
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Supplementary Analyses  
 Although the following analyses do not address this study’s a priori hypotheses, 
they were nonetheless pursued to explore the added value of the novel DCE methodology 
and to examine the predictive power of psychosocial variables shown to predict 
adherence in other domains.  
Clustering versus rating scales. 
To determine whether the discrete choice and rating tasks were measuring similar 
phenomena, Pearson correlations were conducted between the rating items and their 
corresponding discrete choice item total score (Table 25). Notably, only long term side 
effects correlated with its matched DCE variable. Although significant, the correlation 
was small (r = .28, p <.001). It appears, therefore, that people’s overt ratings of what is 
important to them differ from what they are willing to give up in a trade-off situation.  
A Principal Axis Factor Analysis (Oblimin rotation) of the 9 rating items 
corresponding to the discrete choice options suggested three factors, which explained 
70.58% of the total variance. Table 26 illustrates the factor pattern matrix. For an item to 
be considered part of a factor, it had to load: (1) .50 or higher on the primary factor and, 
(2) .40 or lower on all the remaining factors. The factors were labeled: (1) Complexity of 
treatment (Eigen value = 3.13; percent variance = 34.78; items: number of inhalers, 
taking an inhaler every day, taking an inhaler only when I need it; α = .74), (2) Efficacy 
of treatment (Eigen value = 1.77; percent variance = 19.69; items: relieves symptoms in 
minutes, keeps asthma from getting worse in 10 years, and reduces attacks over the next 
6 months; α = .81), (3) Side effects (Eigen value = 1.45; percent variance = 16.11; 
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Table 25 
Correlations between Rating Item and Corresponding Discrete Choice Attribute 
Rating Item DCE Attribute r 
1. Keeps asthma from 
getting worse in 10 years 
Long Term Outcome .14 
2. Number of inhalers Number of Inhalers -.04 
3. Taking an inhaler every 
day 
Frequency of Dose -.04 
4. Taking an inhaler only 
when I need it 
Frequency of Dose .10 
5. Short term side effects Side Effects .04 
6. Long term side effects Side Effects .28** 
7. Risk of Addiction Steroid Dose .15 
8. Relieves Symptoms in 
Minutes 
Immediate Effects -.06 
9. A decrease in asthma 
attacks over the next 6 
months 
Short Term Outcome .06 
**
 p < .001. 
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Table 26 
Pattern Matrix of Rating Scale Items 
 Component 
Item 1 2 3 
Number of inhalers .73 -.11 .06 
Taking an inhaler every day .87 .03 -.37 
Taking an inhaler only when I need 
it 
.50 -.05 .30 
Short term side effects .29 .06 .60 
Long term side effects -.14 -.11 .82 
Risk of addiction .01 .03 .61 
Relieves symptoms within minutes -.05 -.53 .13 
Keeps asthma from getting worse in 
10 years 
.20 -.92 .06 
Reduces attacks over next 6 months .11 -.86 -.11 
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items: short term side effects, long term side effects, risk of addiction; α = .71). Notably, 
long term outcome did not emerge as its own factor. 
Only the efficacy of treatment factor (which includes the long term outcome item) 
correlated with the MARS-T2 scores (r = .21, p< .05). However, when a linear regression 
analysis was performed to examine whether the rating-based preference factor scores 
predicted adherence on the MARS at one month follow-up, none of the factors 
significantly predict asthma adherence scores, R2 = .06, F(3, 109) = 3.4, ns. 
Cost, which was not assessed through the discrete choice scenarios (nor correlated 
with any of the discrete choice attribute total scores), was not significantly correlated 
with MARS scores. 
Other psychological factors as predictors of adherence.  
 Previous studies have demonstrated that patients’ sense of enablement (Haugney, 
Cotton, Rosen, Morrison, & Price, 2007) and satisfaction (Jackson et al., 2004) following  
a clinical encounter influence adherence. In addition, given that asthma (or asthma 
symptoms) has also been associated with increased prevalence of anxiety and panic-fear 
(Jessop, Rutter, Sharma, & Albery, 2004), and that negative affect  has been associated 
with  non-adherence (Lehrer, Feldman, Giardino, Song & Schmaling, 2002), exploratory 
correlations were conducted to see if these factors, if included, would improve the 
predictive power of the regression analysis. None of the factors were correlated with 
MARS or Diary scores, and as such, it was deemed unnecessary to add them to the 
regression analyses. 
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Rescue medication use. 
Although this study was designed to explore the effects of knowledge, beliefs and 
preferences on preventer medication adherence, it is also interesting to note any 
associations with rescue medication use. Rescue medication use was significantly 
correlated only with the belief in the necessity of taking one’s rescue inhaler (r = .27, p 
<.001, rs = .30, p < .001) and the number of asthma symptoms experienced (ridentity = .27, 
p < .05, rs = .26). Individuals in different preference clusters did not differ with respect to 
the frequency of rescue inhaler use, F(68,131) = 1.07, ns. 
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Chapter V: Discussion 
 The main goal of this study was to explore the additive effects of knowledge, 
beliefs and preferences on preventer medication adherence in a sample of patients with 
asthma. Specifically, it was hypothesized that knowledge of asthma pathophysiology as 
well as beliefs about the consequences, chronicity, and controllability of asthma and 
necessity for preventer medications would be preconditions of adherence, but that 
preferences for long term improvements would further predict reported adherence. These 
predictions were borne out by the primary study findings, which are reviewed and 
discussed in the following sections.  
Main Findings Pertaining to MARS Reported Adherence 
As expected, the study findings support the assertion that knowledge, beliefs and 
values pertaining to the understanding and valuing of long term, rather than immediate 
outcomes predicts preventer medication adherence. Specifically, when examined on their 
own,  knowledge of asthma pathophysiology (i.e., recognizing that asthma is a tonic 
inflammatory condition of the lungs), perceiving the need for preventer medications (i.e., 
understanding that they stymie progression of the disease) and preferring long term 
outcomes over short term symptom alleviation, each significantly positively predicted 
reported adherence. When assessed together, preference for long-term improvement in 
asthma accounted for 10% of the variance in adherence beyond that explained by 
knowledge and beliefs alone. As a group, the three classes of variables accounted for 
33% of the variance in adherence beyond that accounted for by demographic and clinical 
factors. The implications of these findings are each discussed in detail below.  
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Knowledge of asthma pathophysiology is important but not sufficient. 
This was the first study to explore the extent to which specific domains of asthma 
knowledge predict adherence. As hypothesized, knowledge about the pathophysiology of 
and functional changes associated with asthma was the only knowledge domain to 
correlate with reported adherence (r = .27). However, when entered along with treatment 
beliefs in a regression predicting adherence, the predictive power of pathophysiology 
knowledge was lost. This suggests that knowledge of pathophysiology is important only 
in so far as it leads one to believe that preventer medication is necessary to treat the 
condition. These findings are considered in greater detail below.  
Knowledge of asthma pathophysiology is the only knowledge domain to predict 
adherence. 
That pathophysiology was the only knowledge domain to predict adherence 
suggests that, in order to adhere, patients need more than simply to know what to do - 
they must understand why they are being asked to do it. The National Asthma Education 
Prevention Program (Bethesda, 1997) recommends that standard content areas, including 
inhaler technique, environmental triggers, roles of medications and self-monitoring 
approaches, all be included in all programs. Yet, as per these study findings, if one wants 
to increase the likelihood of adherence to preventer medication, it may be most 
efficient/cost-effective to ensure that patients understand the tonic pathophysiology of 
asthma and how it is targeted by corticosteroids.   
 Research in other domains has similarly demonstrated that, when given a 
rationale or explanation for a prescribed behaviour, people are more likely to comply. For 
example, Taylor and Bower (2004) found that undergraduates were far more likely to 
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wear protective gloves before applying a liquid plant fertilizer when given the following 
instructions: “Gloves are recommended during application to prevent possible skin 
irritation and/or skin staining” (65% compliance) than when simply told the following 
“Gloves are recommended during application” (23% compliance).  
Moreover, in a series of studies on decision making heuristics and errors, Tversky 
and Kahneman (1983) demonstrated that the more specific a link could be made between 
a cause and outcome, the more easily it could be elaborated upon and perceived as likely. 
This may be especially important for health behaviours, wherein the consequences of 
perceiving an outcome to be less likely than it is really prove dangerous. This danger is 
compounded by people’s general tendency to be optimistically biased with regard to their 
health (Hahn & Reiner, 1998; Renner, Knoll, & Schwarzer, 2000; Weinstein, 1980). So, 
anything that can counter the forces that push people away from taking medication for 
long-term conditions (i.e., helping them understand why the medication is important) 
should be part of the clinical armamentarium.  
To re-iterate, the results of this study suggest that ensuring patients understand 
“why” asthma medications are necessary (i.e., the physiology of asthma and their 
functional impact) will promote adherence. This finding has health policy implications in 
that it suggests that interventions targeting adherence should focus on providing patients 
with the information they need to understand the mechanisms of their condition. Thus, in 
the interest of improving adherence, practitioners arguably should routinely include an 
assessment of patients’ knowledge of asthma pathophysiology.  
To date, however, there has been no clinical tool that adequately assesses patients’ 
knowledge of their asthma. That is, current measures of asthma knowledge tend to tap 
  
120 
patients’ knowledge of medications (e.g., Kritikos, Krass, Chan, & Bosnic-Anticevich, 
2005) or have focused on symptoms, the stigma associated with asthma and perceptions 
of quality of life (e.g., Grant et al., 1999). Of those measures that assess pathophysiology, 
the focus is on the physiology of asthma attacks (acute bronchoconstriction) rather than 
the underlying chronic inflammation. For example, Allen and Jones (1998) asked 
participants in an asthma intervention program whether statements such as “During an 
asthma attack, more mucus is produced in the airtubes” (T) and “During an asthma 
attack the airtubes collapse” (T) were true or false. These items, however, only tap 
knowledge of the physiology of acute airway constriction that give rise to asthma 
symptoms, but not knowledge of the underlying chronic inflammatory mechanisms 
which are treated by preventer medication. Based on the current study’s findings, it could 
be argued that items such as  “People with asthma can have swollen and inflamed 
airways even when they feel well” (T), “Asthma can be cured” (F), “When someone’s 
asthma attack is over it means that the asthma has gone away” (F), “Asthma is a disease 
that does not last for a long time”(F) and “It is possible for someone’s asthma to be 
worse without them noticing a change in their breathing” (T)  also should be included in 
these measures.  
Notably, Schaffer and Yarandi (2007) included two similar items (“People with 
asthma have swollen and inflamed airways even when they feel normal” and “Asthma can 
be completely cured) in their instrument. Similarly, in a survey designed for parents of 
children with asthma, Ho et al. (2003) included “Asthma is due to inflammation in the 
lungs”. However, one or two items are not enough to adequately assess patients’ 
knowledge in this domain. Our scale, which included nine items targeting participants’ 
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understanding of asthma pathophysiology, provided a more comprehensive measure of 
patients’ knowledge in this domain.   
Beliefs about the necessity of a medication mediate the effect of 
pathophysiology on adherence. 
Although knowledge of pathophysiology predicts adherence, it is erroneous to 
assume that this knowledge, in and of itself, directly leads to adherence.  A meditational 
analysis revealed that knowledge of asthma pathophysiology leads to adherence, in part,   
because it enables people to see why they should take their preventer medication; 
individuals must know why they need their medications in order to believe in their 
necessity. In fact, the variable most strongly associated with reported medication 
adherence was the perceived need for medication (r = .36), which accounted for an 
additional 18% of the variance in adherence reports beyond that accounted for by 
participant demographics and asthma knowledge. The strength of the association between 
treatment beliefs and adherence is similar to that observed by Horne and Weinman 
(2002).  
These findings are also consistent with those of others. For example, McHorney 
and Gadkari (2010) found that, across various conditions, patients’ perceived lack of 
medication need (as gauged by a self-report survey) was an important factor for 
medication non-fulfillment rates, stronger than that of medication knowledge. Knowledge 
also has been shown to indirectly affect adherence through behavioural skills (Amico, 
Toro-Alfonso, & Fisher, 2005), personal motivation (Martin, Haskard-Zolnierek, & 
Dimatteo, 2010) as well as health beliefs (McHorney, 2009).  
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In the case of this study, one reason the effect of knowledge of  pathophysiology 
was partly accounted for by beliefs about the need for preventer medication may be 
because the latter  taps not only the why (because asthma is the result of a problem in the 
airways), but also the how (medications keep the airways from getting worse). 
Pathophysiology knowledge and perceived need for preventer medication were modestly 
correlated (r = .22), suggesting that, although beliefs and knowledge are distinct, patients 
must understand that asthma persists even when they are not experiencing symptoms if 
they are to believe that the medications will help in this regard. It is thus not surprising 
that beliefs about the necessity of medications and beliefs about the chronic nature of 
asthma were moderately correlated (r = .42), and that pathophysiology knowledge also 
moderately correlated with the belief that asthma is a chronic condition (r = .48). 
Beliefs about an illness are not as strong a predictor as beliefs about its 
treatments. 
Contrary to prediction, the illness belief subscales did not predict reported 
adherence when considered in conjunction with treatment beliefs. Among other health 
populations, treatment beliefs also have proven to be stronger predictors of adherence 
than illness beliefs (Leventhal et al., 2008; McHorney & Spain, 2011). For example, in a 
sample of 180 stroke survivors, O’Carroll et al. (2011) observed that concerns about 
medications and low perceived medication benefits were the two primary predictors of 
poor medication adherence, whereas illness beliefs were not predictive. Similarly, in a 
path analysis of the effect of beliefs on reported adherence, Horne and Weinman (2002) 
found that necessity beliefs largely mediated the effect of illness perceptions (with the 
exception of consequences beliefs) on reported preventer medication adherence. These 
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findings were essentially replicated in this study by the finding that the association 
between the belief that asthma is a chronic condition and adherence to preventer 
medication was partly mediated by the belief that preventer medications are necessary. 
Why, then, might treatment beliefs better predict adherence than illness beliefs? 
McHorney (2009) recently proposed a proximal-distal continuum of drivers of 
adherence. Adapted from Brenner’s proximal-distal continuum (Brenner, Curbow, & 
Legro, 1995), she argues that the strength of the association between a belief and 
adherence is a function of the beliefs’ proximity to patient decision making about 
whether or not to take a medication. Proximity of a belief or construct is based on how 
specific it is to the decision. Accordingly, McHorney hypothesized that treatment beliefs 
would be most proximal to the decision to not purchase a newly prescribed medication 
(medication non-fulfillment) or to discontinue medication use without consulting a health 
care provider (medication non-persistence). On the basis of bivariate and multivariate 
analyses of treatment beliefs, illness beliefs, and demographic factors, she found that  
only the perceived need for and concern about medication (i.e., treatment beliefs) 
differentiated adherers from non-fulfillers and non-persisters. Demographic and 
psychosocial factors (the most distal in McHorney’s model), were only weakly associated 
with non-adherence, a finding which has been supported by other research (i.e., 
Dimatteo, 2004).  
 This study fails to replicate Horne and Weinman’s (2002) finding that beliefs 
about the consequences of asthma predicts adherence to preventer medication. It should 
be noted, however, that  the direction of their finding  was counter-intuitively negative; 
that is, the worse impact people believed asthma to have on their lives, the less (rather 
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than more) likely they were to adhere. However, given that Horne and Weinman’s (2002) 
study was cross-sectional, the finding might be explained by non-adherence leading to a 
worsening of asthma and thereby augmenting its adverse impact. With reference to the 
current study’s findings, one might propose that,  rather than perceived consequence 
exerting its effect on adherence directly, it acted through the perceived need for preventer 
medication, as these variables were positively correlated (r =.40). However, because 
beliefs about consequences were not significantly correlated with adherence (r = .05), 
there was no effect to be tested for mediation.  
Notably, the only illness belief subscale to correlate with adherence in this study 
was the acute/chronic timeline scale (r = .27), and its effect was, indeed, partially 
mediated by the perceived need for preventer medications. The acute/chronic timeline 
subscale taps beliefs about the long-lasting nature of one’s condition, which, like 
understanding asthma pathophysiology and believing in the necessity of preventer 
treatment, entails an appreciation for long-term outcomes. Beliefs about the cyclical 
nature of the symptoms were not correlated with participants’ beliefs about the chronicity 
of asthma. This suggests that participants differentiated between the fluctuating (or not) 
nature of asthma symptoms and the chronicity of its underlying pathophysiology. 
Appreciating the long-lasting nature of asthma and not the variability in symptoms 
predicted adherence.  Along these lines, Schiaffino and Cea (1995) found that the ability 
to separate beliefs about symptoms and those about a disease predicts outcome in chronic 
pain. That is, they observed that when patients with chronic pain are able to make the 
distinction between their symptoms and their underlying disease, they came to recognize 
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that symptom improvement is not predicated on finding a cure for their disease and, 
consequently, their symptoms seem more manageable.  
Preferences predict adherence above and beyond knowledge and beliefs. 
Previous research already has shown that people with asthma have strong 
preferences regarding treatment. For example, McKenzie and colleagues (2001) 
demonstrated that, as a group, patients see cough as the most important symptom to target 
and reduce. Moreover, McTaggart-Cowen et al. (2008) as well as Haugney et al. (2007) 
found that patients are willing to trade symptom free days for a less complex treatment 
plan. This was the first study, however, to identify clusters of asthma patients based on 
treatment preferences and to subsequently use the clusters to predict adherence 
behaviour. Four groups, those privileging (1) long term benefits, (2) medication side 
effects, (3) a trade-off between side effects and efficacy and (4) all attributes equally, 
emerged. As predicted, a regression analysis indicated that preferences for long term 
outcome predicted improved adherence scores, accounting for an additional 7% in 
variance above that accounted for by knowledge and beliefs. Together, these three classes 
of variables accounted for 39% of the variance in self-reported adherence, an increase of 
almost 20% from previous studies (e.g., Horne and Weinman, 2002). 
As noted earlier, long term considerations are what drove adherence to preventers. 
Namely, those most likely to adhere (1) believed that asthma is a long lasting chronic 
condition, (2) believed that preventer medications are necessary to reduce the progression 
of the disease in the long term, (3) understood that asthma is a problem with the airways 
that will worsen over time (pathophysiology) and (4)  valued the extent to which a 
treatment will produce long term effects above other elements of a medication (e.g., 
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immediate effects, side effects, and complexity of the regimen). In addition, those who 
valued long term outcomes were more likely to acknowledge “airway problems” as a 
cause for their condition and had better knowledge of asthma pathophysiology than those 
who weighed all attributes equally. 
Grouping participants into clusters, as was done here, has some advantages. Until 
recently, preferences for treatments have been explored either at the aggregate (whole 
group) level or at the micro level of individual participants (Singh et al., 1998). However, 
overall group data over-generalizes participants’ views and individual differences are 
lost. Therefore, it is not surprising that interventions based on this “one size fits all” 
group level approach yields inconsistent results. In contrast, data at the individual level 
may be oversensitive to individual variation making it impossible for policy makers to 
systematize intervention. As such, an intermediary step of subgroup analyses is 
particularly useful. Interventions can then target different patient groups who may use 
different decision factors based on their distinct goals, needs, and motivations. For 
example, in the current study, group membership predicted adherence such that those 
who valued long term outcomes were more adherent than those who weighed all 
medication attributes equally. Had we not been able to extract subgroups based on 
preferences, this finding would have been obscured. 
It was expected that those inclined to avoid side effects would be less adherent 
than those focused on long-term outcomes. This prediction was not borne out. One 
possible reason for this null finding may be decisional uncertainty. That is, the side effect 
options contained the term “risk” (i.e., “There is a risk of major/long term side effects” 
versus “There is a risk of minor/short term side effects”), whereas the long term options 
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were phrased more definitively (“Your airways will be worse in 10 years” versus “Your 
airways will be the same in 10 years”). Research in the area of psychology of decision 
making has identified many biases that come into play when individuals judge the 
likelihood of an event (Chapman & Elstein, 2000) and has demonstrated that probability 
theory is often violated under conditions of uncertainty (Redelmeier, Koehler, Liberman, 
& Tversky, 1995). Arguably, the term “risk of” evokes more uncertainty than the more 
decisive wording of the long term outcome options.  Accordingly, certain maintenance of 
airway integrity over the long-term may have carried more weight (and hence “predictive 
punch”) than the possibility of side effects.   
Main Findings Pertaining to Diary-Reported Adherence 
The two  measures of adherence - the medication diary and the MARS scores at one 
month follow-up- were significantly correlated in the expected direction, but the 
magnitude of the association (rs= .35) is lower than observed between the MARS and 
electronic monitoring indices of adherence (rs=.50) (Cohen et al., 2009). Moreover, 
whereas the MARS scores correlated with many of the hypothesized predictors of 
adherence, diary scores correlated with none.  
One explanation for this pattern of findings is a lack of sufficient variation in the 
diary scores, which were “0” (indicting ‘perfect’ compliance) roughly 60% of the time.  
Another explanation is that the MARS scale used in this study and the diary recording 
may actually measure different aspects of adherence.  
Recent data suggests that adherence is not a uni-dimensional construct (Mora et al., 
2011; Clifford et al., 2008). For example, a recent factor analysis of the revised MARS-A 
10 item scale revealed two types of intentional non-adherence: (1) stimulus or symptom 
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driven non-adherence and (2) intentional reduction or avoidance of medications. In the 
first type of non-adherence, patients use somatic signs as cues to take their medications. 
In other words, patients’ bodies provide them with feedback about the effectiveness of 
their medications. Items such as “I only use it when I feel breathless” and “I use my 
inhaler only when my other one doesn’t work” illustrate this construct. The second type 
of intentional non-adherence is more deliberative, whereby patients make decisions as to 
whether or not to take their medication based on their internal working models. Items 
such as “I alter the dose” or “I try to avoid using it” reflect this more deliberative process.  
Unfortunately, Mora et al.’s (2011) version of the MARS (the MARS-A) was not 
available at the time this study was designed and executed. One could predict that had it 
been administered, the subscale tapping somatically-cued adherence would have 
correlated more strongly with the diary measures than the more deliberative subscale, the 
reasoning being that if patients use their fluctuating symptoms as cues to take their 
medications, their diary reports, on which they recorded the times they chose to take 
medications, would reflect this behaviour. To verify this hypothesis, however, future 
research will need to monitor fluctuations in symptoms that occur in tandem with 
medication- taking.  
Moreover, Mora et al. (2011) found the two subtypes of non-adherence to be only 
slightly inter-correlated. If the diary recordings more directly tap the somatically-cued 
adherence behaviours, then we would anticipate only a weak correlation with the MARS 
measures used in this study, as it mostly gauged the second type of intentional non-
adherence. In addition, the adherence behaviours recorded in the diary likely do not 
reflect the more deliberative, planned adherence decisions tapped by the second factor on 
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the MARS-A, as it makes sense that this second factor is more  influenced by knowledge, 
beliefs and preferences. This may explain why MARS, and not the diary measures, 
correlated with the predictors of interest. As is argued in more detail in the sections 
below, while a macro decision to follow health care recommendations may initiate 
adherence, it is enacted through the myriad of daily decisions, which may be better 
reflected in the daily diaries. Perhaps the knowledge, beliefs, and preference variables 
explored in this study drive the macro more so than the daily decisions, and as such, did 
not correlate with the diary measures.  
Other Notable Findings 
Although not the main focus of the study, other findings worthy of comment 
emerged.   
Reported adherence on the MARS increased over time. 
As a group, participants reported higher adherence on the MARS at one month follow 
up than they did initially, just before being seen by their health care provider at the clinic 
visit. Without a control group, we cannot really know whether this is due to the 
Hawthorne effect or due to specific ‘interventions’ that took place between the two 
administrations, namely the self-monitoring requirement of the daily diary, or meeting 
with the clinic physician. Both are plausible mechanisms. With respect to self-monitoring 
as a potential mechanism, in a non-controlled study, Straka et al. (1997) found that after 
completing medication diaries, heart disease patients’ adherence rates (as gauged by 
electronic monitors) increased by 9 percent.  
However, that the effect was observed only for those visiting the clinic for the first 
time and not amongst those coming for repeat visits strongly suggests that, rather than 
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being due to self-monitoring, the meeting with the asthma centre clinician and/or simply 
the novelty of initiating treatment at a specialty clinic (rather than primary care) provided 
the new patients an added incentive to adhere. Accordingly, the more plausible 
explanation, supported by findings reported by DiMatteo et al., (2003) for the increases in 
MARS scores is that patients’ treatment efficacy attitudes were shaped/reinforced during 
their first visit at the specialty clinic which, in turn, increased their tendency to adhere.   
 Discerning preferences. 
 Participants’ overt ratings of the importance of various attributes of their 
treatment regimen did not correlate (all r’s less than .28) with the preferences revealed 
through the DCE task. Moreover, had we relied solely on data from the rating scales, 
subgroup differences would have been obscured. Factor analysis of the rating scales for 
the entire sample yielded four factors, namely: (1) Efficacy of treatment, (2) Complexity 
of treatment, (3) Side effects and, (4) Cost, but long term outcomes did not emerge as a 
factor. Notably, preferences for long term outcomes, inferred from the DCE task, 
emerged as the dominant predictor of adherence, and none of the explicit rating factors 
predicted.  
Rating scales (which require participants to rate their opinions or attitudes on a 
numerical or semantic scale) and ranking tasks (which require respondents to give an 
ordinal ranking of items such that the items that receive the highest ranking are 
considered most important) are widely used in the health research domain (Ryan et al., 
2001; van Helvoort-Postulart, van der Weijden, Dellaert, de Kok, von Meyenfeldt, & 
Dirksen, 2009). Based on an a systematic literature review of quantitative and qualitative 
methods for eliciting public preferences for health care, Ryan et al. (2001) argued that 
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although the ease of both administering and scoring ranking and rating scales makes them 
attractive, they are limited in that they do not take context into consideration. Moreover, 
ranking and ratings entail judgments, not choice, and rating one alternative higher than 
another does not necessarily mean one will choose the former (Payne, Betteman, & 
Johnson, 1992).  
 Unlike rating/ranking scales, DCEs, take context and strength of preference into 
account. Moreover, they assess preferences in a more externally valid way. By comparing 
options that vary along several attributes at once, respondents are impelled to consider 
trade-offs. This has important implications for health care resource allocation. Rating or 
ranking something very highly does not necessarily mean that a health consumer or 
funder wants to allocate all resources (e.g., funds, efforts) to that consideration at the 
expense of everything else. This recognition has resulted in the increased use of discrete 
choice scenarios (which assess trade-offs) in health care research (Ryan, Bate, Eastmond, 
& Ludbrook, 2001; Ryan & Farrar, 2000; van Til, Stiggelbout, & Ijzerman, 2009). Given 
that health care provider time is a limited resource, using this methodology to elicit 
patient preferences may optimize the time spent with health care providers.  
As far back as two decades ago, there was a call for psychologists and economists to 
work more closely together to better explain health choice behaviour and uptake of health 
services (Phillips & Rosenblatt, 1992). Health economists, interested in exploring market 
choices, have established useful methods (such as discrete choice experiments) to explore 
real-world “trade-offs” of medication choices. Yet, classic economic theory cannot 
account for when individuals make irrational choices that seem not to logically balance 
costs against benefits and act/choose so as to maximize their personal advantage (Phillips 
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et al., 2002). Behavioral economists and cognitive psychologists, however, have 
identified systematic ‘non-rational’ yet perfectly understandable biases (e.g., 
representativeness and availability) shown to play out in medical decision making 
(Dawson & Arkes, 1987). There are also biases (e.g., hindsight bias and confirmation 
bias) that affect the judged probability of an adverse health event, as well as the judged 
utility (value) of a given outcome (e.g., framing effects, preference reversals, sunk cost 
bias, decision weights, omission bias, and regret) (Chapman & Elstein, 2000). Therefore, 
the combination of economic methodology to identify what decisions people make, 
psychological research identifying how people come to the decisions as well as how to 
rectify problematic biases will prove extremely useful.  
Clinical Implications 
The value of a given theory is enhanced when it can serve a pragmatic function – in 
this case, improve adherence. Leventhal and Cameron (1987) suggested that the Common 
Sense Model of Illness (CSM) can be incorporated into three types of educational 
interventions. First, in “communication style”- focused interventions, health care 
providers use their relationship with patients to help them accept a message. In essence, 
belief in both the message and the messenger are presumed to encourage behaviour.  
Second, cognitive-focused interventions emphasize less the relationship between the 
parties and more the cost-benefit analysis of beliefs (health threat versus behaviour) as 
motivating factors. Finally, interventions that focus on self-regulation emphasize patients 
as an active problem solvers and their ability to meet the health challenge. While 
interventions guided by these models do tend to improve patients’ abilities to manage 
their disorder, the relative importance of each component as the active ingredient remains 
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unclear (van Dumalen et al., 2004). Moreover, others (Horne et al., 2007) have suggested 
that it is simply beliefs, not education, that motivates behaviour change. 
However, our findings suggest that beliefs and knowledge alone are not enough, and 
that patients’ goals and preferences for treatment also drive adherence. Psychologists 
have long advocated using patient-defined goals to guide treatment and recently, medical 
experts have begun to acknowledge the importance of incorporating goals into treatment 
(Charles, Gafni, & Whelen, 1999). For example, Wilson et al., (2010) randomized 
patients with asthma to either a treatment regimen wherein clinicians and patients worked 
together to accommodate patients’ goals and preferences or a clinical decision group in 
which patients’ goals were not elicited. Both groups received asthma education and two 
in-person and three phone encounters. At one year follow-up, those patients whose 
preferences and goals were targeted were more adherent to their preventer medication 
and used their rescue medication significantly less than the standard care group at two 
year follow-up. 
It may be clinically useful to conceptualize adherence to asthma medications as a 
two-tier process, wherein patients make both macro (i.e., “Will I fill my prescription?) as 
well as micro (i.e., “Shall I take my preventer medication this morning?”) level decisions. 
Preferences for treatment as well as knowledge and beliefs likely target macro level 
decisions. Once the macro decision has been made, behavioural factors, such as patients’ 
skill and ability to take the medications likely play a more important role. Targeting 
patients’ behavioural abilities has been shown to be imperative for the prediction and 
promotion of sexual and reproductive health behaviours (Bryan, Fisher, Fisher, & 
Murray, 2000; Cornman, Schmiege, Bryan, Benziger, & Fisher, 2007; J. Fisher, Fisher, 
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Bryan, & Misovich, 2002; W. Fisher, Williams, Fisher, & Malloy, 1999). For patients 
with asthma, current treatment guidelines suggest using written asthma action plans as 
well as providing education about the techniques associated with inhaler use. These 
strategies have been shown to be moderately effective (Gibson & Powell, 2004), likely 
because patients must first make a decision about whether or not they are going to adhere 
at all; a decision based on their beliefs and preferences. Notably, the technique subscale 
of the asthma knowledge scale used in this study was not correlated with adherence on 
the MARS. Again, it appears that the MARS tap higher order (macro) decisions and not 
daily medication decisions.  
As such, Motivational Interviewing (MI) strategies, emergent from the psychological 
literature, may be particularly useful for targeting patient health care preferences and 
goals that need to be addressed before behavioural skills are taught. MI is a method for 
enhancing change behaviours by exploring and resolving ambivalence (Miller & 
Rollnick, 2002). Incorporating MI into interventions can double the effect size of an 
intervention and improve retention and adherence (Burke, Arkowitz, & Menchola, 2003; 
Hettema, Steele, & Miller, 2005). However, it should be noted that motivational 
interviewing techniques tend to focus on ambivalence around changing behaviour to 
achieve one given goal, in part, by helping people address the actual costs of the 
behaviour change (i.e., Although I want to lose weight, and know that one of the ways I 
can do so is exercise, I’ll sweat when I exercise, and I hate the sensation of sweating). 
Horne et al. (2007) note, however, that patients often present with what appear to be 
contradictory goals. For example, a patient might have as a goal to reduce symptoms of 
the disease but might equally want to reduce the risk of side-effects. If a given medication 
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equally promises/threatens both outcomes, then this patient understandably is in a bind.  
However, individuals often are unaware of the sources of their ambivalence and the 
present study presents a means – DCE- by which to elucidate (for patients, their 
practitioners, and health system planners), the trade-offs individuals are willing to make.  
Main Limitation: The Dependent Measure - Adherence.    
Adherence is likely overestimated.  
Measurement of adherence is both controversial and fraught with methodological 
challenges. Self-report surveys, while the most widely-used in research, tend to 
underestimate non-adherence by approximately 20 percent (Horne & Weinman, 1999), 
probably because patients are loathe to admit (to themselves and others) that they do not 
follow their health care providers’ prescriptions. Moreover, diary records have been 
shown to overestimate medication use (as gauged by electronic monitoring) by more than 
50% (WHO, 2003). There is, however, no ideal way to measure adherence (Clifford, 
Barber, & Horne, 2008) and it is recommended that convenience, participant 
acceptability, and cost be taken into consideration when deciding which measure to use 
(Vitolins, Rand, Rapp, Ribisl, & Sevick, 2000). Given logistic constraints, we chose to 
employ self-report measures of adherence, which reviews of the literature (Haynes et al., 
1980; Stephenson, Rowe, Haynes, Macharia, & Leon, 1993; Bende et al., 2003) have 
shown compare well with more objective measures electronic records and pharmacy 
reports.  
Our primary outcome measure (MARS) was significantly negatively skewed -   
people reported a high degree of adherence. But despite the high scores, 83% of 
participants in our sample admitted to sometimes, always, or often engaging in at least 
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one of the nine non-adherent behaviours. In fact, our sample more readily acknowledged 
non-adherence than did that of Horne and Weinman (2002) who report that only 74% of 
their sample admitted to these behaviours. And, even with this  distributional challenge, 
Horne and Weinman (2007) still observed statistically and conceptually meaningful 
relationship between adherence and their predictors of interest, as did we. The emergence 
of statistically significant associations despite the distributional properties of the 
dependent variable suggests that the relationships are quite robust, and if anything, the 
strength of the predictors is likely underestimated. Accordingly, it may be useful in the 
future to use more objective measures of adherence (though they can be relatively 
expensive monetarily and effort-wise) to explore these relationships further.   
Failing to differentiate intentional and non-intentional non-adherence. 
There are different types of non-adherence including erratic non-adherence (e.g., non-
adherence due to forgetfulness or changing schedules), unwitting non-adherence (i.e., 
unintentional non-adherence stemming from a lack of patient understanding about how to 
take their medications) and intelligent non-adherence (i.e., non-adherence stemming from 
a reasoned choice not to take medication) (WHO, 2003). Clifford, Barber and Horne 
(2008) argue that the hundreds of factors hypothesized to influence adherence can be 
categorized into intentional or non-intentional factors. Non-intentional factors are 
synonymous with unwitting and erratic non-adherence factors described above, in that 
patients may inadvertently be non-adherent either because they have failed to understand 
the skills necessary to take their medications or they cannot manage to take it. Intentional 
non-adherence, on the other hand, is influenced by patients’ beliefs, knowledge and 
motivation. Notably, intentional and nonintentional adherence factors may overlap. For 
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example, patients who have fewer beliefs about the necessity of their medication may be 
less motivated to take it and, as a result, forget to take it more often.  
Clifford et al. (2008) demonstrated differences in treatment beliefs among intentional 
and unintentional adherers. Compared to adherers, intentional (but not unintentional non-
adherers) believed less in the necessity of and had more concerns about their prescribed 
medications. A limitation of the current study is that the MARS contained only one item 
tapping unintentional non-adherence (I forget to use it) which was significantly correlated 
(r’s ranging from .30 to .60) with the other items on the scale (with the exception of “I 
use it only as a reserve”), and so it was not possible to discern the differential predictors 
of intentional and non-intentional adherence in this sample. If Clifford et al.’s (2008) 
measure had been used in this study, one would hypothesize that knowledge, beliefs and 
preferences would predict intentional but not non-intentional non-adherence.  
Future Directions 
The current study was novel in its integration of theory and methodology from a 
number of disciplines which, when combined, suggest that, to the extent to which 
individuals with asthma understand and believe in the long term nature of their disorder 
and the need for medications and value long term outcomes, they will be likely to adhere 
to their preventer medication. While these findings provide a first step to better 
understanding patient decision making in the context of asthma medication adherence, 
more work has to be done to extend the scope of inquiry. In particular, examining a 
broader number of attributes and levels, expanding the focus to other aspects of self-care 
regimens, increasing the length of the prospective sampling period and exploring the 
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reciprocal relationships between the variables are all potential future research directions. 
Each is considered below.  
When developing a discrete choice experiment it is essential to ensure that the design 
involves an appropriate range of levels which capture salient elements of the attributes. 
The levels must be plausible and clinically relevant (Lancsar & Louviere, 2008). The 
attributes chosen in this study were dictated by the study hypotheses and the attribute 
levels were chosen so as to be able to generate cluster scores to subsequently be used to 
predict adherence.  Consequently, only binary attribute levels were employed. While the 
binary attribute is the most common DCE design (Street & Bourgess, 2007), the study 
might have benefited from the inclusion of more nuanced attribute levels. Therefore, 
while the design in the current study met the necessary criteria (i.e., all attributes and 
levels were salient, clinically plausible, and relevant), future research may improve our 
understanding of the effect of preferences on adherence behaviours by incorporating a 
greater range of preference options. 
According to Osterberg and Blaschke (2005), patients with chronic conditions 
demonstrate consistently low rates of adherence that drop dramatically after the first six 
months of treatment. Adherence is of interest largely (if not only) because it should lead 
to decreased morbidity. The limited length of the follow-up period (one month) precluded 
our finding any association between knowledge, attitudes and preferences and changes in 
asthma quality of life, as mediated by adherence. As a result, future research involving a 
longer time frame would be useful for exploring this relationship. 
Given the gravity of the problems associated with asthma medication non-adherence, 
this study was focused specifically on adherence to preventer medication. But, lifestyle 
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factors, including getting rid of pets, exercising to lose weight to improve lung 
functioning, or quitting smoking are also clinically relevant “behavioural prescriptions”.  
It is quite plausible that beliefs and preferences may play an even greater role in 
explaining adherence to these recommendations as they involve more complex trade-offs 
off people’s values (i.e., keeping my pet vs. maintaining my lung function). As such, 
future research should focus not only on the predictors of medication adherence, but also 
on what drives people’s lifestyle modification decisions. 
Finally, this study examined the additive effects of patient preferences on adherence. 
However, the reciprocal nature of the relationship between knowledge, beliefs and 
preferences remains unclear. Future research would benefit from exploring interaction 
effects between these three important constructs. 
Overall Summary and Conclusion 
Adherence is a complex and multifaceted phenomenon. The consequences of non-
adherence are significant and include increases in health care costs and poor medical 
outcomes. Hundreds of factors have been hypothesized to be associated with adherence 
across a number of health conditions, treatments, and populations (Clifford et al., 2008) 
and many health care providers and policy officials have attempted to incorporate the 
associated factors into intervention programs. To date, however, costly and time 
consuming intervention programs have been met with only modest success.  
In an attempt to improve the understanding of patient non-adherence, this thesis 
integrated the theory and methods of three disciplinary literatures, namely, nursing/public 
health, psychology and economics, to explore the additive effects of knowledge, beliefs 
and preferences on medication adherence in a sample of patients with asthma. It was 
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predicted that long term factors- understanding the chronic nature of the disorder, the 
necessity for medications to stymie the progression of the disease and valuing long term 
effectiveness of medications above immediate symptom alleviation, treatment complexity 
and side effects- would improve adherence reports.  
A notable finding is that participants who understood that their asthma was a chronic 
pathophysiological condition which could deteriorate if preventers were not taken as 
prescribed were more adherent to their medication than those who did not hold this 
knowledge and belief. This strongly suggests that, to improve patient adherence to 
asthma preventer medications, patients should be helped to understand why they require 
these medications.  
In a recent position paper, Horne et al. (2007) stated that “In the real world where 
patients make choices that may reflect conflicting priorities, asthma still imposes a 
considerable burden on healthcare systems” (p. 9). Identifying the sources of conflicting 
priorities for each individual, however, is impractical for developing systematized 
interventions. On the other hand, eliciting preferences of overall patient groups over-
generalizes and limits the clinical utility of findings. An intermediate step, subgroup 
analysis, is much more practical. This study was among the first to assess preferences at 
the intermediate step of subgroup levels and represents the first attempt to use latent 
cluster analyses of data from discrete choice experiments to uncover previously 
unidentified heterogeneity among a sample of patients with asthma.   
Identifying what is important to patients and ultimately working collaboratively 
towards valuing long term outcomes will improve adherence rates among patients with 
asthma.  In designing intervention programs, policy makers must understand that 
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knowledge is only half of the story. Programs should focus on making sure patients 
understand the physiology and functional limitations of asthma, why medications are 
required, and help guide them to value long term asthma outcomes. After all, our findings 
suggest that if the why is clear, patients are more likely to adhere.  
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Appendix A 
Results from Expert Panel and Additional Consultation 
Domain 
(Based on 
Schaffer and 
Yarandi) 
Survey Question Expert 
Rating 
Expert Comments Suggested 
Change 
Consultation 
Comments 
Final Question 
Pathophysiology 1. People with 
asthma can have 
swollen and 
inflamed airways 
even when they 
feel normal (T) 
3.62 - Would include “to 
a much lesser degree 
b/c otherwise 
implies lots of 
inflammation 
- Replace normal 
with well 
People with 
asthma can have 
swollen and 
inflamed 
airways even 
when they feel 
well (T) 
 People with 
asthma can have 
swollen and 
inflamed 
airways even 
when they feel 
well (T) 
Pathophysiology 2. During an asthma 
attack, the 
muscles around 
the airways 
tighten and the 
airways become 
narrow (T) 
3.90    During an 
asthma attack, 
the muscles 
around the 
airways tighten 
and the airways 
become narrow 
(T) 
Pathophysiology 3. Having swollen 
airways does not 
increase the risk 
of having an 
asthma attack (F) 
3.43 - Reword to true 
statement (4 
comments) 
-Suggest: “Having 
swollen airways 
increases the risk of 
having an asthma 
attack” 
Having swollen 
airways 
increases the 
risk of having 
an asthma 
attack (T) 
 Having swollen 
airways does not 
increase the risk 
of having an 
asthma attack 
(F) 
  
1
7
0
 
Domain 
(Based on 
Schaffer and 
Yarandi) 
Survey Question Expert 
Rating 
Expert Comments Suggested 
Change 
Consultation 
Comments 
Final Question 
 
Pathophysiology 
 
4. Asthma is a 
disease that comes 
and goes (F) 
 
3.43 
  
-“vary in level of 
symptoms from none 
to quite frequent, but 
never go away 
completely” 
-“can be true” 
-“not sure I  am 
interpreting this 
correctly- I suspect 
most people 
associate the disease 
with symptoms” 
- Pam’s suggestion, 
replace with : 
Asthma is a chronic 
condition  
 
Asthma 
symptoms come 
and go but the 
disease is 
always there.  
(T) 
 
OR: 
 
Asthma is a 
disease that 
does not last for 
a long period of 
time. (F) 
 
The comments 
are correct BUT 
we are not 
asking a 
scientific 
audience and 
don’t expect a 
scientifically 
correct answer.  
So yes, asthma 
can go into 
remission but if 
you are asking 
the question to 
someone with 
current asthma 
the correct lay 
answer is that it 
does not go 
away, it is a 
chronic 
condition. 
I like the 
second 
question. 
 
Asthma is a 
disease that does 
not last for a 
long time. 
  
1
7
1
  
 
     
Domain 
(Based on 
Schaffer and 
Yarandi) 
Survey Question Expert 
Rating 
Expert Comments Suggested 
Change 
Consultation 
Comments 
Final Question 
Medications and 
Their Effects 
5. The purpose of 
steroid medication 
inhalers is to stop 
an asthma attack 
when it happens 
(F) 
3.57 - Consider 
simplifying (steroid 
inhalers stop asthma 
attacks when they 
happen) 
- “Depends on if the 
attack is due to 
bronchoconstriction, 
exacerbation, or 
inflammation” 
- “ICS, in fact, may 
diminish worsening 
asthma symptoms (if 
taken regularly) or if 
combined with 
LABA (ie symbicort 
SMART). “ 
 
The purpose of 
an inhaled 
steroid 
(controller) is to 
stop an asthma 
attack when it 
starts (F) 
An inhaled 
steroid 
(controller) will 
quickly stop an 
asthma attack 
when it starts.  
(F) 
The purpose of 
steroid 
medication 
inhalers is to 
stop an asthma 
attack when it 
happens. (F) 
Medications and 
Their Effects 
6. Controller inhalers 
prevent asthma 
attacks (T) 
3.57 - Do people know 
what a controller 
medication is? 
- Suggest replacing 
prevent with reduce 
 
Inhaled steroids 
(controllers) 
prevent asthma 
attacks (T) 
 Inhaled steroids 
(controllers) 
prevent asthma 
attacks. (T) 
       
  
1
7
2
Domain 
(Based on 
Schaffer and 
Yarandi) 
Survey Question Expert 
Rating 
Expert Comments Suggested 
Change 
Consultation 
Comments 
Final Question 
Medications and 
Their Effects 
7. People with 
asthma do not 
need to take their 
daily steroid 
medication if they 
feel normal (F) 
3.62 - Specify inhaled 
steroid 
-“if their breathing 
feels normal” 
-Replace normal 
with well or have no 
symptoms 
People with 
asthma do not 
need to take 
their daily 
inhaled steroids 
(controller) if 
they feel well 
(F) 
 People with 
asthma do not 
need to take 
their daily 
inhaled steroids 
(controller) if 
they feel well. 
(F) 
Medications and 
Their Effects 
8. Quick relief 
medication should 
be taken every day 
(F) 
3.86 - Add: …should be 
taken every day even 
if you are feeling 
well 
-“This is true only if 
the steroid is needed 
to control the 
eosinophilic 
component” 
Quick relief 
medication 
should be taken 
every day, even 
if people are 
feeling well (F) 
 Quick relief 
medications 
should be taken 
every day, even 
if people are 
feeling well. (F) 
Medications and 
Their Effects 
9. People with 
asthma should 
wait until their 
symptoms are 
really bad before 
using a quick 
relief medication 
(F) 
3.90    People with 
asthma should 
wait until their 
symptoms are 
really bad before 
using quick 
relief 
medication. (F) 
 
 
      
  
1
7
3
 
 
Domain 
(Based on 
Schaffer and 
Yarandi) 
Survey Question Expert 
Rating 
Expert Comments Suggested 
Change 
Consultation 
Comments 
Final Question 
Medications and 
Their Effects 
10. People may not 
notice 
improvements in 
their breathing for 
1-4 weeks after 
they start using 
inhaled steroids 
(T) 
3.52 -“ With adequate 
steroid treatment, 
improvement occurs 
rapidly- within days. 
By a week it is near 
maximal” 
- “People may notice 
improvements 
within days” 
-Suggest: “may not 
notice improvements 
in their symptoms 
(cough, wheeze, 
SOB…)” 
 
 
Leave the same. People may not 
notice 
improvements in 
their breathing 
for 1-4 weeks 
after they start 
using inhaled 
steroids. (T) 
Medications and 
Their Effects 
11. It is okay to take 
inhaled steroid 
medication only 
when people 
notice themselves 
wheezing (F) 
3.57 - “What about 
people with mild 
intermittent asthma 
who are told to start 
inhaled ICS only if 
increase in 
symptoms” 
 
It is ok to take 
inhaled steroids 
(controllers) 
only when 
people notice 
their symptoms 
getting worse 
(F) 
 
 
 
Patients treated 
on an interval 
basis are the 
minority.  
It is okay to take 
inhaled steroids 
(controllers) 
only when 
people notice 
their symptoms 
getting worse. 
(F) 
  
1
7
4
Domain 
(Based on 
Schaffer and 
Yarandi) 
Survey Question Expert 
Rating 
Expert Comments Suggested 
Change 
Consultation 
Comments 
Final Question 
Medications and 
Their Effects 
12. Steroid inhalers 
will relieve an 
asthma attack 
within 20 minutes 
(F) 
3.76  Inhaled steroids 
will relieve an 
asthma attack 
within 20 
minutes 
 Inhaled steroids 
will relieve an 
asthma attack 
within 20 
minutes. (F) 
Technique 13. People with 
asthma should 
breathe out 
partially, but not 
fully, just before 
taking their 
medication (F) 
3.57    People with 
asthma should 
breathe out 
partially, but not 
fully, just before 
taking their 
medication (F) 
Technique 14. People with 
asthma should 
hold their breath 
for 10 seconds 
after each puff of 
their inhaler (T) 
3.71 - “No evidence that 
holding breath for 10 
seconds affects drug 
distribution” 
-Add: “should try 
and hold” 
-Pam suggests: 8-10 
seconds to be 
consistent with clinic 
People with 
asthma should 
try to hold their 
breath for 8-10 
seconds after 
each puff of 
their inhaler 
 People with 
asthma should 
try to hold their 
breath for 8-10 
seconds after 
each puff of 
their inhaler. (T) 
  
 
 
 
 
 
     
  
1
7
5
 
 
Domain 
(Based on 
Schaffer and 
Yarandi) 
Survey Question Expert 
Rating 
Expert Comments Suggested 
Change 
Consultation 
Comments 
Final Question 
Technique 15. People with 
asthma should 
wait about one 
minute between 
puffs of their 
quick relief 
medication (T) 
3.32 - “Not just for quick 
relief. Revise to: ‘… 
between puffs of 
their medication 
when taking 2 or 
more puffs from the 
same inhaler’ “ 
- 30 seconds more 
reasonable (esp. at 
St. Joe’s clinic) 
- What about when 
with a Turbuhaler- 
this does not apply 
People with 
asthma should 
rinse and gargle 
after each use of 
their inhaled 
steroid (T)  
The initial 
question is too 
problematic for 
the reasons 
cited. 
 
However, 
(according to 
the nurse) we 
do try to 
recommend at 
the clinics, 
therefore, I 
would leave it 
in. 
1. People with 
asthma should 
wait about one 
minute between 
puffs of their 
quick relief 
medication (T) 
 
2. People with 
asthma should 
rinse and gargle 
after each use of 
their inhaled 
(controller) 
steroid. (T) 
Symptoms 16. Frequent coughing 
can be a symptom 
of asthma (T) 
3.86 - Cough at night is 
more diagnostic 
  Frequent 
coughing can be 
a symptom of 
asthma. (T) 
Symptoms 17. Asthma may cause 
wheezing during 
exercise (T) 
4.00    Asthma may 
cause wheezing 
during exercise. 
(T) 
  
 
     
  
1
7
6
 
Domain 
(Based on 
Schaffer and 
Yarandi) 
Survey Question Expert 
Rating 
Expert Comments Suggested 
Change 
Consultation 
Comments 
Final Question 
Symptoms 18. It is possible for 
someone's asthma 
to be worse 
without noticing a 
change in their 
breathing (T) 
3.81    It is possible for 
someone's 
asthma to be 
worse without 
them noticing a 
change in their 
breathing. (T) 
Environmental 
Triggers and 
Controls 
19. People with 
asthma can 
usually control 
their symptoms by 
taking medicine 
and avoiding 
things that make 
their asthma worse 
(T) 
3.86 - Suggest adding 
“appropriate 
medication” 
- Replace medicine 
with “medication as 
prescribed” 
-Replace “things that 
make asthma worse” 
with triggers 
Split: 
1. People with 
asthma can 
usually control 
their symptoms 
by taking the 
appropriate 
medications 
2. People can 
usually control 
their symptoms 
by avoiding 
things (triggers) 
that make their 
asthma worse 
 1. People with 
asthma can 
usually help 
control their 
symptoms by 
avoiding things 
(triggers) that 
make their 
asthma worse. 
(T) 
2. People with 
asthma can 
usually help 
control their 
symptoms by 
taking the 
appropriate 
medications. (T) 
       
  
1
7
7
 
Domain 
(Based on 
Schaffer and 
Yarandi) 
Survey Question Expert 
Rating 
Expert Comments Suggested 
Change 
Consultation 
Comments 
Final Question 
Environmental 
Triggers and 
Controls 
20. Keeping bedroom 
windows open at 
night will help 
prevent asthma 
attacks (F) 
3.86    Keeping 
bedroom 
windows open at 
night will help 
prevent asthma 
attacks. (F) 
Environmental 
Triggers and 
Controls 
21. Bedrooms are the 
most important 
room to keep free 
of dust and animal 
fur or feathers (T) 
3.71 - True if allergic to 
those things 
-Factually incorrect 
-only if patient is 
allergic to dust and 
animal dander 
Remove and 
replace with: 
Cold air can 
make asthma 
symptoms 
worse (T) 
Taking steps to 
reduce airborne 
particles such 
as dust and 
animal dander 
can improve 
asthma 
symptoms in 
people allergic 
to them.  (T) 
Cold air can 
make asthma 
symptoms 
worse. (T) 
Environmental 
Triggers and 
Controls 
22. Carpets that smell 
moldy can trigger 
asthma (T) 
3.48 -“smells don’t 
trigger asthma” 
-change can to might 
-“molds are over-
rated” 
Remove and 
replace with 
more generic: 
Stress is never a 
trigger for 
worsening 
asthma 
symptoms (F) 
Molds can 
trigger asthma 
symptoms in 
some people.  
(T) 
Molds can 
trigger asthma 
symptoms in 
some people.  
(T) 
  
 
     
  
1
7
8
Domain 
(Based on 
Schaffer and 
Yarandi) 
Survey Question Expert 
Rating 
Expert Comments Suggested 
Change 
Consultation 
Comments 
Final Question 
Environmental 
Triggers and 
Controls 
23. Covering pillows 
and mattresses 
with plastic covers 
can improve 
asthma (T) 
3.33 - “We don’t 
recommend this” 
-“True only for dust 
mite allergy” 
 
Remove We don’t 
recommend this 
at the clinic so 
patients will not 
know about it. 
REMOVE 
Other Asthma 
Facts 
24. Untreated asthma 
can cause death 
(T) 
3.81    Untreated 
asthma can 
cause death. (T) 
Other Asthma 
Facts 
25. Asthma can be 
completely cured 
(F) 
3.67 -Drop completely 
because tautological 
-“This is true when it 
is caused by 
avoidable allergens 
or occupational 
sensitizers” 
-What about post-
infectious asthma- 
isn’t that cured after 
the infection? 
-“use other wording 
to prevent ‘cured’ 
from being confused 
with ‘controlled’” 
  Asthma can be 
cured. (F) 
Other Asthma 
Facts 
26. People with 
asthma should 
avoid exercise (F) 
3.90    People with 
asthma should 
avoid exercise. 
(F) 
  
1
7
9
Domain 
(Based on 
Schaffer and 
Yarandi) 
Survey Question Expert 
Rating 
Expert Comments Suggested 
Change 
Consultation 
Comments 
Final Question 
Other Asthma 
Facts 
27. It does not bother 
a person's asthma 
when others 
smoke cigarettes 
around them (F) 
3.76 -Perhaps rephrase: 
“second hand smoke 
is irritating to a 
person with asthma’s 
airways even if it 
does not worsen 
symptoms” 
- 
Second hand 
smoke can 
make a person’s 
asthma worse, 
even if people 
do not notice a 
change in their 
symptoms(T) 
 Being around 
others who 
smoke does not 
bother a 
person’s asthma, 
as long as they 
don’t smoke 
themselves. (F) 
Other Asthma 
Facts 
28. Taking an 
antibiotic such as 
penicillin will help 
most bad asthma 
attacks (F) 
3.81 - Drop “such as 
penicillin” 
  Taking an 
antibiotic such 
as penicillin will 
help most bad 
asthma attacks. 
(F) 
Other Asthma 
Facts 
29. If asthma attacks 
stop, it means that 
the asthma has 
gone away (F) 
3.71 - Near duplicate of 
25 
- “Not sure if saying 
asthma attacks stop 
means asthma is 
gone when patients 
still experience 
symptoms” 
 When 
someone’s 
asthma attack is 
over it means 
that the asthma 
has gone way. 
When 
someone’s 
asthma attack is 
over it means 
that the asthma 
has gone way. 
(F) 
Other Asthma 
Facts 
30. If a person does 
not have asthma 
by the time they 
are 40, they will 
never get it (F) 
3.62 - Suggest: “By the 
age of 40” 
If a person does 
not have asthma 
by age 40, they 
will never get it 
(F) 
 If a person does 
not have asthma 
by age 40, they 
will never get it. 
(F) 
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Appendix B 
 Asthma Knowledge Questionnaire 
Please place a mark in the box marked “TRUE” for statements you believe are correct, 
“FALSE” for those statements that are not correct, and “UNSURE” if you do not know if 
the statement is true or false. 
 TRUE FALSE UNSURE 
1. People with asthma can have swollen and 
inflamed airways even when they feel well 
 
   
2. Asthma is a disease that does not last for a long 
time 
   
3. Quick relief medications should be taken every 
day, even if people are feeling well 
 
   
4. People with asthma should try to hold their breath 
for 8-10 seconds after each puff of their inhaler 
 
   
5. It is possible for someone's asthma to be worse 
without them noticing a change in their breathing 
 
   
6. Molds can trigger asthma symptoms in some 
people   
   
7. Asthma can be cured 
 
   
8. Being around others who smoke does not bother a 
person’s asthma, as long as they don’t smoke 
themselves 
 
   
9. Inhaled steroids (controllers) prevent asthma 
attacks 
 
   
10. People with asthma should wait until their 
symptoms are really bad before using a quick 
relief medication 
 
   
11. During an asthma attack, the muscles around the 
airways tighten and the airways become narrow 
 
   
12. People with asthma should rinse and gargle after 
each use of their inhaled (controller) steroid 
 
   
13. A person with asthma can use a combination 
inhaler for quick relief, even if they do not use it 
   
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every day 
 
14. Taking an antibiotic such as penicillin will help 
most bad asthma attacks 
 
   
15. People may not notice improvements in their 
breathing for 1-4 weeks after they start using 
inhaled steroids 
   
 
   
16. Cold air can make asthma symptoms worse 
 
   
17. Frequent coughing can be a symptom of asthma 
 
   
18. A combination inhaler includes two types of 
medication to control asthma 
 
   
19. Having swollen airways does not increase the risk 
of having an asthma attack 
 
   
20. The purpose of steroid medication inhalers is to 
stop an asthma attack when it happens 
 
   
21. People with asthma can usually help control their 
symptoms by taking the appropriate medications 
 
   
22. People can usually help control their symptoms 
by avoiding things (triggers) that make their 
asthma worse 
 
   
23. People with asthma should avoid exercise 
 
   
24. When someone’s  asthma attack is over it means 
that the asthma has gone way 
 
   
25. It is okay to take inhaled steroids (controllers) 
only when people notice their symptoms getting 
worse 
 
   
26. Inhaled steroids will relieve an asthma attack 
within 20 minutes 
 
   
27. People with asthma should wait about one minute 
between puffs of their quick relief medication 
 
   
28. People with asthma do not need to take their daily 
inhaled steroids (controller) if they feel well 
   
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29. People with asthma should breathe out partially, 
but not fully, just before taking their medication 
 
   
30. Asthma may cause wheezing during exercise 
 
   
31. Keeping bedroom windows open at night will 
help prevent asthma attacks 
 
   
32. Untreated asthma can cause death 
 
   
33. If a person does not have asthma by age 40, they 
will never get it 
 
   
34. Chest tightness is a common symptom of asthma    
35. People with asthma get relief from their 
symptoms at night 
 
   
36. Asthma attacks often come on suddenly without 
any warning 
   
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Appendix C 
Rating Scale 
There are different things people have to weigh when deciding whether or not to use an 
inhaler. For example, while some people with asthma may worry about a medication’s 
side effects, they feel that the benefits from the medication are worth the risk. Others are 
not so sure.    
We are interested in what kinds of things you consider when deciding whether or not to 
use an inhaler.  Trying to keep the list of things below in mind, please rate on a scale of 
1-10, the importance of each of the following. 
 
1 
Least 
Important 
2 3 4 5 6 7 8 9 10 
Most 
Important 
 
1. The number of different inhalers I need to take ______ 
2. Having to take an inhaler every day ______ 
3. Being able to take an inhaler only when I need it ______ 
4. Possible short-term side-effects of the inhaler ______ 
5. Possible long- term side-effects of the inhaler ______ 
6. Risk of addiction to the inhaler ______ 
7. The inhaler can  take my symptoms away within minutes ______ 
8. The inhaler can  help keep my asthma from getting worse over the next 10 years 
___ 
9. The inhaler can reduce how often I get  asthma attacks over the next six months 
___ 
10. The cost of the inhaler ______ 
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Appendix D 
Discrete Choice Experiment Scenarios 
Your Preferences for Asthma Treatments (Card 1 of 8) 
When considering your asthma treatment program, if you were offered the choice 
between program A or B, which would you most prefer? 
 Program A Program B 
In 10 years, your asthma 
will be… 
The Same Worse 
Over the next 6 months, 
you will have… 
Fewer asthma attacks The same number of 
asthma attacks 
Your treatment program 
will provide you with… 
Symptom relief within 5 
minutes 
Symptom relief within 30 
minutes  
The dose of steroids in 
your medication will be… 
Low High 
You take your medication 
… 
 
Every day at set times and 
extra if you need it 
Only when you need it 
You will get… 
 
2 Inhalers 1 Inhaler 
Because of your 
medication, you may 
experience… 
Major and/or long-term 
side effects 
Minor and/or short-term 
side effects 
 
Please tick the box (√) below to indicate which treatment (A or B) you would choose. 
Remember, you may have to select some features you do not like because, all 
things considered, you prefer it over the other treatment.  
 
 
 
 
 
A B 
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Your Preferences for Asthma Treatments (Card 2 of 8) 
When considering your asthma treatment program, if you were offered the choice 
between program A or B, which would you most prefer? 
 Program A Program B 
In 10 years, your asthma 
will be… 
The Same Worse 
Over the next 6 months, 
you will have… 
The same number of 
asthma attacks 
Fewer asthma attacks 
Your treatment program 
will provide you with… 
Symptom relief within 30 
minutes 
Symptom relief within 5 
minutes 
The dose of steroids in 
your medication will be… 
High Low 
You take your medication 
… 
 
Every day at set times and 
extra if you need it 
Only when you need it 
You will get… 
 
2 Inhalers 1 Inhaler 
Because of your 
medication, you may 
experience… 
Minor and/or short-term 
side effects 
Major and/or long-term 
side effects 
 
Please tick the box (√) below to indicate which treatment (A or B) you would choose. 
Remember, you may have to select some features you do not like because, all 
things considered, you prefer it over the other treatment.  
 
 
 
 
 
 
 
A B 
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Your Preferences for Asthma Treatments (Card 3 of 8) 
When considering your asthma treatment program, if you were offered the choice 
between program A or B, which would you most prefer? 
 Program A Program B 
In 10 years, your asthma 
will be… 
Worse The Same 
Over the next 6 months, 
you will have… 
Same number of asthma 
attacks 
Fewer asthma attacks 
Your treatment program 
will provide you with… 
Symptom relief within 5 
minutes 
Symptoms relief within 30 
minutes 
The dose of steroids in 
your medication will be… 
Low High 
You take your medication 
… 
 
Only when you need it Every day at set times and 
extra if you need it 
You will get… 
 
1 Inhaler 2 Inhalers 
Because of your 
medication, you may 
experience… 
Minor and/or short-term 
side effects 
Major and/or long-term 
side effects 
 
Please tick the box (√) below to indicate which treatment (A or B) you would choose. 
Remember, you may have to select some features you do not like because, all 
things considered, you prefer it over the other treatment.  
 
 
 
 
 
 
 
A B 
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Your Preferences for Asthma Treatments (Card 4 of 8) 
When considering your asthma treatment program, if you were offered the choice 
between program A or B, which would you most prefer? 
 Program A Program B 
In 10 years, your asthma 
will be… 
The Same Worse 
Over the next 6 months, 
you will have… 
Fewer asthma attacks The same number of 
asthma attacks 
Your treatment program 
will provide you with… 
Symptom relief within 5 
minutes 
Symptom relief within 30 
minutes 
The dose of steroids in 
your medication will be… 
High Low 
You take your medication 
… 
 
Only as needed Every day at set times and 
extra if you need it 
You will get… 
 
1 Inhaler 2 Inhalers 
Because of your 
medication, you may 
experience… 
Minor and/or short-term 
side effects 
Major and/or long-term 
side effects 
 
Please tick the box (√) below to indicate which treatment (A or B) you would choose. 
Remember, you may have to select some features you do not like because, all 
things considered, you prefer it over the other treatment.  
 
 
 
 
 
 
 
A B 
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Your Preferences for Asthma Treatments (Card 5 of 8) 
When considering your asthma treatment program, if you were offered the choice 
between program A or B, which would you most prefer? 
 Program A Program B 
In 10 years, your asthma 
will be… 
Worse The Same 
Over the next 6 months, 
you will have… 
Fewer asthma attacks The same number of 
asthma attacks 
Your treatment program 
will provide you with… 
Symptom relief within 30 
minutes 
Symptom relief within 5 
minutes 
The dose of steroids in 
your medication will be… 
Low High 
You take your medication 
… 
 
Every day at set times and 
extra if you need it 
Only when you need it 
You will get… 
 
1 Inhaler 2 Inhalers 
Because of your 
medication, you may 
experience… 
Minor and/or short-term 
side effects 
Major and/or long-term 
side effects 
 
Please tick the box (√) below to indicate which treatment (A or B) you would choose. 
Remember, you may have to select some features you do not like because, all 
things considered, you prefer it over the other treatment.  
 
 
 
 
 
 
 
A B 
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Your Preferences for Asthma Treatments (Card 6 of 8) 
When considering your asthma treatment program, if you were offered the choice 
between program A or B, which would you most prefer? 
 Program A Program B 
In 10 years, your asthma 
will be… 
The Same Worse 
Over the next 6 months, 
you will have… 
The same number of 
asthma attacks 
Fewer asthma attacks 
Your treatment program 
will provide you with… 
Symptom relief within 30 
minutes 
Symptom relief within 5 
minutes 
The dose of steroids in 
your medication will be… 
Low High 
You take your medication 
… 
 
Only when you need it Every day at set times and 
extra if you need it 
You will get… 
 
1 Inhaler 2 Inhalers 
Because of your 
medication, you may 
experience… 
Major and/or long-term 
side effects 
Minor and/or short-term 
side effects 
 
Please tick the box (√) below to indicate which treatment (A or B) you would choose. 
Remember, you may have to select some features you do not like because, all 
things considered, you prefer it over the other treatment.  
 
 
 
 
 
 
 
A B 
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Your Preferences for Asthma Treatments (Card 7 of 8) 
When considering your asthma treatment program, if you were offered the choice 
between program A or B, which would you most prefer? 
 Program A Program B 
In 10 years, your asthma 
will be… 
Worse The Same 
Over the next 6 months, 
you will have… 
The same number of 
asthma attacks 
Fewer asthma attacks 
Your treatment program 
will provide you with… 
Symptom relief within 5 
minutes 
Symptom relief within 30 
minutes 
The dose of steroids in 
your medication will be… 
High Low 
You take your medication 
… 
 
Every day at set times and 
extra if you need it 
Only when you need it 
You will get… 
 
1 Inhaler 2 Inhalers 
Because of your 
medication, you may 
experience… 
Major and/or long-term 
side effects 
Minor and/or short-term 
side effects 
 
Please tick the box (√) below to indicate which treatment (A or B) you would choose. 
Remember, you may have to select some features you do not like because, all 
things considered, you prefer it over the other treatment.  
 
 
 
 
 
 
 
A B 
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Your Preferences for Asthma Treatments (Card 8 of 8) 
When considering your asthma treatment program, if you were offered the choice 
between program A or B, which would you most prefer? 
 Program A Program B 
In 10 years, your asthma 
will be… 
Worse The Same 
Over the next 6 months, 
you will have… 
The same number of 
asthma attacks 
Fewer asthma attacks 
Your treatment program 
will provide you with… 
Symptom relief within 30 
minutes 
Symptom relief within 5 
minutes 
The dose of steroids in 
your medication will be… 
High Low 
You take your medication 
… 
 
Only when you need it Every day at set times and 
extra if you need it 
You will get… 
 
2 Inhalers 1 Inhaler 
Because of your 
medication, you may 
experience… 
Major and/or long-term 
side effects 
Minor and/or short-term 
side effects 
 
Please tick the box (√) below to indicate which treatment (A or B) you would choose. 
Remember, you may have to select some features you do not like because, all 
things considered, you prefer it over the other treatment.  
 
 
 
A B 
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Appendix E 
Pilot Study Ethics Approval 
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Appendix F 
 
Proportion of Sample that Responded Correctly, Incorrectly or was Unsure of 
Responses to Knowledge Questionnaire Items 
Category Item % Correct % Incorrect % Unsure 
Pathophysiology 2. Asthma is a disease that does not 
last for a long time (F) 
94.6 1.8 3.6 
 
24. When someone’s asthma attack 
is over it means that the asthma has 
gone away (F) 
91.1 5.4 17.9 
 
11. During an asthma attack, the 
muscles around the airways tighten 
and the airways become narrow (T) 
89.3 3.6 7.1 
 
33. If a person does not have 
asthma by age 40, they will never 
get it (F) 
85.5 1.8 12.7 
 
32. Untreated asthma can cause 
death (T) 
78.6 8.9 12.5 
 
1. People with asthma can have 
swollen and inflamed airways even 
when they feel well (T) 
75 5.4 19.6 
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Category Item % Correct % Incorrect % Unsure 
 
19. Having swollen airways does 
not increase the risk of having an 
asthma attack (F) 
75 7.1 17.9 
 
5. It is possible for someone’s 
asthma to be worse without them 
noticing a change in their breathing 
(T) 
66.1 16.1 17.8 
 7. Asthma can be cured (F) 64.3 1.8 33.9 
Medication 21. People with asthma can usually 
help control their symptoms by 
taking the appropriate medications 
(T) 
98.2 1.8 0 
 
10. People with asthma should wait 
until their symptoms are really bad 
before using a quick relief 
medication (F) 
92.9 1.8 5.4 
 
28. People with asthma do not need 
to take their daily inhaled steroids 
if they feel well (F) 
91.1 7.1 1.8 
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Category Item % Correct % Incorrect % Unsure 
 
18. A combination inhaler includes 
two types of medication to control 
asthma (T) 
67.9 10.7 21.4 
 
25. It is okay to take inhaled 
steroids only when people notice 
their symptoms getting worse (F) 
66.1 16.1 17.9 
 
14. Taking an antibiotic, such as 
penicillin, will help most bad 
asthma attacks (F) 
64.3 5.4 30.4 
 
3. Quick relief medications should 
be taken every day, even if people 
are feeling well (F) 
58.9 26.8 14.3 
 
20. The purpose of steroid 
medication inhalers is to stop an 
asthma attack when it occurs (F) 
50 32.1 17.9 
 
9. Inhaled steroids (controller) 
prevent asthma attacks (T) 
44.6 35.7 19.6 
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Category Item % Correct % Incorrect % Unsure 
 
15. People may not notice 
improvements in their breathing for 
1-4 weeks after they start using 
inhaled steroids (T) 
37.5 26.8 35.7 
 
26. Inhaled steroids will relieve an 
asthma attack within 20 minutes (F) 
37.5 32.1 30.4 
 
13. A person with asthma can use a 
combination inhaler for quick 
relief, even if they do not use it 
everyday (F) 
12.5 62.5 25 
Technique 12. People with asthma should 
rinse and gargle after each use of 
their inhaled steroid (T) 
94.6 1.8 3.6 
 
4. People with asthma should try to 
hold their breath for 8-10 seconds 
after each puff of their inhaler (T) 
93 5.4 1.8 
 
29. People with asthma breathe out 
partially, but not fully, just before 
taking their medication (F) 
67.9 19.6 12.5 
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Category Item % Correct % Incorrect % Unsure 
 
27. People with asthma should wait 
about one minute between puffs of 
their quick relief medication (T) 
60.7 32.1 7.1 
Environmental 
Triggers 
22. People can usually help control 
their symptoms by taking avoiding 
things that make their asthma worse 
(T) 
98.2 1.8 0 
 
6. Molds can trigger asthma 
symptoms in some people (T) 
96.4 0 3.6 
 
8. Being around others who smoke 
does not bother a person’s asthma, 
as long as they don’t smoke 
themselves (F) 
94.6 1.8 3.6 
 
16. Cold air can make asthma 
symptoms worse (T) 
94.5 1.8 3.6 
 
23. People with asthma should 
avoid exercise (F) 
92.9 5.4 1.8 
 
 
    
  
198 
Category Item % Correct % Incorrect % Unsure 
 
31. Keeping bedroom windows 
open at night will help prevent 
asthma attacks (F) 
64.3 8.9 12.5 
Symptoms 30. Asthma may cause wheezing 
during exercise (T) 
94.6 1.8 3.6 
 
35. People with asthma get relief 
from their symptoms at night (F) 
93.3 3.3 3.4 
 
34. Chest tightness is a common 
symptom of asthma (T) 
90 3.3 6.7 
 
17. Frequent coughing can be a 
symptom of asthma (T) 
82.1 1.8 16.1 
 
36. Asthma attacks often come on 
suddenly without any warning 
symptoms (F) 
13.3 80.0 6.7 
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Appendix G 
Full Study Ethics Approval 
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Appendix H 
 
Letter of Information 
  
LETTER OF INFORMATION 
Project Title:     The additive and interactive effects of patients’ asthma knowledge, 
beliefs and treatment preferences on medication choices  
 
Investigators:  Dr. Leora Swartzman, Psychology, UWO 
Ms. Naomi Gryfe, Psychology, UWO  
Dr. Christopher Lisckai, St Joseph’s Health Centre 
Purpose of the Study 
As an individual attending the asthma clinic, you are being invited to voluntarily 
participate in a research study looking at patients’ views about asthma and what you feel 
is important for your treatment.  
The purpose of this letter is to provide you with the information you require to make an 
informed decision to participate in this research.   
Procedures 
Approximately 120 patients will be approached to take part in this study. If you decide to 
participate you will be asked to sign the consent form and then complete: 
 
1. Surveys while you wait to see your physician today. These surveys will take 
approximately 15 minutes to complete and will ask you about your experiences 
while having an asthma attack and some information about you.  
 
2. Surveys after you see your physician today. These surveys will take 
approximately 25-30 minutes to complete. In these questionnaires, you will be 
asked about your thoughts about asthma, what you feel is important for your 
treatment, and the way in which you are currently using your medications (if any 
medications have been prescribed for you). 
 
3. At home tonight, you will be asked to complete a 5 minute survey about your 
satisfaction with your appointment. You may complete these surveys online or on 
paper copies which will be provided to you. Should you choose to complete these 
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surveys on paper copies, you will also be provided with a postage paid envelope 
and asked to mail the surveys back to the investigators. 
 
4. For one week after your appointment, you will be asked to record your symptoms 
and when you take your medications. Again, you will have the option of 
completing these surveys online or by hand. You must return this package by mail 
(postage will be paid) or e-mail. 
 
5. Four weeks after your appointment, you will be contacted by phone or email 
(your preference) and asked to again record your symptoms and medication s for 
one week (online or on paper copies which will be mailed to you). You will also 
be asked a few questions about how you take your medications and your quality 
of life. You must return the package by mail (postage will be paid) or e-mail. 
Reimbursement 
You will be reimbursed $10.00 for completing the portion of the study at today’s visit. 
You will also receive $20.00 for completing each of the week-long symptom diaries and 
surveys. In total, you will be paid $50.00 to compensate you for your time.  If you 
withdraw from the study early, you will be reimbursed according to the portion of the 
study that you complete. 
Risks and Discomforts 
We do not believe this study poses any risk to your health or safety.  
Benefits 
This research project may lead to the development of improved clinical care for patients 
suffering from asthma. You may not benefit personally from participation in the study. 
Withdrawal 
Participation in this study is completely voluntary.  You may refuse to participate, refuse 
to answer questions, or withdraw from the study at any time with no effect on your future 
care. 
Confidentiality 
Maintaining your confidentiality is of the upmost importance to us. Your physician will 
not see any of your answers and if the results of this study are published, no one will 
know you were a part of the study. Your names will be removed from all of your answer 
booklets, and the unidentifiable information will be stored in a locked cabinet at the 
University of Western Ontario. 
 
Should you decide to complete your questionnaires online, all of your information will be 
password protected on a secure network through the University of Western Ontario. All 
of your personal information will be removed from your answers one they are received. 
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We will only release your records should representatives of the University of Western 
Ontario Health Sciences Research Ethics Board wish to contact you or require access to 
your study-related records to monitor the conduct of the research. 
 
Contact Person 
If you have any questions about the study procedure or content, please feel free to contact 
Ms. Naomi Gryfe. 
If you have questions about your rights as a research participant or the conduct of the 
study you may contact Dr. David Hill, Scientific Director, Lawson Health Research 
Institute. 
Legal Rights 
You do not waive any of your legal rights by signing the consent form. 
This letter is yours to keep. 
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Appendix I 
Informed Consent 
        
 
Consent to participate in the study entitled: 
The Additive and Interactive Effects of Patients’ Asthma Knowledge, Beliefs, and 
Treatment Preferences on Medication Choices 
 
I, ______________________________, have read the Letter of Information, had the 
nature of the study explained to me, and I agree to participate. 
 
All questions have been answered to my satisfaction. 
 
______________________________ ______________________________ 
 DATE          SIGNATURE 
 
______________________________________________ 
NAME OF PERSON OBTAINING CONSENT (please print) 
 
_________________________________________ 
SIGNATURE OF PERSON OBTAINING CONSENT 
 
  
2
0
4
Appendix J: Medication Diary 
Please complete the chart below at the end of each day of the week: 
MEDICATION Example 
Thursday, 
March 2, 2010 
Day 1    
Date: _____ 
___________ 
Day 2    
Date: _____ 
___________ 
Day 3 
Date:_____ 
_________ 
Day 4 
Date:_______ 
____________ 
Day 5 
Date:_______ 
____________ 
Day 6 
Date:_______ 
____________ 
Day 7 
Date:_______ 
____________ 
I took my 
preventer 
medication 
at: 
 
9:00 am 
3:00 pm 
       
I took a total 
of  __ puffs of 
my rescue 
inhaler today 
 
2        
I used my 
rescue 
inhaler at 
____ 
 
1:00 pm 
4:00 pm 
       
 
On day one, please record the number listed on your preventer inhaler. If you have more than one inhaler, please record the number on each inhaler:   
Inhaler 1: __________   Inhaler 2:_____________ Inhaler 3:_____________   Inhaler 4:___________ 
At the end of the week, please record the number listed on your preventer inhaler. If you have more than one inhaler, please record the numbers on each of the 
inhalers.  
Inhaler 1: _______________      Inhaler 2: _________________      Inhaler 3: _______________   Inhaler 4:__________________ 
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Appendix K 
Demographic Information 
ABOUT YOUR ASTHMA 
  
1. Have you been diagnosed with asthma (please circle yes or no)? 
 
YES 
If YES:  
1. At what age were you given an asthma diagnosis: 
________ 
2. In what year were you given an asthma diagnosis: 
________ 
 
 
NO 
 
2. Is this your first visit to this asthma clinic (please circle yes or no)? 
 
NO 
If NO: Not including this visit, how many times have you been seen at 
this asthma clinic (please circle)? 
 
YES 
1 Time 2 Times 3 Times More 
than 3 
Times 
 
3. In the past year, how many times have you had to: 
 
i. Go to see your family doctor for breathing problems? ________ 
ii. Go to the emergency room (ER) for breathing problems? _______ 
 
4. Have you been prescribed any medications to help control your asthma (by your 
family doctor, the ER, or a doctor at this clinic)? Please circle yes or no. 
 
 
YES 
If YES: Please list the names of the medications: 
 
 
Are you currently taking these medications?      YES      NO 
 
NO 
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ABOUT YOU 
 
Sex (please circle):    Male     Female 
Date of Birth: _______________ (DD/MM/YYYY) 
 
1. What is the highest grade of school that you have ever attended? Add one year 
for each additional year beyond grade 13 (For example, two years of college would 
be 15 years).  
____________ Years 
 
2. Which of the following best describes your current job status (please check one)? 
Employed outside of the home (30  
    or more hours a week)   
Retired 
Homemaker 
Working from home 
Student 
Employed outside the home, part time (less than 30 
hours 
    a week)   
Unemployed 
On disability (Is this related to your asthma?  Yes   No) 
Other, please specify: ______________ 
 
3. What certificates, diplomas or degrees have you obtained? 
None 
Secondary/ High School Certificate 
Trade certificate or diploma 
Community College 
Bachelor Degree(s) (ex: B.A., B.Sc.) 
Master Degree(s) 
Professional Degree (Medicine, dentistry, law) 
Doctorate Degree 
 
4. Describe the range in which your annual household income falls (please check 
one): 
Under $20,000 
$21,000- $40,000 
$41,000-$60,000 
$81,000-$100,000 
Over $100,000 
I would prefer not to say 
  $61,000-$80,000  
 
5. Your current relationship status is: 
Legally married (not separated) 
Separated or divorced 
Living common law 
In a relationship, but not living together 
Single 
Widowed  
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Appendix L 
Percentage of Sample who Answered Knowledge Items Correctly and Incorrectly 
Category Item Percent 
Correct 
Percent 
Incorrect 
Percent 
Unsure 
Pathophysiology 19. Having swollen airways 
does not increase the risk of 
having an asthma attack 
71.9 6.5 21.6 
 24. When someone’s asthma 
attack is over it means that the 
asthma has gone away 
94.2 2.9 2.9 
 11. During an asthma attack, 
the muscles around the airways 
tighten and the airways become 
narrow 
94.2 .7 5.1 
 2. Asthma is a disease that does 
not last for a long time 
91.4 2.2 6.5 
 33. If a person does not have 
asthma by age 40, they will 
never get it 
80.6 1.4 18.0 
 32. Untreated asthma can cause 
death 
78.4 1.4 20.1 
 19. Having swollen airways 
does not increase the risk of 
having an asthma attack 
71.9 6.5 21.6 
 1. People with asthma can have 
swollen and inflamed airways 
even when they feel well  
68.8 12.3 18.8 
 5. It is possible for asthma to be 
worse without noticing a 
change in their breathing 
61.4 11.4 26.4 
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Category Item Percent 
Correct 
Percent 
Incorrect 
Percent 
Unsure 
 7. Asthma can be cured 57.9 14.3 27.1 
Medication 21. People with asthma can 
usually help control their 
symptoms by taking the 
appropriate medications 
95.0 1.4 3.6 
 28. People with asthma do not 
need to take their daily inhaled 
steroids if they feel well 
89.9 5.1 5.0 
 10. People with asthma should 
wait until their symptoms are 
really bad before using a quick 
relief medication 
86.3 7.9 5.8 
 18. A combination inhaler 
includes two types of 
medication to control asthma 
79.9 2.9 17.3 
 3. Quick relief medications 
should be taken every day, even 
if people are feeling well 
71.9 18 10.1 
 25. It is okay to take inhaled 
steroids only when people 
notice their symptoms getting 
worse 
71.2 17.3 11.2 
 9. Inhaled steroids (controller) 
prevent asthma attacks 
65.2 18.1 16.7 
 14. Taking an antibiotic, such 
as penicillin, will help most bad 
asthma attacks 
 
 
56.8 35.3 7.9 
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Category Item Percent 
Correct 
Percent 
Incorrect 
Percent 
Unsure 
 20. The purpose of steroid 
medication inhalers is to stop an 
asthma attack when it occurs 
51.8 35.3 12.9 
 15. People may not notice 
improvements in their breathing 
for 1-4 weeks after they start 
using inhaled steroids 
38.8 28.8 32.4 
 26. Inhaled steroids will relieve 
an asthma attack within 20 
minutes 
33.3 33.3 33.3 
 13. A person with asthma can 
use a combination inhaler for 
quick relief, even if they do not 
use it everyday 
13.7 56.8 29.5 
Technique 12. People with asthma should 
rinse and gargle after each use 
of their inhaled steroid 
97.8 .7 1.4 
 4. People with asthma should 
try to hold their breath for 8-10 
seconds after each puff of their 
inhaler 
91.4 3.6 4.3 
 27. People with asthma should 
wait about one minute between 
puffs of their quick relief 
medication 
61.9 21.6 16.5 
 29. People with asthma breathe 
out partially, but not fully, just 
before taking their medication 
 
52.5 28.8 18.7 
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Category Item Percent 
Correct 
Percent 
Incorrect 
Percent 
Unsure 
Environmental 
Triggers 
6. Molds can trigger asthma 
symptoms in some people 
97.1 1.4 1.4 
 23. People with asthma should 
avoid exercise 
95.7 .7 3.6 
 8. Being around others who 
smoke does not bother a 
person’s asthma, as long as they 
don’t smoke themselves 
94.2 2.2 3.6 
 22. People can usually help 
control their symptoms by 
taking avoiding things that 
make their asthma worse 
93.5 5.0 1.4 
 16. Cold air can make asthma 
symptoms worse 
91.4 3.6 5.0 
 31. Keeping bedroom windows 
open at night will help prevent 
asthma attacks. 
56.1 10.8 33.1 
Symptoms 30. Asthma may cause 
wheezing during exercise 
94.2 1.4 4.3 
 34. Chest tightness is a 
common symptom of asthma 
90.6 2.2 7.2 
 35. People with asthma get 
relief from their symptoms at 
night 
85.6 3.6 10.8 
 17. Frequent coughing can be a 
symptom of asthma 
84.2 4.3 11.5 
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Appendix M 
Summary of Hierarchical Regression Analysis with Patient Preferences Entered at 
Step One 
 Model 
Variable 1 β 2 β 
Preferences   
  Long Term – Equal Group -.40*** -.25** 
  Long Term – Side Effects -.02 .74 
  Long Term to Efficacy -.17 -.16 
Pathophysiology Knowledge  .07 
Beliefs   
  Timeline- Acute/Chronic  .03 
  Necessity of Medication  3.34*** 
  Concern of Medication  -.78 
R2 .14 .33 
∆R2  .19 
F 5.44** 4.00*** 
∆F  3.10 
 
**
 p < .01. *** p < .001. 
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